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Hepatocellular carcinoma (HCC) is the most common type of liver cancer that accounts for 4.7% 
of the total number of new cases of cancer worldwide every year. HCC is a highly heterogeneous 
and complex disease with an estimated 5-year survival rate of only 18%. A better understanding 
of the mechanisms involved in the development, progression and recurrence of this tumour could 
not only guide us in the improvement of preventive strategies but also in the expansion of 
alternative target therapies for HCC patients. 
 
The aim of this thesis is to investigate new diagnostic and prognostic markers, both on genetic 
and molecular levels, in the context of HCC. The results section is divided in two, called Chapter 
I and Chapter II. 
 
HCC presents a distinct mutational landscape and Chapter I describes how we developed a 
HCC-specific custom made sequencing panel, containing the genes most commonly affected by 
somatic mutations and copy number alterations (CNAs) in the disease. We created a panel that 
was tested in different kinds of patient biopsies: frozen tissues, formalin-fixed paraffin-embedded 
(FFPE) tissues and also liquid biopsies. Moreover, to have reliable and reproducible sequencing 
data, we created a solid and user friendly somatic variant calling pipeline specific for Ion Torrent 
sequencing data.  
 
In Chapter II, we aimed to investigate the molecular mechanism of HMGA1 in HCC and to explore 
its molecular targets. HMGA1 is an architectural transcription factor that was found often 
overexpressed in HCCs. We explored its DNA-binding landscape and, after deregulating HMGA1 
in a HCC in vitro environment, its expression signature both at the RNA and protein levels. With 
the analysis of the binding partners of HMGA1, we recognised the vast range of mechanisms of 
action of this complex protein. We identified several RNA regulators that bind HMGA1, including 
Alyref, which plays a role in the regulation of the transcription. Further work should aim to 
determine the non-canonical role of HMGA1 involved in the binding and the regulation not only at 
the DNA but also at the RNA level.  
 
Both chapters describe the steps of this work on the identification and the functional 
understanding of HCC biomarkers. This may lead in the future to more individualised treatment 
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approaches, a need that in cancers with low survival rate such as HCC is not only highly desirable 
but is also a necessity.
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I. The hallmarks of cancer 
Nowadays cancer is still among the leading causes of death worldwide, with more than 9.5 million 
cancer-related deaths and ~18 million new cases worldwide in 2018 1,2. Cancer is a group of 
diseases involving abnormal cell growth with the potential to invade or spread to other parts of 
the body. Cancer has been demonstrated to be a multistep process 2 involving genetic and 
nongenetic alterations such as changes in the genotype (e.g. mutations in the DNA) or changes 
in the phenotype that do not involve DNA alteration, called epigenetic changes (e.g. DNA 
methylation, histone modifications, non-coding RNA mechanisms). These modifications affect 
how a gene is read by a cell and empower the gain of new capabilities.  
 
When cells grow locally without invading adjacent tissues the tumour is classified as benign. 
Tumours that invade nearby tissues are called malignant; when a cell (or a group of cells) in the 
primary tumour gains the ability to extrude the initial tissue and disseminate into the body via the 
lymphatic system or through the bloodstream, the tumour is called invasive. Metastasis happens 
when the disseminated cells from the primary tumour seed and proliferate in a new distant site 
forming another tumour site 3. Cancer cells are less specialised than normal cells, they can 
proliferate uncontrollably and avoid apoptosis. As tumours grow, the number of mutations will 
increase and the accumulation of mutations will confer survival advantages over time 4,5. These 
advantages are biological capabilities (gain or loss of functions) that can describe the 
development of cancer and they can be combined into 10 groups, as Hanahan and Weinberg 
proposed 6, summarised shortly below. The hallmarks of cancer are, to date, the fundamentals 
for understanding the biology of cancer. 
 
1. Sustaining proliferative signaling 
One of the most critical abilities that a cell can gain is to sustain chronic proliferation by 
deregulating growth-promoting signals. Mutations in growth factors principally, or in any of the 
genes encoding for proteins involved in the subsequent intracellular signaling pathways that 
regulate progression, can influence not only the cell cycle and growth but also other cell-biological 
properties, such as cell survival and energy metabolism 7,8. 
 
2. Evading growth suppressors 
In addition to the sustaining proliferative signaling, cancer cells can also circumvent pathways 
that negatively regulate cell proliferation, with alterations in tumour suppressor genes. Tumour 
suppressor proteins function as gatekeepers of cell cycle progression, these proteins are involved 
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in the combination of inputs of stress and abnormality from extracellular and intracellular sources 
and  regulate the entry of a cell through its growth and division cycle 9,10. 
 
3. Enabling replicative immortality 
This refers to the ability to avoid senescence and apoptosis. Normal cells have a limited number 
of cell division cycles assured by the telomeres, the tandem repeats at the ends of chromosomes. 
After reaching their maximum number of divisions, cells undergo senescence, a non-proliferative 
but viable state, and then enter into a crisis phase, which involves cell death/apoptosis 11,12. 
Cancer cells develop an ability to maintain telomeric DNA at lengths sufficient to avoid triggering 
senescence or apoptosis. In the majority of the cases by upregulating expression of telomerase 
or, sometimes, using an alternative maintenance mechanism of recombination of telomeres 13. 
 
4. Resisting cell death 
This ability allows tumours to attenuate apoptosis. Apoptosis is triggered in cells in response to 
various physiologic stresses. Cancer cells can experience these brunts during the course of 
tumourigenesis or as a result of anticancer therapy 14. The apoptosis machinery is composed by 
several regulators that can receive and process internal and external signals and can initiate a 
cascade of proteolysis involving effector components for the execution phase of apoptosis. When 
this fine counterbalance of pro- and antiapoptotic members is deregulated, cells may become 
resistant to inhibit apoptosis 14-16. 
 
5. Avoiding immune destruction 
Tumoural cells also gain the ability to avoid detection by the immune system. The immune 
surveillance is constantly monitoring cells in the body and is able to recognise and eliminate the 
majority of nascent cancer cells. The cells in a new tumour managed to avoid or limit the 
immunological detection and killing, thereby evading elimination 17,18. 
 
6. Tumour promoting inflammation 
Immune cells can not only recognise and eliminate cancer cells in the body, but they can also, 
paradoxically, enhance tumourigenesis and progression. Inflammation can contribute to the 
acquisition of multiple capabilities by supplying active molecules to the tumour microenvironment 
(growth, survival and angiogenic factors, inductive signals and extracellular matrix-modifying 
enzymes). Every tumour contains immune cells at different densities that can be used to promote 
aggressiveness and invasiveness 19,20.  
 
7. Inducing angiogenesis 
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All tissues, including tumoural, need sustenance (nutrients and oxygen) and an evacuation 
system (for metabolic wastes and carbon dioxide). Big tumours acquire the ability to create new 
vasculature (angiogenesis) to address these needs by deregulation of signaling proteins that 
induce or inhibit angiogenic regulators. In this way, angiogenesis remains always activated and 
the tumour does not risk to undergo necrosis 21,22. 
 
8. Deregulating cellular energetics 
This indicates the ability of cancer cells to reprogram their glucose metabolism, and therefore 
their energy production, by limiting their energy metabolism mostly to glycolysis even in presence 
of oxygen, a state called “aerobic glycolysis”. The specific deregulation of oncogenes and tumour 
suppressor confers benefits for the reliance of glycolysis 23,24. Today the rationale for this choice 
is still unclear, the most accredited theory states that the increase of glycolysis allows the 
deviation of glycolytic intermediates into various biosynthetic pathways; this supports the large-
scale biosynthesis of the macromolecules programs that are required for active cell proliferation 
25-27.  
 
9. Activating invasion and metastasis 
Tumour cells can gain the ability to develop alterations in shape and modification in attachment 
approaches to other cells and to the extracellular matrix. Deregulation or mutational inactivation 
and activation of key cell-to-cell and cell-to-extracellular matrix adhesion molecules is frequently 
observed in cancer and accelerates the capability for invasion and metastasis 28,29. 
 
10. Genome instability and mutation 
Last but not least, the ability of tumour cells to increase the rates of mutation is one of the 
hallmarks that confers major selective advantages on tumour clonal cells. The system in normal 
cells to detect and resolve defects in the DNA is extremely complicated but well-organised and 
interconnected. For this reason, the rate of spontaneous mutation is usually very low during a cell 
generation life. During tumourigenesis, cancer cells often increase the rates of mutation by 
disruption and break of one or more components in these genome maintenance systems (DNA 
damage, recognition and repair machinery factors). The accumulation of mutations sometimes 
force cells into senescence or apoptosis but can also trigger the acquisition of mutant genotypes 
that confer selective advantages and that can be maintained in the successive clonal expansions 
30-33.  
 
It is evident that the multistep process of human tumour pathogenesis needs the acquisition of 
new traits for normal cells to become tumourigenic and later malignant. The summary of these 
traits is well realised in the hallmarks of cancer proposed by Hanahan and Weinberg and an 
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illustrative summary is shown in Figure 1.1. The hallmarks contribute to provide a structure for 
the understanding of the complex biology of cancer. 
 
 
Figure 1.1: Hallmarks of cancer. Taken and mod. from Hanahan and Weinberg 2011 6. This illustration encompasses 
the ten hallmark capabilities of cancer proposed by Hanahan and Weinberg. 
 II. Genetics of cancer 
Considering the hallmarks of cancer, it is vital to understand the causes that lead to the 
uncontrolled growth of cells. One of the primary causes of cancer is genetic mutations 4,5. The 
errors in the DNA of a cell can occur due to several factors (e.g. spontaneous errors during DNA 
replication process, heredity, radiation and chemicals) and can contribute to the dedifferentiation, 
the loss of the specificity of a cell variant.  
 
Types of mutations  
A mutation can be germline or somatic. Germline mutations are genetically inherited alterations 
that are present in the germ cells (sperm or eggs) and that are then contained in all cells of the 
individual 2,34. Carrying germline mutations in cancer related genes increases the probability to 
develop cancer during a person’s lifetime. On the other hand, somatic mutations are not inherited 
and they first appear in differentiated cells. Somatic mutations are therefore inherited by the 
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progeny of these particular cells during their divisions but they would not be inherited by the 
offspring of the person carrying the mutations.  
 
Each person has a unique combination of genetic changes, but not all contribute to cancer 
progression. The accumulation of somatic genetic changes arising during a person’s lifetime in a 
tissue can allow a tissue to acquire certain selective advantages compared to neighbouring cells, 
including the ability to drive tumourigenesis. The somatic alterations conferring a selective 
advantage on the cell, the so-called “driver” mutations, are kept during divisions, while the 
disadvantageous ones usually undergo negative selection 4,35-37. It is hypothesised that the vast 
majority of mutated genes have no involvement in tumourigenesis; their mutations are passengers 
rather than drivers 38. Thanks to the most recent next generation sequencing technologies, 
distinctive patterns of DNA mutations in different tumour types were revealed 39.  
 
Genetic alterations can be classified into three main classes: (non-)synonymous mutations, 
structural variations and copy number variations (CNVs). The first category includes substitutions 
(e.g. silent, nonsense, missense, splice site) and insertions and deletions of one or more 
nucleotides (that result in frameshifts and in-frame mutations). The structural variation category 
consists of larger insertions, deletions, rearrangements or translocations of chromosomal regions. 
The CNVs are instead gene amplifications or losses, ending with a different number of copies of 
a locus. To identify the mutational pattern of a tumour we need to analyse the mutation types and 
the heterogeneity of mutation rate. One of the first and biggest consortium aimed at sequencing 
the exomes of thousands of tumours of more than thirty frequent cancer types is The Cancer 
Genome Atlas (TCGA) 40 and the Figure 1.2 represents an overview of their results, showing the 
number of mutations in coding regions divided per cancer type. Other pan-cancer projects 
followed and they led to some important findings in the discovery of driver mutations in driver 
genes in primary malignancies 41,42. Recently, similar projects aim to reveal not only the landscape 
of driver alterations of advanced malignancies, but also to identify driver mutations in non-coding 
regions and regulatory sequences 41,43,44, as shown in the example in Figure 1.3. The importance 
of epigenetics as another main cause of tumourigenesis has been well acknowledged and a 
deeper elucidation of these epigenetic mechanisms might materially change our overall 






Figure 1.2: Number of mutations in coding genes per cancer type. Taken and mod. from Martínez-Jiménez et al. 2020 
45. Mutation burden (top) and mutation type (bottom) of tumours from cancer types represented by at least two cohorts. 
Cohorts are coming from datasets of tumour mutations collected from the public domain and analysed with IntOGen 
pipeline. The number of cohorts and samples contributing to the distribution of each cancer type are shown below the 
plot. Adeno., adenocarcinoma; CLL, chronic lymphocytic leukaemia; Hartwig, Hartwig Medical Foundation; ICGC, 
International Cancer Genome Consortium; PCAWG, Pan-Cancer Analysis of Whole Genomes; St Jude, St Jude 
Children’s Research Hospital; TARGET, Therapeutically Applicable Research to Generate Effective Treatments; 





Figure 1.3: Non-coding point mutations in Pan-Cancer Analysis of Whole Genomes (PCAWG). Taken and mod. from 
Rheinbay et al. 2020 41. Significant non-coding elements (Q < 0.1 of Brown’s combined P values of up to 13 driver 
discovery methods) identified in cohorts with at least one hit. Colour represents significance levels. *Potential technical 
artefact; #targets affected by mutational processes. AdenoCA, adenocarcinoma; CNS, central nervous system; Eso, 
oesophageal; GBM, glioblastoma; HCC, hepatocellular carcinoma; Medullo, medulloblastoma; Panc, pancreatic; Prost, 
prostate; RCC, renal cell carcinoma; Repr., reproductive organs; SCC, squamous cell carcinoma; TCC, transitional cell 
carcinoma; Thy, thyroid. HIST1H2AM is also known as H2AC17; Ala.TGC as TRA-TGC3-1; Met.CAT as TRM-CAT1-
1; and Gly.GCC as TRG-GCC2-3. PTDSS1/MTERF3 denotes that 5′ UTR mutations in PTDSS1 also overlap the 
MTERF3 promoter. 
 
Cancer is a dynamic disease characterised by clonal evolution of cells, therefore usually it 
presents diverse characteristics inside the same site that are representative of its heterogeneity. 
One tumour can include a diverse collection of cells (subpopulations) harbouring distinct 
molecular signatures. This non-uniform distribution can be across and within disease sites (spatial 
heterogeneity) or can be due to temporal variations (temporal heterogeneity) 46. Recognizing and 













































































































































































































































insights not only into tumourigenesis but also into the drug resistance process that often results 
in differential levels of sensitivity to treatment for patients. 
 
Oncogenes and tumour suppressors 
Despite the genetic differences between cancer, two main classes of genes generally affected by 
somatic genetic alterations in cancers are recognised: proto-oncogenes and tumour suppressor 
genes. They typically encode for proteins involved in the major control of the pathways in the 
cells, and therefore play a key role in cancer development. A proto-oncogene generally encodes 
for a protein involved in the viability of the cell and enhances cell proliferation 47,48. When mutated, 
damaged or amplified it becomes oncogenic and can enable tumour cells to circumvent the 
checks and balances that are in place during homeostasis to drive tumour growth. Tumour 
suppressor genes, on the other hand, encode for proteins implicated in the inhibition of 
uncontrolled cell proliferation and in the driving of cell death 49,50. For this reason they are also 
often mutated in cancer; their proteins undergo loss of function and inactivation. Their inactivation 
might constitute driver events that are thought to occur in the earliest stages of carcinogenesis 
49,50. Once a gene is mutated, its product can be affected in different ways: the protein can not be 
functional anymore, the protein expression can be completely blocked, or the way of function of 
a protein can be modified. A mutation can also cause the activation of a gene that is not usually 
expressed in certain tissues or inactivate the expression of a gene important in normal conditions 
2. For example, ras, one of the most commonly mutated genes in all cancers, becomes oncogenic 
thanks to point mutations resulting in single amino acid substitutions at critical positions 51. The 
first such mutation discovered was the substitution of valine for glycine at position 12. When ras 
shows this mutation, Ras protein is constitutively in the active GTP-bound conformation and 
drives unregulated cell proliferation 52. Another example is about APC tumour suppressor gene. 
Hotspots mutations are mainly concentrated in the exon 15, often resulting in a truncated non-
functional protein 53. Moreover, it has been found that hypermethylation of the promoter region of 
this gene constitutes  an  alternative  mechanism  of  gene  inactivation 54. DNA methylation is 
indeed one of the most commonly studied epigenetic mechanisms associated with the 
transcriptional silencing of tumour suppressor genes and the effectiveness of inactivation is the 
same with mutations 55.  
 
To characterise and to understand the mutational and epigenetic changes in tumour samples is 
therefore not only changing research and clinical practice but has also driven the implementation 
of molecular testing into clinical practice. 
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III. Importance of next generation sequencing for the clinic 
In the last two decades, sequencing technologies have allowed the discovery of distinctive 
patterns of mutations in different tumour types. Since then, many researchers have contributed 
to the exploration of the functions and mechanisms of the mutated gene products, their pathways 
and their implications in tumour processes. These discoveries led to the development of drugs 
that can target the mutated gene products (proteins or enzymes) and stop the informational 
cascade underneath 56,57. Therefore, targeted drugs can turn off signals that make cancer cells 
grow, or can enhance internal tumoural signals leading to apoptosis. More deeply we understand 
about the mechanism resulting from these genetic changes, more precisely we might identify 
targets to develop strategic therapies 56,57. Despite the enormous effort in this kind of research 
worldwide, so far only a few types of cancers are routinely treated using targeted drugs, and often 
they are in combination with other common therapies. Another reason might be the limited number 
of approved sequencing tests for diagnostic research 58,59.  
 
The traditional genetic tests used in clinical practices have been replaced in the last decade by 
next generation sequencing. Not only this kind of technology is cost and time effective, but it 
allows the generation of bigger and still accurate and reliable information from the genome. A 
clinical next-generation sequencing test can target a panel of selected genes, the exome or, more 
rarely,  the entire genome. Next-generation sequencing has revolutionised not only the oncology 
field, helping the identification of genetic variants in human cancers, but also the research for 
many other diseases, especially hereditary disorders in the pediatric area 60. The main part of 
clinical tests are done on DNA samples from biopsy (for somatic mutations). The use of DNA from 
blood is instead mainly adopted in case of tumours of the haematopoietic and lymphoid 
malignancies and to reveal germline mutations. 
Biopsy 
Biopsies are samples of tissue taken from the body to get more information about possible 
anomalies. The information achievable from biopsies includes the presence, the cause or the 
extent of the disease. They are frequently used by pathologists to recognise if in the tissue there 
is a lesion, a mass or a tumour and they represent an invaluable source of biological material. 
There are two main approaches to store biopsies for extended duration by preserving the 
morphology and cellular details of the tissues: by formalin-fixation and paraffin-embedding (FFPE) 
and by snap freezing (Figure 1.4). 
 
In the first case, the biopsy is fixed in formaldehyde, to preserve mostly the proteins and the 
structures of the tissue, important for immunohistochemistry. When a biopsy is rapidly frozen after 
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removal from the tissue, it is possible to preserve better all the components for molecular analysis 
61. Both methods show pros and cons and depending on the main use of the biopsies and the 
laboratory opportunities, one or both storage processes can be chosen. FFPE tissue samples can 
be stored at room temperatures and they do not need specialised equipment. This is a cost-
effective storage method that makes it possible to keep a large collection of tissues accessible 
for a long time. 
 
Even if the formalin and wax ensure that cell structures and proteins are well preserved, they are 
denatured and no longer biologically active. The fixation often leads to cross-linking, degradation 
and fragmentation of DNA and especially RNA molecules. These alterations inevitably affect the 
use of FFPE samples in molecular and genetic analysis and the results obtained are not 
comparable to the ones from frozen tissue samples 62. 
Fresh tissue samples require a quicker but more expensive storage process. The need for 
specialised equipment, such as ultra-low temperature freezer, its preservation and maintenance 
with the problem of the rapid deterioration of the samples at room temperature, make this storage 
method not feasible for a big amount of samples for a long time. On the other hand, the proteins 
are still preserved in their native state and frozen tissue material is the gold standard especially 
for sequencing due to its superiority in preserving DNA and RNA 62,63. 
 
 
Figure 1.4: Biopsy collection and storage. A) A small sample of tissue is taken from the tumour and is immediately 
snap frozen in liquid nitrogen and then stored at -80°C for long or short periods of time. B) A small sample of tissue is 
taken from the tumour and undergoes formalin-fixation and paraffin-embedding (FFPE) process. The FFPE tissue 




The invasive nature of biopsy has encouraged investigations into the use of plasma liquid biopsy, 
a potentially minimally invasive alternative method that allows to explore plasma-derived cell-free 
DNA (cfDNA) for molecular profiling in several disease areas (Figure 1.5). When a healthy, 
inflamed or tumour cell undergoes apoptosis or necrosis, its content, including DNA, is released 
into the bloodstream. Circulating tumour DNA (ctDNA) is a small fraction of cfDNA found in the 
bloodstream and refers to DNA that comes from cancerous cells 64. It is characterised by the 
presence of somatic variants representative of the tumoural genetic situation 65. ctDNA levels 
change during disease progression and during chemotherapy, for this reason ctDNAs can be 
investigated not only as good candidate biomarkers for the screening of cancer patients but also 
for monitoring recurrence 66,67. In recent years, the development of highly sensitive assays that 
can detect ctDNA from plasma contributed to make it an attractive investigative modality.  
 
However, the applicability of liquid biopsy in the clinical routine, despite being a simple and non-
invasive alternative for the patients to surgical biopsies, is still in an emerging state. Recently, the 
Food and Drug Administration approved some mutation tests for DNA from plasma of patients 
with cancer. For example, a gene mutation detection system working with both DNA from tissue 
samples or cfDNA from plasma, can help to personalise treatment of breast cancer patients with 
the identification of hotspots mutations in PIK3CA 68. There is also a test for DNA from non-small 
cell lung cancer patients’ plasma able to identify mutations in one of the most common mutated 
genes for this tumour, the epidermal growth factor receptor (EGFR), that can be responsible for 
resistance to therapy 69.  
 
Figure 1.5: Liquid biopsy collection and storage. Whole blood is drawn. The plasma is then separated from the red 





In conclusion, nowadays it is possible to discover and analyse the complex mutational signature 
present in the tumoural DNA of a patient thanks to next generation sequencing techniques with 
minimal efforts and costs. These technologies have the great potential to uncover the clonal 
heterogeneity of tumours and to identify druggable targets, significant steps for targeted therapy 
advancement. Genetic panels developed by clinical molecular laboratories can assess multiple 
potential genetic causes of a tumour and meanwhile reduce the cost and time of diagnostic 
testing. In the clinic, up to the present time, approved and recognised sequencing panels that are 
tumour specific are being used; however, not all tumour patients have the possibility to be 
screened with a distinct approved genomic test. Among those patients, there are also liver cancer 
cases.  
IV. Hepatocellular carcinoma 
When a tumour cell starts to multiply and affect the liver in the first place, and it is not a metastasis 
developed from another part of the body, we talk about primary liver cancer. Primary liver cancers 
account for 4,7% of the total number of new cases of cancer worldwide every year, with >800000 
cases in 2018.  Liver cancer has its highest burden in Asian countries, where 72% of the new liver 
cancer cases worldwide per year are diagnosed 70,71. Despite in Europe it constitutes only the 
10%, the death rate is surmounting almost any other cancers, including breast, stomach and 
prostate cancers 1.  
 
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, it consists of  
approximately 85% of all primary liver cancers. The remaining 15% includes intrahepatic 
cholangiocarcinoma and extrahepatic bile-duct carcinoma 72,73. HCC has been estimated to be 
the fourth most common cause of cancer-related death overall worldwide 74 Unfortunately, the 
large global disparity in the incidence and mortality from HCC is due to the existing differences in 
assessing the disease in early or late stages, healthcare resource availability and level of 
exposure to risk factors 74,75. Less than half of the patients are eligible for curative treatments, that 
are represented by surgical resection or radiofrequency ablation of the tumour and, in the worst 
cases, liver transplantation. However these kinds of treatments are only possible if the patient is 
diagnosed at an early stage, otherwise receiving a palliative cure is the only opportunity. This is 
one of the reasons why the estimated 5-year survival rate for HCC is only 18% overall worldwide 
76.  
The majority of the HCC cases occur in patients with underlying liver diseases, mostly as a result 
of hepatitis B or C virus (HBV or HCV) infections, alcohol abuse or aflatoxin B1 (AFB1) exposure 
77. Even though HBV and HCV are the major causes of HCC, around 30% of patients do not show 
neither virus infection nor alcohol abuse, suggesting that other risk factors can have a big impact 
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on HCC development 78. In the last few decades the importance of other etiologic factors such as 
metabolic syndromes, obesity and diabetes has been investigated and it has been shown a clear 
association with HCC 79. 
 
Understanding the hidden process that goes between metabolic diseases, such as non-alcoholic 
fatty liver disease, autoimmune hepatitis, hereditary hemochromatosis and the development of 
liver tumour, but also the mechanism underlying cigarette smoking or alcohol abuse, can help us 
to increase the possibilities of cure for HCC patients. 
Prevention 
Nowadays the major part of prevention studies are focused on the main causes of HCC, the HBV 
and HCV infections. 
The first line of prevention is a vaccination against HBV. This virus is considered to be the most 
critical environmental carcinogen to which humans are exposed. This is why the World Health 
Organization recommends the vaccination especially to the newborns and to high risk adult 
subjects in all countries 80. Several studies have found evidence of efficacy of HBV vaccine and 
reduced incidence of HCC 81-83. 
On the other hand, the infection with HCV is predominantly acquired in adulthood, mainly due to 
intravenous transfusion with contaminated products. Also in this case, antiviral treatments in 
patients with HCV-related cirrhosis result in lower risk of HCC development 84,85. Interferon 
therapy is known to be used to reduce the risk of HCC in patients carrying HCV infection. 
However, it is not very efficient in patients with severe fibrosis or cirrhosis 86. Alternatively, the 
development of direct-acting antiviral agents led to a high improvement both in the response rates 
and the tolerability of treatment of HCV infected patients 87. They are protease or polymerase 
inhibitors that interfere with specific steps of the HCV replication process but the rapid evolution 
of the virus led to a wide variety of innate defence mechanisms, multidrug resistant-virus and in 
the end to the recurrence of HCC. For this reason, the debate about risk and benefit of the direct-
acting antiviral agents is still challenging 88.  
In first world countries, the only other evident line of prevention is a healthy lifestyle with low 
alcohol consumption. Patients having alcohol disorders can reduce the incidence of alcohol-
associated cirrhosis by adopting abstinence behaviour. 
In low-income countries, on the other hand, a great challenge would be to minimise both sources 
of contamination of fungus Aspergillus, the fungus that produced AFB1, and AFB1 contaminated 
food manufacturing. To change agricultural practices in regions of high dietary AFB1 intake, to 
improve storage methodologies and conditions  and to screen food to search for contaminations 
would be long term and effective lines of prevention. However, due to some countries’ resources 
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and/or education, those are difficult and ambitious solutions that cannot be easily accomplished 
and that certainly are important research areas. 
Genomic landscape  
As already mentioned, the treatment possibilities for HCC patients are not many and they often 
aim to extend lives more than cure the disease. This is because hepatocarcinogenesis is a 
complex cascade of multistep events that ends in a malignant transformation of a hepatocyte. 
When cirrhotic hyperplastic nodules are present in the liver, the regenerating hepatocytes can be 
subjected to genetic and morphological changes and form pre-malignant dysplastic lesions 89. 
This kind of lesions alters the liver architecture and they are clearly recognisable because of their 
cytological characteristics, for example for their cellular changes in shape or for the presence of 
nuclear crowding 90. Usually these lesions advance into HCC because of an accumulation of 
alterations in genes involved in one or more hallmarks of cancer pathways, creating unbalanced 
mechanisms in the cells. On average, HCCs harbour around 40 mutations in the exome, some 
are well known driver mutations and for others the role is uncertain 91,92. Despite the 
characterisation of known modified oncogenes and suppressor genes, cell cycle regulators and 
immune response genes, not all molecular pathways that play a pivotal role in liver tumour 
development are fully identified. What we know about alterations in HCC was due to next 
generation sequencing techniques that were essential in the identification of key driver mutated 
genes. One of the main investigations up to the present is a massive sequencing study performed 
on more than three hundred HCC cases by exome sequencing performed by the TCGA network 
a couple of years ago 93, showing that up to 40% of patients present mutations in TP53, PIK3CA, 
and CTNNB1 (ß-catenin). Other genes often mutated include ARID1A, ARID1B, ARID2, BAP1, 
MLL, MLL3, PBRM1 (all involved in chromatin remodelling), KEAP1, NFE2L2 (involved in the 
response to oxidative stress) and AXIN1, another component of the Wnt/β-catenin pathway 





Figure 1.6: The Genomic Landscape of Liver Hepatocellular Carcinoma. Taken from TCGA 2017 93. The illustration 
summarises the mutational signatures in their HCC cohort (n=363). The top panel shows individual tumour mutation 
rates. The middle panel details ethnicity, tumour grade, age, gender, hepatitis C virus (HCV) and hepatitis B virus (HBV) 
infection status, and cirrhosis for each patient. Bottom panel shows genes with statistically significant levels of mutation 
(MutSig suite, FDR < 0.1). The bottom six rows display significant DNA copy number alterations in likely cancer driver 
genes. Mutation types are indicated in the legend at the bottom. 
 
Even if we were able to identify common alterations in cancer related genes in HCC patients, this 
type of tumour is characterised by high heterogeneity. For example, one of the causes is the 
presence or absence of hepatitis virus infections. It has been investigated that HBV-associated 
HCCs show mutations in the Wnt/β-catenin and JAK/STAT pathways in 65.2% and 45.5% of 
cases, respectively; while HCV-associated HCCs have 62.5% of mutations in CTNNB1. Alcohol-
associated HCCs, instead, show mutations principally in chromatin remodelling genes 91,92. One 
of the many interesting discoveries derived from the analysis of the mutational landscape is the 
high presence of mutations in the promoter of the  telomerase reverse-transcriptase (TERT) gene, 
present in more than half of all HCC cases 96. TERT gene codes for telomerase, one of the 
fundamental elements for aging in the cells, and therefore one of the molecular components 
involved in tumourigenesis. In the recent years mutations in TERT were found in several tumours 
97,98 and they were also found to be associated with cirrhosis in humans 99. These studies show 
that these mutations in the promoter could not only increase the promoter activity and therefore 
TERT transcription in general, but also create a potential binding site for other unusual 
transcription factors.  
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When talking about the HCC landscape, it is also important to mention the copy number 
alterations (CNAs). As for other, in HCC cases gains and losses are in specific chromosomal 
regions (for example, gain of chromosomes 1q, 5, 6p, 7, 8q, 17q, and 20, and loss of 1p, 4q, 6q, 
8p, 13q, 16, 17p and 21 are the most frequent). Deletions in CDKN2A-CDKN2B were identified 
in 6.4% of cases, followed by deletions in AXIN1 (3.2%) and IRF2 (3.2%) 91,92. 
 
Thanks to modern sequencing techniques, a significant number of HCCs has been analysed. The 
characterisation not only at genomic level but also at transcriptional level, opened the possibility 
to the identification of molecular subtypes for HCC. Several research were performed to address 
this question, but the complexity and the heterogeneity of this kind of tumour did not allow a 
recognised unique classification. There are classifications based on transcription data correlated 
with clinical and molecular features 100 and on differences in the rate of chromosomal instability 
101. The classification proposed by the most recent TCGA study, already mentioned previously 93, 
is based on genetic (CNAs) and transcription data. Each subgroup was characterized by clinical 
associations. Briefly, they divided HCC tumours in three subgroups: iClust 1 (main features: high 
vascular invasion and tumour grade, low rate of CTNNB1, TERT and HNF1A mutations); iClust2 
(low vascular invasion and tumour grade, high rate of CTNNB1,TERT and HNF1A mutations); 
iClust3 (high rate not only of CTNNB1, TERT and HNF1A mutations, but also of TP53 mutations 
and chromosome instability). Additionally to these components, they also added the correlation 
of epigenetic features, by analysis of DNA methylation profile, microRNA and protein expression, 
performed only in some of HCC cases of their cohort. To investigate the epigenetic of HCC is 
indeed the new frontier for the characterisation of HCC tumours. 
 
In conclusion, the heterogeneity as well as the background aetiology might also be responsible 
for differential mutation rates of cancer drivers and associated pathways among different studies. 
The majority of genetic studies in HCC have been performed using comprehensive sequencing 
panels, or straight to whole exome sequencing 102-104. So far, the majority of the genes often 
mutated only in HCC but rarely in other tumours (such as those important for hepatocyte 
differentiation and inflammatory response in liver) are not or partially targeted in commercially 
available panels. 
V. HMGA1 
HMGA protein family 
The High Mobility Group A (HMGA) protein family is a group of small non-histone nuclear proteins 
known as ‘architectural transcriptional factors’. The HMGA gene family consists of the HMGA1 
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(human chr 6p21) and HMGA2 (human chr 12q14) genes. The HMGA1 gene contains 8 exons 
distributed over a region of about 10 kb while the HMGA2 gene contains 5 exons distributed over 
a much larger genomic region of about 160 kb, because of its longer untranslated regions and 
introns 105.  
HMGA1 and HMGA2 together encode four proteins: HMGA1a, HMGA1b, HMGA1c and HMGA2 
106. HMGA1a and HMGA1b are encoded by the HMGA1 gene and are isoforms assembled 
through alternatively spliced mRNA that differ by 11 amino acid residues between the first and 
the second AT-hook domains (107 and 96 amino acids, respectively). HMGA1c (156 amino acid) 
is the rarest and most recently identified isoform 107. It is also encoded by the HMGA1 gene by 
alternative splicing using non-canonical splice donor and acceptor sites. This alternative splicing 
results in a frame shift such that HMGA1a and HMGA1c are identical in their first 65 amino acids 
but differ thereafter 107. HMGA2 (109 amino acid) is encoded by the HMGA2 gene and presents 
a structure very similar to HMGA1b, but contains a short peptide of 12 amino acid residues 
between the third AT-hook and the acidic C-terminal 108,109. All the proteins in the HMGA family 
contain three basic “AT-hook” domains and an acidic C-terminal region that allow them to bind 
AT-rich DNA sequences in the minor groove of the double helix (Figure 1.7) 108,109. 
 
 
Figure 1.7: Characteristics of the HMGA genes and proteins. Taken from Fusco 2007 108. 
 
The expression of HMGA proteins is high during embryogenesis whereas it is undetectable or 
very low in differentiated adult tissues, except for a few specific tissues such as the testis and the 
thymus 105,110. Nonetheless, especially HMGA1 was found to be again highly expressed in a broad 
range of malignancies 111-121. For this reason, several  studies have been tried to elucidate its role 
in cell transformation and its mechanism of action. To date, the discoveries reveal a complex 
situation, with numerous interaction systems for both DNA and transcription factors 122-127.  
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Mechanisms of action  
The most studied mechanism of action of HMGA proteins is represented by the interaction and 
the binding with the DNA and the following recruitment of transcription factors. HMGA proteins 
bind the DNA, at that point they bind transcription factors, both with a direct and indirect binding, 
to form macromolecular complexes and together they can promote or repress the expression of 
target genes 128,129. Another way HMGA proteins use to modify gene transcription is by binding 
with a transcription factor, therefore they are able to modify its conformation and improve its DNA 
binding affinity 108,130. Finally, HMGA proteins can alter the chromatin structure 131. For example, 
it has been shown that HMGA1 competes with histone H1, is able to displace it, to open the minor 
groove and to facilitate the recruitment of transcription factors 132. For these reasons, whilst 
HMGA1 does not have transcriptional activity per se, its overexpression could trigger the 
deregulation of oncogene and tumour suppressor gene expression, leading to transformation and 
cancer progression 108,115. It is indeed acknowledged that HMGA1 proteins participates in a myriad 
of cellular processes implicated by all hallmarks of cancer 133, including cell cycle regulation and 
chromosomal changes, DNA replication and repair, apoptosis, but also mitochondrial function and 
retroviral integration 134-140. Figure 1.8 simplifies the complexity of HMGA1 networks in cancer 





Figure 1.8: HMGA1 networks involve all hallmarks of cancer. Taken from Sumter et al. 2016 133. 
HMGA1 and its role in carcinogenesis 
HMGA1 overexpression was first associated with the neoplastic phenotype in rat thyroid 
transformed cells 141 and it has been described since in many human carcinomas, including those 
of the colon, breast, pancreas, ovary, lung, oesophagus, amongst others 111-120. Importantly, the 
expression level of HMGA1 has been found to correlate with the aggressiveness of colorectal 
carcinomas 110,112. HMGA1 overexpression is associated with invasion-positive and advanced 
staged colorectal carcinomas and with the presence of distant metastasis. To further support the 
role of HMGA1 in tumour progression, its expression levels have been found to be associated 
with histologic grades of breast and ovarian carcinomas, where HMGA1 expression increases 
progressively from no expression in normal breast tissue, to moderate expression in hyperplastic 
lesions to strong overexpression in ductal carcinomas 114, and from a weak expression in ovarian 
carcinomas with low invasive potential to high expression in invasive carcinomas 115.  
 
Regarding its molecular targets, it was recently demonstrated that HMGA1 binds to the AT-rich 
promoter of osteopontin, a protein involved in the acquisition of fully transformed features in 
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human carcinomas 142. Not only is HMGA1 able to bind the osteopontin promoter, it is also able 
to compete and interfere with other regulators of transcription present in the same sites of this 
promoter 142. Conversely, HMGA1 binding to the promoter regions of TP53 results in negative 
transcriptional regulation 143. Furthermore, several studies have demonstrated that HMGA1 
directly activates specific gene-subsets involved in tumour growth, migration, invasion, resistance 
to drug-induced cell death as well as to epithelial-mesenchymal transition in cancer cells 142,144,145. 
Another study describes how HMGA1 promotes an undifferentiated pluripotent stem-like cell state 
throughout the induction of several genes including SOX2, LIN28 and cMYC 143,146. In human 
embryonic stem cells, HMGA1 binds to the promoters of these genes, thus suggesting that it can 
directly regulate their expression 147. In fact, direct evidence of the role of HMGA1 in 
carcinogenesis, tumour progression and induction of stem-like properties has been provided in 
several experimental animal models 148-151. These data demonstrate the multi-faceted function of 
HMGA1 and the intricate ways it regulates other cellular processes implicated in carcinogenesis. 
Despite the molecular characterisation of HMGA1 function carried out to date, a systematic 
analysis of the genes directly and/or indirectly regulated by HMGA1 have not been performed.   
HMGA1 and HCC 
The locus where HMGA1 is located is gained in around 40% of HCCs 91. An early study suggested 
that HMGA1 is expressed in 30% of primary HCC on the mRNA level and 13% on the protein 
level 152. It should be noted that in this study, HMGA1 expression was only assessed in treated 
HCCs and thus HMGA1 levels may have been altered as a result of treatment. Moreover, earlier 
iterations of HMGA1 antibodies were fraught with issues of specificity. More recently, the 
expression of HMGA1 in HCC cases was investigated by my team in our laboratory 121. HMGA1 
expression was evaluated in two independent cohorts of 59 and 192 HCC cases through gene 
expression microarray and immunohistochemistry. We demonstrated that HMGA1 levels increase 
through progression stages from normal liver to HCC, both at mRNA and protein levels. 
Furthermore, we showed that more than 50% of HCCs are HMGA1-positive and this high 
expression is associated with poor prognosis. Finally, functional examinations supported the 
involvement of HMGA1 in cell growth and migration in liver cancer cells 121. 
 
All these findings demonstrated not only an overexpression of HMGA1 in the HCC context, but 
also evidence that HMGA1 confers a neoplastic advantage to liver cancer cell lines. However, 
given its multifaceted functions, HMGA1 cannot currently be exploited as a therapeutic target and 




2- Rationale and Aims of the Thesis 
 
The main objective of my project was to investigate new diagnostic and prognostic markers, both 
on a genetic and molecular level, in the context of hepatocellular carcinoma (HCC). A better 
understanding of these mechanisms may guide alternative target therapies for HCC patients. 
 
In Chapter I, we aimed to develop an HCC-specific custom made sequencing panel using the Ion 
Torrent platform, containing the genes and loci most commonly affected by somatic mutations 
and copy number alterations (CNAs) in HCC. We wanted to create a panel that generates reliable 
data using all kinds of patient biopsies, from frozen to formalin-fixed paraffin-embedded (FFPE) 
tissues to liquid biopsies. Moreover, we wanted to make the analysis user friendly but reliable and 
reproducible and, with the work of the bioinformaticians in our laboratory, we created a somatic 
variant calling pipeline specific for Ion Torrent sequencing data.  
 
In Chapter II, we focused our work on the investigation of the oncogenic role of HMGA1 in HCC. 
This protein is often overexpressed in many types of cancers including HCC, in which we 
demonstrated that HMGA1 levels increase through progression stages from normal liver to HCC 
121. To better understand the significance of HMGA1 overexpression, we aimed to molecularly 
characterise HMGA1 and to explore its molecular targets in the HCC in vitro environment.     
 
Both chapters underline the importance of the discovery and the functional understanding of 
tumour markers and their molecular mechanisms in HCC. The findings may lead to more 






3.1- Chapter I 
Design and validation of a custom made 
sequencing panel for the screening of 
HCC somatic mutations 
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Hepatocellular carcinoma (HCC), as the other type of cancer, presents a distinct mutational 
landscape. There are numerous genes commonly mutated in HCC but not frequently in other 
tumours that are currently not targeted, or are only partially targeted, in commercial sequencing 
panels. Our objective was to construct a high-throughput and cost effective sequencing panel 
specifically to screen for the most common somatic alterations in HCC. We wanted to develop a 
sequencing-panel applicable for frozen tissues but also with low input material such as formalin-
fixation and paraffin-embedded (FFPE). Moreover, we wanted to be valuable also if used with 
plasma derived cell-free DNA (cfDNA). Last but not least, we developed a high sensitive and 
specific somatic variant calling pipeline to use to analyse this kind of sequencing data.  
 
This chapter contains my work on the design, the validation and the feasibility of this HCC specific 
sequencing panel and its use to identify alterations in HCC patients. It is divided in three parts, 
resulting in three manuscripts reported after the summary of the comprehensive work.  
 
The first one, “Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic 
Screening”, aimed to design an amplicon-based sequencing panel for Ion Torrent technology, the 
most available and economical sequencing methods in diagnostic laboratories. The design of the 
panel was performed using genomic regions frequently altered in HCC according to publicly 
available data, as explained in details in the manuscript. The panel testing was achieved using a 
cohort of fresh frozen and FFPE biopsies of HCC tissue samples and the results were compared 
to the  results obtained by whole exome sequencing (WES) performed on the same samples. All 
but one mutation identified from WES were detected by using our custom HCC panel. Additional 
mutations within the coding regions were identified thanks to the higher depth of the sequencing 
obtained with the panel compared to WES. Moreover, several mutations detected with the HCC 
panel were within the promoter and long non-coding RNA (lncRNA) regions, so not possible to be 
found by WES and not currently targeted by commercial panels. We demonstrated that our 
custom panel is high-throughput and cost effective and allows the screening for somatic 
alterations specific for HCC samples even with the use of low-input DNA. Furthermore, we 
demonstrated that, using this kind of samples, it is also possible to detect copy number variations 
in genes commonly gained or lost in HCC.  
 
Because of the invasive nature of tissue biopsies, plasma-derived cfDNA is becoming a new 
potential alternative to tissue biopsies for the screening of mutations for detection and surveillance 
of the tumour. In the second part of this chapter, “Genetic profiling using plasma-derived cell-free 
DNA in therapy-naïve HCC patients: a pilot study”, we explored whether somatic mutations in 
HCC driver genes could be detected with high confidence using our custom amplicon-based 
sequencing panel in the cfDNA of HCC patients who have not undergone systemic therapy. We 
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used blood samples synchronously collected with a core needle tumour biopsy from a prospective 
cohort study and we determined if the range of mutations in the cfDNA is representative of the 
tumour biopsy. The potential of liquid biopsy-based biomarker identification led us to a publication 
of another study aimed to evaluate the feasibility of cfDNA extraction and somatic mutation 
assessment in 30-year-old sera that had been collected from patients with breast cancer (see 
Annex). Our conclusions support the robustness of current next generation sequencing to 
accurately sequence cfDNA to detect cancer-specific mutations in these old samples, despite the 
long cryopreservation and repeated changes of storage location. These findings encourage the 
use of long-term storage of biological samples in longitudinal studies prior to analysis, with the 
possibility to assess the prognostic role of pathogenic mutations in cfDNA present at diagnosis 
by comparing overall and relapse-free survival between patients with or without specific 
mutations.  
 
The third part, “PipeIT: A Singularity Container for Molecular Diagnostic Somatic Variant Calling 
on the Ion Torrent Next-Generation Sequencing Platform”, is our solution to the extensive manual 
review of the results required for a diagnostic laboratory to analyse somatic mutations data 
obtained by Ion Torrent sequencing platforms. Moreover, the lack of optimised analysis workflows 
for custom targeted sequencing panels usually lead  to poor reproducibility and portability. Thanks 
to our bioinformaticians, we developed PipeIT, a stand-alone singularity container of a somatic 
mutation calling and filtering pipeline for matched tumour-normal Ion Torrent sequencing data, 
able to generate data with high positive predictive value and high sensitivity. This pipeline ensures 
the reproducibility of data and reduces the need for manual curation of the results. 
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Commercially available targeted panels miss genomic regions frequently altered in hepatocellular
carcinoma (HCC). We sought to design and benchmark a sequencing assay for genomic screening of HCC.
We designed an AmpliSeq custom panel targeting all exons of 33 protein-coding and two long non-
coding RNA genes frequently mutated in HCC, TERT promoter, and nine genes with frequent copy
number alterations. By using this panel, the profiling of DNA from fresh-frozen (nZ 10, 1495!) and/or
formalin-fixed, paraffin-embedded (FFPE) tumors with low-input DNA (n Z 36, 530!) from 39 HCCs
identified at least one somatic mutation in 90% of the cases. Median of 2.5 (range, 0 to 74) and 3
(range, 0 to 76) mutations were identified in fresh-frozen and FFPE tumors, respectively. Benchmarked
against the mutations identified from Illumina whole-exome sequencing (WES) of the corresponding
fresh-frozen tumors (105!), 98% (61 of 62) and 100% (104 of 104) of the mutations from WES were
detected in the 10 fresh-frozen tumors and the 36 FFPE tumors, respectively, using the HCC panel. In
addition, 18 and 70 somatic mutations in coding and noncoding genes, respectively, not found by WES
were identified by using our HCC panel. Copy number alterations between WES and our HCC panel
showed an overall concordance of 86%. In conclusion, we established a cost-effective assay for the
detection of genomic alterations in HCC. (J Mol Diagn 2018, 20: 836e848; https://doi.org/10.1016/
j.jmoldx.2018.07.003)
Sequencing technologies have allowed the discovery of
genetic alterations essential in the diagnosis and treatment of
human cancer or approval of new targeted therapies.1 In
addition, the presence of subclonal mutations has direct
implications in the development of drug resistance.2,3 In the
era of precision medicine, the development of rapid, accu-
rate, high-throughput, and cost-effective genomic assays to
accommodate the increasingly genotype-based therapeutic
approaches is required.4,5 Currently, the costs of whole-
genome and whole-exome sequencing (WES) are still
prohibitive in the clinical setting, especially for small
institutions. Furthermore, although DNA from fresh-frozen
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tissue is ideal for genomic screening, it is not part of routine
diagnostic practice at most hospitals and institutions.
Instead, DNA from formalin-fixed paraffin-embedded
(FFPE) material is frequently the only option. Moreover,
DNA from small tumors, after reserving materials for his-
topathologic analyses, may be extremely limited. For
research institutes, being able to exploit and revisit archival
materials associated with long-term follow-up but whose
DNA may potentially be degraded is also highly desirable.
Given these limitations, PCR-based sequencing panels may
be more broadly applicable than capture-based solutions.
Existing commercial sequencing panels, such as the
amplicon-based Ion Torrent Oncomine Comprehensive
Assay version 3 (Thermo Fisher Scientific, Waltham, MA)
and the capture-based Foundation Medicine FoundationOne
assay, are broadly applicable to common cancer types.
Compared with other common cancer types, however, he-
patocellular carcinoma (HCC) has a distinct mutational
profile. Although HCC driver genes TP53 and CTNNB1 are
also frequently mutated in cancers such as those of the
lungs, the breasts, and colon,6 genes such as APOB, ALB,
HNF1A, and HNF4A are significantly mutated only in
HCC.7e17 The distinct mutational landscape of HCC is
likely a result of the unique biology of hepatocyte differ-
entiation and liver functions. Of note, the frequently altered
APOB, ALB, and HNF4A are not targeted by most com-
mercial assays. In the noncoding regions, recent commer-
cially available panels include TERT promoter mutation
hotspot (c.-124C>T). However, long noncoding RNA
(lncRNA) genes frequently mutated in HCC, such as
MALAT1 and NEAT1,16 have yet to be included in
commercial panels or in exome capture panels. Recent
whole-genome studies have also uncovered mutation clus-
ters in promoter regions of genes such as MED16, WDR74,
and TFPI216,18 that are not covered in commercial panels.
In this study, we designed a high-throughput and cost-
effective amplicon-based sequencing panel specifically to
screen for somatic mutations and copy number alterations
(CNAs) in HCC. Our panel includes genes and regions
frequently altered in HCC, including those not currently
covered by commercial panels. We tested the sequencing
panel by using fresh-frozen and FFPE materials with
low-input DNA to evaluate the feasibility of this panel in
routine diagnostics.
Materials and Methods
Targeted Panel Design and Generation
A custom targeted sequencing panel that focused on the
most frequently altered genes in HCC7e18 was designed by
using Ion Ampliseq Designer (Thermo Fisher Scientific).
The panel (hereafter the HCC panel) covers all exons of 33
protein-coding genes; recurrently mutated lncRNA genes
MALAT1 and NEAT1; and the recurrently mutated promoter
regions of TERT, WDR74, MED16, and TFPI2 (Figure 1A
and Supplemental Table S1).7e18 Nine genes frequently
altered by CNAs and mutation hotspots in seven cancer
genes are also covered (Figure 1A and Supplemental Table
S1).7e18 The HCC panel was designed by using the FFPE
option for smaller amplicon size. The nine genes for CNA
profiling were designed to be covered by at least 10 non-
overlapping amplicons evenly distributed across the length
of the genes. The designed panel was further inspected by
Figure 1 Design of the hepatocellular carcinoma (HCC) sequencing panel and the
study. A: Frequencies of somatic mutations and copy number alterations in the genes
included on the HCC panel according to previously published studies.10,15e17 B: Outline of
the study with the number of samples for each analysis performed. CNA, copy number
alteration; FFPE, formalin-fixed, paraffin-embedded; prom, promoter; TCGA, The Cancer
Genome Atlas; WES, whole-exome sequencing.
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the white glove service (Thermo Fisher Scientific) for
primer specificity in a multiplex PCR reaction. The HCC
panel consists of 2120 amplicons split into two primer pools
and covers genomic regions of approximately 203 kb.
Tissue Samples
Human tissues were obtained from patients undergoing
diagnostic liver biopsy at the University Hospital Basel,
Basel, Switzerland. Written informed consent was obtained
from all included patients. Ultrasound-guided needle bi-
opsies were obtained from tumor lesion(s) and adjacent
nontumoral liver tissue (Figure 1B). The study was
approved by the ethics committee of the northwestern part
of Switzerland (protocol EKNZ 2014-099). For all patients
except cases 2, 6, 7, and 9, a single tumor biopsy was
included (Supplemental Table S2). For cases 6 and 7, two
tumor biopsies were included, and for cases 2 and 9, three
tumor biopsies were included. A portion of each biopsy was
FFPE for clinical purposes, and the remaining portion of
each biopsy was snap-frozen and stored at "80#C for
research purposes. For this study, 45 fresh-frozen tumor
biopsies and 39 fresh-frozen nontumor biopsies from 39
patients were included. FFPE tissue samples that remained
after diagnostic routine (36 tumor biopsies and 31 nontumor
biopsies from 36 patients) were included. Pathologic
assessment of tumor content was performed by two expert
hepatopathologists (M.S.M. and L.M.T.) with the use of
diagnostic hematoxylin and eosin slides.
DNA Extraction
DNA from fresh-frozen biopsies was extracted by using the
ZR-Duet DNA/RNA MiniPrep Plus kit (Zymo Research,
Irvine, CA) according to the manufacturer’s instructions.
Before extraction, tissue samples were crushed in liquid ni-
trogen to facilitate lysis. For DNA extraction from FFPE
samples, one 5-mmethick slide was cut directly in the tube,
and DNA was extracted with the DNeasy Blood and Tissue
Kit (Qiagen, Hilden, Germany) according to manufacturer’s
instructions as previously described.19,20 DNA was quantified
by using the Qubit Fluorometer (Thermo Fisher Scientific).
Library Preparation and Deep Sequencing Using the
HCC Panel
Library preparation for the HCC panel was performed by
using the Ion AmpliSeq library kit version 2.0 (Thermo
Fisher Scientific) according to the manufacturer’s guide-
lines. For cases 2, 6, 7, and 9, DNA extracted from multiple
fresh-frozen tumor biopsies was pooled equimolar before
library preparation (Supplemental Table S2). In total, 20
fresh-frozen samples (10 tumor samples and 10 nontumoral
counterparts) and 67 FFPE samples (36 tumor biopsies and
31 nontumoral counterparts) were sequenced by using the
HCC panel.
The HCC panel consists of two pools of amplification
primers. Ten nanograms of DNA per sample was used for
library preparation for each pool. Amplification was per-
formed according to the manufacturer’s guidelines. The
amplicons from the two pools were combined and treated to
digest the primers and to phosphorylate the amplicons. The
amplicons were then ligated to Ion Adapters (Thermo Fisher
Scientific) by using DNA ligase. Finally, cleaning and pu-
rification of the generated libraries were performed with
Agencourt AMPure XP (Beckman Coulter, Brea, CA)
according to the manufacturer’s guidelines. Quantification
and quality control were performed with the Ion Library
TaqMan Quantitation Kit (Thermo Fisher Scientific). Sam-
ples were diluted to reach the concentration of 40 pmol and
then were pooled for sequencing. Twenty-five mL of the
pooled libraries was loaded on Ion 530 Chip (Thermo Fisher
Scientific) and processed in Ion Chef Instrument (Thermo
Fisher Scientific). Sequencing was performed on Ion S5 XL
system (Thermo Fisher Scientific).
Sequence Data Analysis for the HCC Panel
Sequence reads were aligned to the human reference genome
hg19 by using TMAPwithin the Torrent Suite Software version
5.4 (ThermoFisher Scientific;https://github.com/iontorrent/TS)
for the Ion S5XL system. Coverage analysis was performed by
using Picard’s CollectTargetedPcrMetrics tool version 2.4.1
(http://broadinstitute.github.io/picard) (Supplemental Table
S3). Uniformity of sequencing was defined as the proportion
of target bases covered at >20% of mean amplicon coverage
for a given sample. Comparison of the coverage for the two
primer pools was performed by using paired Wilcoxon test.
Somatic mutations were identified with Torrent Variant
Caller version 5.0.3 (Thermo Fisher Scientific; https://github.
com/iontorrent/TS). For fresh-frozen samples, the corre-
sponding fresh-frozen nontumoral samples were used as the
germline control. For FFPE samples, FFPE nontumoral sam-
pleswere used as thematched germline sample when available.
When FFPE nontumoral samples were not available, the cor-
responding fresh-frozen nontumoral samples were used as
germline control. Mutations at hotspot residues were white-
listed.21,22 Mutations supported by <8 reads, and/or those
covered by<10 reads in the tumor or<10 reads in thematched
nontumoral counterpart were filtered out. Only those for which
the tumor variant allele fraction (VAF) was >10 times that of
the matched nontumoral VAF were retained to ensure the so-
matic nature of the variants. Because of the repetitive nature
and the high GC content of the TERT promoter region, TERT
mutation hotspots (chr5:1295228 and chr5:1295250) were
additionally screened. TERT promoter mutations were
considered present if supported by at least five reads or VAF of
at least 5%. All mutations were manually inspected by using
the Integrative Genomics Viewer version 2.3.69 (https://
software.broadinstitute.org/software/igv).23
CNAs were defined as follows. For each sample, end-to-
end sequence reads were extracted separately for the two
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amplicon pools. A copy number reference for each pool was
generated by using all nontumoral samples to estimate
overall read depth, log2 ratio, and variability by using the
reference function from CNVkit version 0.9.0 (https://
github.com/etal/cnvkit).24 Amplicons with <100 read
depth, absolute log2 ratio >1.5, or spread >1 were removed
from copy number analysis. Protein-coding genes for which
the complete coding region was included in the panel or for
which amplicons were specifically designed for copy num-
ber analysis were included. Samples with excessive residual
copy number log2 ratio (segment interquartile range >0.8)
were excluded, as previously described.25
For each tumor/nontumor pair, log2 ratio was computed for
each amplicon, separately for the two amplicon pools by using
Varscan2 version 2.4.3 (https://github.com/dkoboldt/
varscan).26 Log2 ratios for the two pools were separately
centered thenmerged for segmentation by using circular binary
segmentation.27 CNAs were determined, adopting a previously
described approach.20 In brief, SD of the log2 ratios of the 40%
of the central positions ordered by their log2 ratios was
computed. Copy number gains and amplifications/high gains
were defined as þ2 SDs and þ6 SDs, respectively. Copy
number losses and deepdeletionswere definedas"2.5 SDs and
"7 SDs, respectively. All gene amplifications and deep de-
letions were visually inspected by using log2 ratio plots.
To evaluate the impact of tumor purity on CNA analysis,
an in silico simulation was performed on 12 cases (six
frozen and six FFPE, selected on the basis of the presence of
gene amplification/high gain or deep deletion), by replacing
tumor reads with reads sampled from the normal samples to
simulate tumor content 5%, 10%, 20% up to the actual
tumor content for the samples. CNA analysis was performed
as described above.
WES
WES was performed for DNA extracted from the 45 tumor
biopsies and 39 nontumoral counterparts from the 39




Figure 2 Coverage analyses and statistics of the hepatocellular carcinoma (HCC) panel. A: Distribution of the amplicon sizes on the HCC panel. B: Violin
plots of the mean amplicon coverage across fresh-frozen nontumor; fresh-frozen tumor; formalin-fixed, paraffin-embedded (FFPE) nontumor; and FFPE tumor
samples. C: Coverage uniformity, defined as the percentage of target bases covered at >20% of the mean coverage, in fresh-frozen and FFPE nontumor
samples. D: Percentages of target regions covered at various depths (1!, 2!, 10!, 20!, and 30!) across fresh-frozen nontumor, fresh-frozen tumor, FFPE
nontumor, and FFPE tumor samples. E: Scatter plot of GC content and mean normalized coverage for all amplicons in fresh-frozen and FFPE samples. Color of
the dots indicates the SD of mean normalized coverage within each group. Dashed red lines indicate the mean normalized coverage at 0.1 and 0.05.
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patients (Supplemental Table S2). Whole-exome capture
was performed by using the SureSelectXT Clinical Research
Exome (Agilent, Santa Clara, CA) platform according to the
manufacturer’s guidelines. Sequencing (2 ! 101 bp) was
performed at the Genomics Facility of ETH Zurich
Department of Biosystems Science and Engineering (Basel,
Switzerland) by using Illumina HiSeq 2500 (Illumina, San
Diego, CA) according to the manufacturer’s guidelines.
Sequence reads were aligned to the reference human
genome GRCh37 by using Burrows-Wheeler Aligner-MEM
version 0.7.12 (http://bio-bwa.sourceforge.net).28 Local
realignment, duplicate removal, and base quality adjustment
were performed by using the Genome Analysis Toolkit
version 3.6 (https://software.broadinstitute.org/gatk)29 and
Picard version 2.4.1 (http://broadinstitute.github.io/picard).
For WES samples, sequence reads overlapping with the
target regions of the HCC panel were extracted for further
comparative analyses. Sequencing statistics were evaluated for
the overlap of the target regions of the WES and the HCC
panel. For cases 2, 6, 7, and 9, for which DNA from multiple
fresh-frozen tumor biopsies was pooled before sequencing by
using the HCC panel, WES reads from the multiple biopsies
were merged to facilitate downstream comparisons. For all
four cases, the number of reads obtained from WES of indi-
vidual biopsies was comparable (Supplemental Table S3).
Somatic single nucleotide variants and small insertions and
deletions (indels) were detected by using MuTect version 1.1.4
(https://software.broadinstitute.org/cancer/cga/mutect)30 and
Strelka version 1.0.15 (https://github.com/Illumina/strelka),31
respectively. Single nucleotide variants and small indels
outside of the target regions, those with VAF of <1%, and/or
those supported by<3 reads were filtered out. Only variants for
which the tumor VAF was >5 times that of the matched
nontumoral VAF were retained. Further, variants identified in
at least two of a panel of 123 nontumoral liver tissue samples,
using the artifact detection mode of MuTect2 implemented in
Genome Analysis Toolkit version 3.6 were excluded,29 where
the panel of 123 nontumoral liver tissue samples included the
39 nontumoral samples in the present study and were captured
and sequenced with the same protocols. All indels were
manually inspected by using the Integrative Genomics
Viewer.23 Copy number analysis was performedwith FACETS
version 0.5.13 (https://github.com/mskcc/facets),32 and genes
targeted by amplifications or deep deletions were defined by
using the same thresholds as above.
Pairwise Comparisons between Mutations Identified by
WES, Fresh-Frozen and FFPE Tissues
Pairwise comparisons of the somatic mutations identified by
WES and by the HCC panel were performed, according to
the originating biopsies (Supplemental Table S2). Discor-
dant variants were reevaluated and interrogated for their
presence by supplying Torrent Variant Caller version 5.0.3
with their positions as the hotspot list (for Ion Torrent
sequencing) or by Genome Analysis Toolkit version 3.6
Unified Genotyper by using the GENOTYPE_GIVE-
N_ALLELES mode (for WES).
Sanger Sequencing
To validate the discordant variants, Sanger sequencing was
performed on both DNA from the fresh-frozen and the corre-
sponding FFPE tumor biopsies. PCR amplification of 5 ng of
genomic DNA was performed with the AmpliTaq 360
Master Mix Kit (Thermo Fisher Scientific) on a Veriti Thermal
Cycler (Thermo Fisher Scientific) as previously described
(Supplemental Table S4).20 PCR fragments were purified with
ExoSAP-IT (Thermo Fisher Scientific). Sequencing reactions
were performed on a 3500 Series Genetic Analyzer instrument
by using the ABI BigDye Terminator chemistry version 3.1
(Thermo Fisher Scientific) according to the manufacturer’s in-
structions. All analyseswere performed in duplicate. Sequences
of the forward and reverse strands were analyzed with Mac-
Vector software version 15.1.3 (MacVector, Inc., Apex, NC).20
Analysis of TCGA Data
To determine the frequencies of high-level copy number
gains/focal amplifications and deep deletions/focal homo-
zygous deletions in HCC, the GISTIC 2.0 copy number
calls for The Cancer Genome Atlas (TCGA) HCC cohort
from the cBioPortal were obtained.33 High-level gains and
deep deletions were defined as those with GISTIC copy
number state 2 and "2, respectively. Focal amplifications
and focal homozygous deletions were defined as high-level
gains and deep deletions that affected <25% of a given
chromosome arm. For the 37 genes included in the copy
number analysis, the frequencies of high-level gains/deep
deletions and of focal amplifications/focal homozygous
deletions were computed.
Statistical Analysis
Correlation analyses were performed with Pearson’s r and
r2. Statistical analyses were performed in R version 3.4.2
(The R Foundation, Vienna, Austria).
Results
HCC-Specific Custom Targeted Sequencing Panel
Design and Quality Assessment
An HCC sequencing panel was designed to specifically
target genes and genomic regions frequently altered in
HCC7e18 (Figure 1A and Supplemental Table S1). The
HCC panel consisted of complete coding regions of 33
genes involved in several pathways implicated in HCC
pathogenesis, including the WNT pathway (CTNNB1,
AXIN1), chromatin remodeling (ARID1A, ARID2, and
BAP1), cell cycle regulation (CDKN1A, CDKN2A,
CDKN2B, CCND1, RPS6KA3, RB1, and TP53),
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inflammatory response (IL6R, IL6ST ), and hepatocyte dif-
ferentiation (ALB, APOB, HNF1A, and HNF4A). In addi-
tion, the HCC panel also targeted recurrently mutated
lncRNA genes MALAT1 and NEAT1 and recurrently
mutated promoter regions of TERT, WDR74, MED16, and
TFPI2. Genes frequently altered by CNAs (eg, CCNE1,
VEGFA, TERT ) and mutation hotspots in BRAF, EEF1A1,
HRAS, IL6ST, KRAS, NRAS, and PIK3CA were also tar-
geted. To enable the efficient profiling of DNA samples
derived from potentially degraded FFPE materials, the panel
was designed by using the FFPE option for smaller ampli-
con size, with a mean amplicon size of 118 bp (range, 63 to
252 bp) (Figure 2A). The HCC panel was tested on the
DNA extracted from 20 fresh-frozen samples (10 from
tumor biopsies and 10 from nontumoral counterparts) and
67 FFPE samples (36 from tumor biopsies and 31 from
nontumoral counterparts) obtained from 39 patients
(Figure 1B and Supplemental Table S2).
A coverage analysis of the HCC panel was performed with
the 10 fresh-frozen and 31 FFPE nontumoral DNA samples. In
the fresh-frozen and FFPE nontumoral DNA samples, a mean
coverage of 1478! (range, 925! to 2420!) and 580! (range,
263! to 1300!), respectively, were achieved (Figure 2B and
Supplemental Table S3). No difference was found between the
depth of coverage of the two pools of amplicons (PZ 0.9879,
paired Wilcoxon test) (Supplemental Figure S1A). At least
96.8% and 91.1% of the amplicons were covered at>30! and
at least 98.7% and 95.6% of the amplicons were covered at
>10! in the fresh-frozen and FFPE nontumor samples,
respectively (Figure 2C and Supplemental Figure S1B). Me-
dian uniformity (defined as the proportion of target bases
covered at >20% of the mean amplicon coverage of a given
sample)was89.9% (range, 86.8% to91.5%) in the fresh-frozen
samples and 89.0% (range, 73.3% to 92.3%) in the FFPE
samples (Figure 2D). As expected, depth of sequencing of the
ampliconswas associatedwithGCcontent, with reduced depth
at extreme GC content (Figure 2E).
HCC Panel Captures Somatic Mutations Concordant
with WES and Identifies Additional Mutations
Next, the somatic mutations identified in the 10 fresh-frozen
tumor/nontumoral pairs sequenced with the HCC panel
were evaluated. A median sequencing depth of 1495!
(range, 1026! to 1855!) in the tumor samples was ach-
ieved (Figure 2B and Supplemental Table S3). A median of
2.5 somatic mutations (range, 0 to 74 somatic mutations)
were identified, including a median of 2 mutations (range,
0 to 52 mutation) in protein-coding genes (Figure 3A and
Supplemental Table S4). No somatic mutations were iden-
tified for 2 of 10 cases (cases 3 and 12), although both cases
had %50% tumor cell content (Supplemental Table S2). One
case (case 9) exhibited a hypermutator phenotype with 74
somatic mutations identified.
To evaluate the somatic mutations defined with the HCC
panel, the somatic mutations derived fromWES, generated on
the orthogonal Illumina technology, of the sameDNA aliquots
from the fresh-frozen tumors and matched nontumor samples
were used as a benchmark (Figure 1B). By considering only
the coding regions covered by the HCC panel, the median
depths of WES were 114! (range, 92! to 345!) and 51!
(range, 45! to 84!) in the fresh-frozen tumors and matched
nontumor samples, respectively (Supplemental Table S3).
WES analysis confirmed that nomutations were present within
the targeted protein-coding regions in cases 3 and 12 and that
case 9 was hypermutated (Figure 3B). Of the 62 mutations in
the coding region identified from WES analysis, 61 (98%)
were also called by the HCC panel analysis (Figure 3B). One
NRAS Q61K hotspot mutation (case 6) was missed by using
the HCC panel analysis. Manual review of this position
revealed that themutation hadVAFof 2.5%byWES and 2.0%
by the HCC panel (Supplemental Figure S2 and Supplemental
Table S4). Note, however, that 2% is close to the detection
limit of the current sequencing technologies.
Compared with the WES analysis, the HCC panel anal-
ysis revealed an additional six mutations in the coding re-
gions, including five in case 9 and one in case 11
(Figure 3B). Manual review of the WES data showed that
all six mutations were in fact supported by at least one read
in WES, but those positions were covered at reduced depth,
with 4 of 6 covered by &40 reads (including three in
LRP1B) and 5 of 6 &80 reads (Supplemental Figure S2C
and Supplemental Table S4). This suggested that the
increased sensitivity in the HCC panel analysis was likely
due to the increased depth achieved.
Additional to the mutations in the protein-coding regions,
the HCC panel also targeted the lncRNA genes MALAT1
and NEAT1 and the promoter regions of TERT, WDR74,
MED16, and TFPI2 (Figure 1A). Within these noncoding
regions, an additional 32 mutations were identified across
the 10 cases, representing a 48% gain of information
compared with sequencing the protein-coding genes alone
(Figure 3B). TERT promoter mutations were found in 60%
(6 of 10) of cases and 16 somatic mutations in the lncRNA
gene NEAT1 were identified in 40% (4 of 10) of cases
(Figure 3B and Supplemental Table S4).
Taken together, for the protein-coding genes frequently
mutated in HCC, the HCC panel analysis produced highly
reliable results compared with WES. Given the increased
sequencing depth achieved by using the HCC panel, somatic
mutations that were missed by WES were identified. Of
importance, the HCC panel analysis enabled us to identify
somatic mutations in promoter regions and frequently
mutated lncRNA genes.
HCC Panel Analysis Identifies Somatic Mutations in
FFPE Diagnostic Biopsies with Low-Input DNA
Nucleic acids from diagnostic specimens are frequently
derived from small FFPE samples. Therefore, it would be
important to determine whether the HCC panel could also
be used for somatic mutational screening on low-input DNA
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(20 ng) extracted from FFPE samples. The DNA extracted
from 36 diagnostic FFPE tumor biopsies was subjected to
HCC panel sequencing to a median depth of 530! (range,
192! to 1257!) (Figures 1A and 2, B and C, and
Supplemental Table S3). The median tumor content for
these 36 cases was 90% (range, 5% to 100%) (Supplemental
Table S2), thus representative of the distribution of tumor
content in diagnostic samples in clinical practice. A median
of three mutations (range, 0 to 76 mutations) per sample,
including a median of two mutations (range, 0 to 53 mu-
tations) in the coding regions was identified (Figure 4,
Supplemental Figure S3, and Supplemental Table S4). No
somatic mutations were identified for 8% (3 of 36) of cases
(cases 7, 12, and 37), indicating that at least one somatic
mutation could be detected in 92% of HCC diagnostic
samples. Of note, although somatic mutations in the one
biopsy with 5% tumor content could not be detected, so-
matic alterations in samples with 30% to 40% tumor content
were detected.
The mutations identified in protein-coding genes from
these 36 FFPE diagnostic biopsies were compared with
those identified by WES of the DNA from the corre-
sponding fresh-frozen biopsies. All 104 mutations identified
from WES analysis were also called based on the HCC
panel analysis (Figure 4 and Supplemental Figure S3), with
21 of 36 cases (58%) harboring CTNNB1 mutations, a
higher proportion than the TCGA and other HCC cohorts
that was likely due to the higher percentage of alcohol-
associated HCC (Supplemental Tables S1 and S2).15 In
addition, analysis of the HCC panel identified 18 mutations
in the coding regions that were not found in the WES
analysis in 11 cases. Of these 18 mutations, 13 were evident
in WES but were not identified as mutations in the WES
analysis, predominantly because of low sequencing depth
(Supplemental Figures S2D and S3). The remaining five
mutations were verified to be present in the corresponding
FFPE samples but absent in the fresh-frozen samples by
Sanger sequencing (Supplemental Figure S4 and
Supplemental Table S4), indicating that they were genuine
discordances between the fresh-frozen and FFPE DNA and
not false positive calls from the HCC panel assay. Of note,
two of five mutations validated to be absent from the fresh-
frozen DNA affected mutation hotspots in CTNNB1 (D32N
and S45A) (Figure 4 and Supplemental Figure S4). The
increased number of detected mutations by the HCC panel
analysis was likely due to a combination of intratumor
heterogeneity and the higher sequencing depth achieved.
Considering the 36 FFPE diagnostic biopsies, the HCC
panel identified 70 somatic mutations in lncRNA genes and
promoter regions, including 22 TERT promoter mutations
(Figure 4 and Supplemental Table S4). Somatic mutations in
lncRNA genes and promoter regions accounted for 37% of
the total number of somatic mutations identified in the FFPE
samples.
Compared with the high correlation of VAF between the
sequencing platforms used in the fresh-frozen samples
(r Z 0.89, r2 Z 0.79, Pearson correlation), the correlation
between WES from fresh-frozen samples and HCC panel by
using FFPE samples was more modest (r Z 0.67,
r2 Z 0.45, Pearson correlation) (Supplemental Figure S2, A
and B). Mutations with large deviations in VAFs between
the sequencing platforms used in the fresh-frozen samples
tended to be covered at reduced depths on either platform
(Supplemental Figure S2C). Similar observations could be
made between VAFs of exome (fresh-frozen) and HCC
panel (FFPE) (Supplemental Figure S2D). The deviations in
the latter may be more noticeable by the overall lower depth
achieved in the FFPE samples than in the HCC panel
sequencing of the fresh-frozen samples. Intratumor hetero-
geneity between the fresh-frozen and FFPE aliquots likely
contributed to the reduced correlation.
Taken together these results suggested that the HCC
panel analysis has high specificity and sensitivity in somatic
mutation detection. Furthermore, somatic mutations in
promoter regions (TERT promoter) and lncRNA genes
(MALAT1 and NEAT1) highly mutated in HCC could also
be detected.
Copy Number Analysis of the HCC Panel Reveals High
Concordance with WES
To determine whether the HCC panel could also be used to
detect CNAs, 42 genes whose coding regions were entirely
covered or were tiled across the lengths of the genes for
CNA detection were evaluated (Figure 1A and
Supplemental Table S1). Using the 41 nontumoral samples,
the variability of the depth of coverage in the amplicons
targeting the 42 genes was assessed (Materials and
Methods). After removing amplicons with low depth of
coverage or high variability, 1483 amplicons were used for
CNA profiling. To assess the ability to detect per-gene
CNA, each nontumoral sample was further paired with
two other randomly selected, sex-matched nontumoral
samples. The copy number log2 ratio of five genes, namely
LRP1B, ALB, BRD7, ACVR2A, and IRF2, was variable
(SD > 0.3); therefore, these genes were excluded from
further CNA analyses. Thirty-seven genes were included in
the CNA analysis.
Figure 3 Comparison of somatic mutations defined by whole-exome sequencing (WES) and hepatocellular carcinoma (HCC) panel in fresh-frozen tissues.
A: Number of coding and noncoding mutations per case identified in 10 fresh-frozen biopsies by using the HCC panel. B: Comparison of somatic coding and
noncoding mutations found by WES and the HCC panel in the fresh-frozen samples. Heatmaps indicate the variant allele fractions of the somatic mutations
(blue, see color key) or their absence (gray) in the eight cases in which at least one somatic mutation was identified. Mutation types are indicated as colored
dots according to the color key. Mutations that were not called by mutation caller but were supported by at least one sequencing read are indicated by
asterisks.
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The copy number profiles of matched fresh-frozen tumor/
nontumor pairs and those derived fromWESwere compared.
Of the 10 fresh-frozen pairs sequenced by using the HCC
panel, one was excluded for excessive residual copy number
log2 ratio (segment interquartile range, >0.8).
25 For the nine
evaluable samples, a correlation of rZ 0.80 (r2Z 0.64) was
found between the copy number log2 ratio of the two plat-
forms (Figure 5A). When the copy number profiles of the 34
evaluable FFPE tumors were compared with the matched
profiles fromWES, a correlation of rZ 0.73 (r2Z 0.54) was
observed between the copy number log2 ratios (Figure 5A).
Overall, 86% of the evaluable genes had concordant copy
number states (Figure 5B).
It has previously been reported that tumor purity had an
impact on the ability to make CNA calls.25,34 The impact of
tumor purity on CNA analysis was therefore evaluated by
using an in silico simulation on 12 cases (six fresh-frozen
and six FFPE, selected on the basis of the presence of
gene amplification/high gain or deep deletion), by replacing
tumor reads with reads sampled from the normal samples to
simulate tumor content 5%, 10%, 20% up to the actual
tumor content for the samples. It was observed that ampli-
fications/high gains were readily detected at 5% tumor
content in many cases and at 20% in all cases (Supplemental
Figure S5). In this cohort, deep deletions could not be
detected at tumor content <40%.
Taken together, these results demonstrated that, despite
profiling only a small number of genes, the HCC panel was
able to detect CNAs in genes frequently gained or lost in
HCC in both fresh-frozen and FFPE tumor samples with
low-input DNA.
Discussion
HCC has a distinct mutational landscape compared with the
major tumor entities. Numerous genes have been found to be
mutated frequently in HCC but rarely in other tumors, such as
those important for hepatocyte differentiation (ALB, APOB,
HNF1A, HNF4A) and inflammatory response (IL6R, IL6ST ).
Given the relative rarity of HCC, these genes are currently not
targeted or are only partially targeted in commercial panels
[eg, Oncomine Comprehensive Panel version 3 (Thermo
Fisher Scientific)] and in panels used by sequencing services
[eg, FoundationOne assay (Foundation Medicine, Cam-
bridge, MA)] (Supplemental Table S1). Thus, the currently
available commercial assays for genomic profiling have
suboptimal utility for HCC, and a targeted sequencing panel
specifically designed for HCC is warranted.
In this study, we designed a custom Ion Torrent Ampli-
Seq sequencing panel, targeting all exons of 33 protein-
coding genes, two lncRNA genes, promoter regions of four
Figure 4 Comparison of somatic mutations defined by whole-exome sequencing (WES) and hepatocellular carcinoma (HCC) panel in formalin-fixed paraffin-
embedded (FFPE) tissue. Barplot illustrates the number of somatic coding and noncoding mutations found in 36 FFPE tumor biopsies by using the HCC panel.
In the main panel, each row represents a gene on the HCC panel and each column represents a sample. The mutations identified by WES in the fresh-frozen
biopsies and those defined by sequencing the corresponding FFPE samples by using the HCC panel are placed next to each other. Mutation types are color
coded according to the color key. The presence of multiple mutations in the same gene is illustrated by asterisks. Noncoding regions below the dashed line
were not covered by WES.
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genes previously found to be recurrently mutated in HCC,
nine genes frequently affected by CNAs, and mutation
hotspots in seven cancer genes.7e17 Of importance, a
number of the genes targeted by using the HCC panel are
not currently on these two commercial panels. Of the 39
cases profiled with the HCC panel (including both fresh-
frozen and FFPE samples), at least one somatic mutation
was detected in 90% (35 of 39) of the cases. Of the muta-
tions in coding genes found using this panel, 22% (42 of
189) would have been missed by both Oncomine Compre-
hensive Panel version 3 and the FoundationOne assay. In
addition, recent whole-genome studies of HCC have
revealed frequent mutations in lncRNA genes NEAT1 and
MALAT1, both of which are not currently targeted by
commercial panels. In fact, it was found that approximately
one-third of the mutations on the HCC panel were within the
promoter and lncRNA regions.
Mutation screening and copy number profiling results
from the HCC panel were benchmarked against those ob-
tained from WES by the orthogonal Illumina sequencing
technology. All but one mutation identified from WES were
detected by using the HCC panel. An additional 10% to
15% of mutations within the coding regions were identified.
Most of these additional mutations were in fact supported
by few reads by WES; thus, the increased sensitivity was
likely a direct result of the increased sequencing depth of
both the tumor and the matched normal samples achieved.
Crucially, however, evidence of intratumor genetic hetero-
geneity between adjacent fresh-frozen and FFPE biopsies,
including two CTNNB1 mutations, was found, suggesting
that in these cases the CTNNB1 mutations were not trunk
mutations.
Although CNA detection using capture-based methods
has been successful for targeted sequencing panel of several
hundred genes,35 CNA detection using amplicon-based
targeted sequencing has proven more difficult. A recent
study investigated the use of an amplicon-based sequencing
strategy that targeted all exons of 113 genes related to DNA
repair.25 The researchers demonstrated that, with an appro-
priate analysis strategy and quality control, amplicon-based
sequencing strategy is feasible and cost-effective for CNA
profiling in FFPE samples.25 In the present study, the
strategy of computing and centering the log2 ratios for the
primer two pools separately, before merging and segmen-
tation proved to be an effective strategy in resolving issues
associated with variable amplification efficiencies, with 86%
of the genes showing concordant copy number states.
Considering few studies have investigated the use of small
targeted sequencing panel for CNA profiling, further
benchmarking studies comparing analysis strategies and
including larger sample size will likely improve the
accuracies.
In the clinical setting, the quality, type, and amount of
input materials for genomic profiling are crucial consider-
ations, particularly in light of the smaller tumors being
detected in screening programs. Here, we demonstrated that
the HCC panel could be used for genomic screening with
high sensitivity and specificity with low-input DNA (20 ng)
derived from FFPE samples without compromising the re-
sults. Although based on an analysis of the TCGA HCC
cases, 92% and 85% of the cases would have exhibited at
least one nonsynonymous mutation by using the Founda-
tionOne and the Oncomine assays, respectively, the HCC
panel holds the advantage of much lower input requirement
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Figure 5 Copy number profiling by using the he-
patocellular carcinoma (HCC) panel. A: Scatter plots
illustrate the copy number log2 ratio of whole-exome
sequencing (WES) and HCC panel sequencing of the
fresh-frozen and the formalin-fixed, paraffin-
embedded (FFPE) tumor samples. B: Barplots illustrate
the number of genes with concordant (dark gray) or
discordant (light gray) copy number states, binned by
the absolute difference in copy number log2 ratio
between WES and HCC panel sequencing of the fresh-
frozen and FFPE samples.
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than that required for commercial panels (eg, >40-mm tissue
samples for the FoundationOne assay) and for capture-based
targeted sequencing strategies.35 In addition, somatic ge-
netic alterations (somatic mutations and amplifications)
could be detected from tumor samples with as low as 30%
tumor content. Considering that mutations in the one sample
with 5% tumor content could not be detected, 30% may be
the lower limit of successful genomic profiling. Although
lower limits (approximately 20%) have also been reported,36
samples were not available to verify this. The samples
included in this study are de facto samples obtained from
routine diagnostic practice, and it was demonstrated that the
low-input DNA requirement facilitates genomic profiling
from small biopsies.
Driver genetic alterations have not yet become a tangible
tool in clinical decision making for the treatment of HCC;
thus, the immediate clinical application of our panel may be
limited. However, recent studies have described the asso-
ciation of TERT promoter and CTNNB1 exon 3 mutations
with increased risk of malignant transformation of hepato-
cellular adenomas,37,38 more frequent HNF1A and IL6ST
mutations in hepatocellular adenomas than HCCs,37 as well
as TP53 mutation as a poor prognostic indicator in
HCC.39e41 These associations suggest a potential utility of
genomic profiling in prognostication for hepatocellular ad-
enomas and HCCs, in tissues or even in cell-free DNA.41,42
In terms of potential targetable alterations, three somatic
mutations identified in our cohort of HCC are molecular
targets in other cancer types according to OncoKB.43 These
include ATM loss of function mutation using olaparib in
prostate cancer (level 4; biological evidence), NRAS hotspot
mutation with binimetinib or in combination with ribociclib
in melanoma (level 3; clinical evidence), and TSC2 mutation
with everolimus in central nervous system cancer (level 2;
standard of care).43 Application of our panel in clinical
decision may become feasible in the future.
This study has several limitations. First, the targeted na-
ture of the HCC panel means that copy number profiling is
not genome-wide and is restricted to the genes included on
the panel. Clinically, focal amplifications, compared with
gains of chromosome arm, are more likely to be true driver
genetic event and may be considered drug targets. The
targeted nature of the HCC panel makes it difficult to
distinguish the two scenarios. However, a re-analysis of the
TCGA data suggests that high-level gains of chr11q13.3
(encompassing CCND1, FGF19, FGF3, FGF4) are almost
always focal amplifications (>93%), whereas 50% to 70%
of high-level gains of TERT and VEGFA are focal amplifi-
cations (Supplemental Table S5). By contrast, high-level
gains of chr1q (SETDB1 and IL6R) and chr8q (NCOA2,
MYC, and PTK2) are frequently nonfocal (<10%), consis-
tent with the frequent high-level gain of entire arms of chr1q
and chr8q.17 For deletions, most deep deletions are focal
deletions, including all deletions (100%) in ARID2, AXIN1,
CDKN2A/B, PTEN, and TSC1/2. These results suggest that
CNAs affecting some of the most promising drug targets on
the HCC panel are frequently true focal CNAs. Second,
given that a median of two to three mutations per tumor
were identified, tumor mutational burden, a putative
biomarker for response to immune therapy, may not be
accurately defined.44 Third, the HCC panel does not include
unique molecular identifiers, which would be useful to
assess library complexity, particularly for samples with
low-input DNA. We envisage that the addition of unique
molecular identifiers would be particularly beneficial for the
study of cell-free DNA from HCC patients.41,42 Fourth, we
designed the panel specific for HCC. Recent studies have
revealed that mixed HCC/cholangiocarcinoma and chol-
angiocarcinoma have recurrent mutations in genes such as
IDH1/2,45 whereas FRK mutations decrease in frequency
from hepatocellular adenoma to HCC.37 These genes are not
covered by the HCC panel. However, as an amplicon-based
sequencing panel, adding amplicons to include genes that
may assist in the differential diagnosis of HCC is
straightforward.
Conclusion
This study demonstrated that the HCC panel is a cost-
effective strategy for mutation screening and copy number
profiling for routine diagnostic HCC samples with low-input
DNA.
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Background: Hepatocellular carcinomas (HCCs) are not routinely biopsied, resulting in a lack of tumor materials for molecular
profiling. Here we sought to determine whether plasma-derived cell-free DNA (cfDNA) captures the genetic alterations of HCC
in patients who have not undergone systemic therapy.
Patients and methods: Frozen biopsies from the primary tumor and plasma were synchronously collected from 30 prospectively
recruited, systemic treatment-naı̈ve HCC patients. Deep sequencing of the DNA from the biopsies, plasma-derived cfDNA and
matched germline was carried out using a panel targeting 46 coding and non-coding genes frequently altered in HCCs.
Results: In 26/30 patients, at least one somatic mutation was detected in biopsy and/or cfDNA. Somatic mutations in
HCC-associated genes were present in the cfDNA of 63% (19/30) of the patients and could be detected ‘de novo’ without prior
knowledge of the mutations present in the biopsy in 27% (8/30) of the patients. Mutational load and the variant allele fraction of
the mutations detected in the cfDNA positively correlated with tumor size and Edmondson grade. Crucially, among the seven
patients in whom the largest tumor was"5 cm or was associated with metastasis, at least one mutation was detected ‘de novo’
in the cfDNA of 86% (6/7) of the cases. In these patients, cfDNA and tumor DNA captured 87% (80/92) and 95% (87/92) of the
mutations, suggesting that cfDNA and tumor DNA captured similar proportions of somatic mutations.
Conclusion: In patients with high disease burden, the use of cfDNA for genetic profiling when biopsy is unavailable may be
feasible. Our results support further investigations into the clinical utility of cfDNA in a larger cohort of patients.
Key words: hepatocellular carcinoma, cell-free DNA, circulating tumor DNA, somatic mutations, liquid biopsy, mutation
screening
Introduction
The invasive nature of biopsy has prompted investigations into
the use of plasma-derived cell-free DNA (cfDNA) as a potential
minimally invasive surrogate for molecular profiling in several
cancer types [1–4]. In contrast to most solid tumor types, hepato-
cellular carcinoma (HCC) diagnosis is frequently on the basis of
radiology alone and in the absence of tumor biopsy. Therefore,
nucleic acids for genetic profiling of HCC are typically obtained
from tumor resection, a procedure that is only carried out in
patients with limited, early-stage disease. In unresectable HCC
patients, should the need for molecular profiling arises, the tumor
materials would have to be collected in a non-routine invasive
VC The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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procedure. The lack of routinely collected tumor materials is a
hurdle for wider adoption of tumor profiling.
Studies have found that cfDNA concentration in serum or
plasma of HCC patients is 3–4 times higher than in patients with
chronic hepatitis and is up to 20 times higher than in healthy in-
dividuals [5–7]. Moreover, cfDNA concentration was found to
be associated with tumor size, portal vein invasion and may be
prognostic [5–8]. Molecular studies of circulating tumor DNA
(ctDNA) in HCCs have investigated the size profiles of ctDNA
[9], or were mutational studies of few cases, of resected materials,
carried out at very low depth or investigated few mutation hot-
spots [10–14]. The use of resected materials, however, restricts
molecular analyses to patients with early-stage, resectable disease.
Given the correlation of cfDNA concentration and tumor size,
one may speculate that patients with later stage disease would
have higher mutational burden in cfDNA, as has been shown in
other cancer types [4, 15].
Restricting molecular studies of ctDNA to mutation hotspots
risks missing a substantial number of mutations, as most somatic
mutations in HCC, even those in HCC-associated driver genes,
do not fall into mutation hotspots [16–21]. Besides TP53 (p53),
CTNNB1 (b-catenin) and TERT promoter, a wide range of
HCC-associated driver genes and recurrently mutated promoter
regions have been discovered, including those involved in
chromatin remodeling (e.g. ARID1A, ARID1B, ARID2, BAP1),
Wnt/b-catenin pathway (e.g. AXIN1, FGF19), and response to
oxidative stress (e.g. KEAP1, NFE2L2) [16–21]. Additionally,
long non-coding RNA genes (lncRNA, e.g. NEAT1, MALAT1)
and promoter regions of WDR74, TFPI2 and MED16 are also re-
currently mutated [18, 19, 22].
In this exploratory study, we sought to determine whether
somatic mutations in HCC driver genes can be detected with
high confidence using next-generation sequencing in the plasma-
derived cfDNA of HCC patients who have not undergone sys-
temic therapy, and if the repertoire of mutations in the cfDNA is
representative of the synchronously collected tumor biopsy. To
address these questions, we prospectively recruited 30 HCC pa-
tients from whom we synchronously collected diagnostic core
needle tumor biopsy and whole blood (supplementary Table S1,
available at Annals of Oncology online) and carried out deep
sequencing targeting HCC driver genes and mutation hotspots
(supplementary Table S2, available at Annals of Oncology online).
Patients and methods
Patients
Thirty patients diagnosed with HCC at the University Hospital Basel,
Basel, Switzerland or at Ospedale Cardarelli, Naples, Italy, were prospect-
ively recruited for this study after written informed consent (supplemen-
tary Table S1, available at Annals of Oncology online). Patients who had
previous systemic therapy for HCC were excluded. One patient was
treated with radio-frequency thermal ablation 21 months before sample
collection. From each patient undergoing diagnostic liver biopsy, two
ultrasound-guided core needle biopsies of the primary tumor and whole
blood were collected at diagnosis at the same time. Of the two primary
tumor biopsies, one was processed and embedded in paraffin for clinical
purposes and the other one was snap-frozen and stored at#80$C for re-
search purposes. Ten millilitres of whole blood was collected in a 10 ml
Cell-Free DNA Blood Collection Tube (BCT, Streck) and processed
immediately (supplementary methods, available at Annals of Oncology
online). Plasma was stored at#80$C until cfDNA extraction.
Tumor size, tumor location, macrovascular invasion, multifocality,
and extrahepatic spread of each patient were assessed radiologically.
Clinical staging of the patients was determined according to the
Barcelona Clinic Liver Cancer (BCLC) staging system [23]. Sex of the pa-
tients, serum alpha-fetoprotein (AFP) levels, primary risk factors (hepa-
titis B/C virus infection, alcoholic liver disease, non-alcoholic fatty liver
disease) were retrieved from clinical files. Histologic grading was carried
out according to the 4-point scale Edmondson and Steiner system [24]
(supplementary methods, available at Annals of Oncology online).
Approval for the use of these samples has been granted by the ethics com-
mittee (Protocol Number EKNZ 2014-099).
Targeted sequencing and analysis
Tumor and germline DNA was extracted from fresh frozen biopsies and
peripheral blood leukocytes (‘buffy coat’). Circulating cfDNA was ex-
tracted from 3 to 6 ml of plasma (supplementary methods, available at
Annals of Oncology online). DNA samples from the tumors, plasma-
derived cfDNA and germline DNA were subjected to targeted sequencing
using an Ampliseq panel targeting all exons of 33 liver cancer-associated
protein-coding genes, all exons of the recurrently mutated lncRNA genes
MALAT1 and NEAT1, recurrently mutated promoter region of TERT,
WDR74, TFPI2 and MED16, as well as hotspots mutations in an add-
itional seven cancer genes (supplementary Table S2, available at Annals of
Oncology online). Sequencing was carried out on an Ion 530 chip using
the Ion S5 XL system (Thermo Fisher Scientific, supplementary methods
and Table S3, available at Annals of Oncology online). Sequencing data
have been deposited in the Sequence Read Archive under the accession
SRP115181.
Sequence reads were aligned to the human reference genome hg19
using TMAP. Somatic mutations were defined using Torrent Variant
Caller (TVC) v5.0.3. We filtered out mutations supported by%8 reads,
and/or those covered by<10 reads in the tumor/cfDNA or<10 reads in
the matched germline. We only retained mutations for which the tumor
variant allele fraction (VAF) was at least 10 times that of the matched nor-
mal VAF to ensure we kept only the somatic variants (supplementary
methods, available at Annals of Oncology online). Due to the repetitive
nature and the high GC content of the TERT promoter region, TERT mu-
tation hotspots (chr5: 1295228 and chr5: 1295250) were additionally
screened, and were considered present if supported by at least 5 reads or
VAF of at least 5%. Mutations identified using the above steps are
referred to as those found by ‘de novo’ methods.
To account for somatic mutations that may be present at low VAF in
either the tumor biopsy or the matched cfDNA samples but not both, all
somatic mutations identified using the ‘de novo’ methods in one of the
two samples were interrogated for their presence in the matched sample
by supplying TVC with their positions as the ‘hotspot list’. Mutations
supported by at least 2 reads were considered to be present. Mutations
identified using the above steps are referred to as those found by ‘interro-
gation’. Clinical actionability was assessed using OncoKB [25].
Statistical analysis
All statistical analyses were carried out in R v3.3.1. Correlations between
the number of mutations, cfDNA concentrations and continuous/or-
dinal clinical variables (supplementary methods, available at Annals of
Oncology online) were assessed using the Spearman’s q. Comparisons of
continuous/ordinal clinical variables between patients with and without
somatic mutations in the cfDNA were carried out using Mann–Whitney
U tests. Comparisons of categorical clinical variables and between pa-
tients with and without somatic mutations in the cfDNA were carried out
using Fisher’s exact tests. All statistical tests were two-tailed and P< 0.05
was considered statistically significant; 95% confidence intervals (CIs)
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were estimated by leaving out 20% of the data points, computed
over 100 runs.
Results
Of the 30 patients prospectively recruited into this study, 33%
(10/30) had BCLC stages B/C/D disease (Table 1; supplementary
Table S1, available at Annals of Oncology online). Multifocal and
metastatic diseases were seen in 11 and 1 patients, respectively.
Median diameter of the largest tumor was 34 mm (range
13–220 mm). At least one primary risk factor was identified for
all patients (except HPU025 for whom the information is un-
available). Cirrhosis was seen in 87% (26/30) of the cases.
From each patient undergoing diagnostic liver biopsy, a core
needle biopsy and whole blood were collected at the same time
for targeted sequencing. A median of 94.6 ng (range 19.8–
1710 ng) of plasma cfDNA was obtained from 10 ml of whole
blood per patient (supplementary Table S1, available at Annals of
Oncology online). We carried out deep sequencing of the HCC
biopsies, cfDNA and matched germline using an in-house
custom-made panel targeting 46 coding and lncRNA genes fre-
quently altered in HCCs (median 1339& in biopsies and plasma,
range 703–9385&, supplementary Tables S2 and S3, available
at Annals of Oncology online). To mimic the potential use of
plasma-derived cfDNA in the absence of available resected tumor
material or a core needle biopsy in a clinical setting, we defined
the somatic mutations for each HCC and cfDNA samples in-
dependently without prior knowledge of the repertoire of muta-
tions present in the biopsy/cfDNA counterpart following a
stringent set of analysis criteria (or ‘de novo’). Additionally, to
account for mutations that may be present at frequencies
below the detection limit of the ‘de novo’ approach, we further
examined the sequencing data of the biopsies for all mutations
detected in the cfDNA (or ‘by interrogation’), and vice versa. In
26/30 patients, at least one somatic mutation was detected in the
biopsy and/or cfDNA (Figure 1 and supplementary Table S4,
available at Annals of Oncology online).
Using the ‘de novo’ approach, we detected at least one som-
atic mutation in the cfDNA of 27% (8/30) of the patients
(median 3, blue/gold bars, Figure 1). Considering the 7 non-
hypermutator cases with at least one detectable mutation in the
cfDNA, 81% (17/21) of the mutations detected in the cfDNA
were also independently detected in the biopsy counterparts. In
the hypermutator case (HPU207), 97% (64/66) of the muta-
tions detected in the cfDNA were also independently detected in
the biopsy counterpart (blue bars, Figure 1). All six apparently
cfDNA-specific mutations were found to be present at low fre-
quencies in their biopsy counterparts by interrogation (gold
bars, Figure 1), suggesting that, in accordance with a recent
study [13], cfDNA may be useful in overcoming intra-tumor
genetic heterogeneity within the biopsies in therapy-naı̈ve HCC
patients. On the other hand, of all mutations detected in the
non-hypermutator and the hypermutator cases, 78% (78/100)
and 7% (5/71), respectively, were detected only in the HCC
biopsies using the ‘de novo’ approach (dark/light red bars,
Figure 1). However, 31% (24/78) and 100% (5/5) of these muta-
tions could in fact be detected in the cfDNA by interrogation
(dark red bars, Figure 1). Taken together, these results demon-
strate that at least one somatic mutation can be detected in the
cfDNA without prior knowledge of the repertoire of mutations
in the HCC biopsies in 27% (8/30) of HCC patients and that at
least one mutation was present, including those identified by in-
terrogation, in 63% (19/30) of the cases.
Comparing the clinicopathologic parameters, we found that
the 8 cases for whom at least one somatic mutation was detected
in the cfDNA using the ‘de novo’ approach were associated with
larger tumors (diameter of the largest tumor) and increasing
Edmondson grade (P¼ 0.012 and P¼ 0.010, Mann–Whitney U
tests, Figure 1; supplementary Table S5, available at Annals of
Oncology online). Across all patients, the number of mutations
detected ‘de novo’ in the cfDNA was positively correlated with
the diameter of the largest tumor and Edmondson grade
(r¼ 0.482, P¼ 0.007 and r¼ 0.470, P¼ 0.012, respectively,
Spearman’s q). The diameter of the largest tumor and
Edmondson grade were also correlated with the maximum vari-
ant allele fractions of the mutations detected in the cfDNA
(r¼ 0.496, P¼ 0.005 and r¼ 0.502, P¼ 0.007, respectively,
Table 1. Clinicopathologic parameters of 30 therapy-naı̈ve HCC included in
this study
Age (N¼ 30) Median years 72 (49–86)
Gender (N¼30) Female 10
Male 20




Associated with cirrhosis (N¼30) Yes 26
No 4
Edmondson grade (N¼28) 2 17
3 7
4 4
Largest tumor diameter (mm) (N¼30) Median (mm) 34 (13–220)
Macrovascular invasion (N¼29) Absent 28
Present 1
Presence of metastasis (N¼30) Absent 29
Present 1
Multifocal (N¼30) Absent 19
Present 11
AFP (ng/ml) (N¼29) Median (ng/ml) 9 (1.6–7852)
Macrovascular invasion (N¼29) Absent 28
Present 1
HBV (N¼29) Absent 27
Present 2
HCV (N¼29) Absent 12
Present 17
ALD (N¼29) Absent 19
Present 10
NAFLD (N¼29) Absent 26
Present 3
Prior treatment (N¼30) No 29
Yes 1 (RFTA)
AFP, alpha-fetoprotein; ALD, alcoholic liver disease; BCLC, Barcelona
Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD,
non-alcoholic fatty liver disease; RFTA, radio-frequency thermal ablation.
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Spearman’s q) and cfDNA concentration (r¼ 0.889, P< 0.001
and r¼ 0.439, P¼ 0.020, respectively, Spearman’s q; supplemen-
tary Table S5, available at Annals of Oncology online).
Additionally, at least one mutation was detected ‘de novo’ in the
cfDNA in 40% (8/20) of male patients compared with 0% (0/10)
of female patients, and in 75% (3/4) of HCCs not associated with
cirrhosis compared with 19% (5/26) of HCCs with cirrhosis
(P¼ 0.029 and P¼ 0.048, respectively, Fisher’s exact tests; sup-
plementary Table S5, available at Annals of Oncology online).
Among the seven cases in whom the largest tumor was"5 cm
or was associated with metastasis, at least one mutation was de-
tected ‘de novo’ in the cfDNA of 86% (6/7) of the cases, with a
median of 75% (range 0%–100%) of the mutations detected in
the cfDNA (Figure 2). Importantly, 87% (80/92, 95% CI 84% to
91%) of the mutations were detected ‘de novo’, and all but two
remaining mutations could be detected by interrogation in the
cfDNA counterparts. Conversely, 95% (87/92, 95% CI 93% to
97%) of the mutations were detected ‘de novo’ in the tumor
biopsies, suggesting that mutation profiling of cfDNA in these
patients captured similar proportion of mutations as tumor
profiling would. By contrast, only 9% (7/78, 95% CI 6% to
11%) of the mutations were detected in the cfDNA of the
remaining 23 patients with small (largest tumor%5 cm), non-
metastatic HCC. These results suggest that in most HCC
patients with high tumor burden, somatic mutations can be de-
tected in the cfDNA with high confidence and that the repertoire
of somatic mutations detected in cfDNA is representative of
that in the primary HCC biopsy.
Discussion
HCC differs from most other tumor types in that biopsies are
rarely carried out as they are usually not required for diagnosis.
Thus, in patients not eligible for tumor resection (i.e. patients
with large or metastatic disease and/or with poor performance
status), tumor materials are usually unavailable for molecular
profiling. Here we describe a prospective study to investigate the
utility of cfDNA collected at the time of biopsy for molecular
profiling in HCC patients. Targeting the most significantly
mutated genes and regions in HCCs, we found that, even without
the prior knowledge of the somatic mutations in the HCCs, high-
depth sequencing analysis of plasma-derived cfDNA revealed
that at least one somatic mutation in HCC driver genes can be
detected in 27% (8/30) of therapy-naı̈ve HCC patients. In an
additional 11 cases, cfDNA captured mutations present below
‘de novo’ detection limit in the biopsies, demonstrating that som-
atic mutations were present in the cfDNA of 63% (19/30) of HCC
patients at diagnosis. Importantly, among the patients with high
disease burden (large tumor or metastasis) and most likely to be
ineligible for resection, cfDNA profiling captured nearly as many
mutations as primary tumor biopsy profiling alone. Of note, a
TSC2 frameshift mutation detected in the cfDNA and the pri-
mary tumor of the metastatic patient HPU209 is targetable by
everolimus in cancers of the central nervous system as standard
of care (supplementary Table S4, available at Annals of Oncology
online). Taken together, our results demonstrate that the reper-
toire of mutations in HCC-associated genes identified in the
cfDNA is representative of that in the biopsy.
Figure 1. Number of somatic mutations detected in plasma-derived cell-free DNA and clinicopathologic information of the 30 patients with
therapy-naı̈ve hepatocellular carcinoma. The number of somatic mutations were categorized based on whether they were detected
‘de novo’ or ‘by interrogation’ (i.e. without or with prior knowledge of the repertoire of mutations in the biopsy/cfDNA counterpart, respect-
ively, see color key). Clinicopathologic information is color-coded. White indicates unavailable information.
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Many HCC patients present with multifocal or metastatic dis-
ease and variable levels of heterogeneity with branched and paral-
lel evolutionary patterns have been detected in HCC patients [13,
14]. Here we found a number of mutations that were detected
with high confidence in the cfDNA but could only be detected by
interrogation in the biopsy counterparts, reinforcing the notion
that genetic analysis of a single diagnostic biopsy of the primary
tumor may not be representative of the disease. Studies into the
use of cfDNA as a minimally invasive surrogate for molecular
profiling in HCC patients are therefore of particular clinical
relevance.
Our study was limited in cohort size but as a proof of principle
study and interpreted in the context of other tumor types [1–3],
we found strong evidence that somatic mutations can be reliably
detected in patients with high disease burden. As a prospective
study, we have not assessed the prognostic significance of our
findings. Furthermore, our filtering steps for the ‘de novo’ ap-
proach were deliberately stringent to closely recapitulate a poten-
tial clinical scenario. It is plausible that the limited sensitivity in
detecting mutations ‘de novo’ in patients with low tumor burden
is related to stringent filters. In fact, the number of mutations
detected by interrogation suggests that advanced sequencing
technologies incorporating molecular barcoding or alternative
high-fidelity sequencing techniques will likely increase detection
sensitivity in the clinical setting. Despite these limitations, the
observed correlation of detectable somatic mutations and disease
burden has important implications in the implementation of pre-
cision medicine [3]. Our results point toward the use of cfDNA
for genetic profiling in HCC patients ineligible for resection and
provide an argument for not subjecting patients with high disease
burden to otherwise diagnostically unnecessary invasive proced-
ure. Our results support further investigations into the clinical
utility of cfDNA in a larger cohort of patients.
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Figure 2. Somatic mutations found in cfDNA and in their primary tumor biopsies. Heatmaps indicate the variant allele fractions of the somatic
mutations (blue, see color key) or their absence (grey) in the 26 pairs of tumor biopsy and cfDNA for which at least one somatic mutation was
identified. Mutation types are indicated as colored dots. Orange boxes denote the mutations detected using the ‘de novo’ approach (i.e. with-
out prior knowledge of the mutations in the biopsy/cfDNA counterpart). Mutations not detected by the ‘de novo’ approach but were covered
by<100 reads are indicated by an asterisk. Cases are grouped according to the diameter of the largest tumor. T, tumor; PL, plasma.
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The accurate identification of somatic mutations has become a pivotal component of tumor profiling
and precision medicine. In molecular diagnostics laboratories, somatic mutation analyses on the Ion
Torrent sequencing platform are typically performed on the Ion Reporter platform, which requires
extensive manual review of the results and lacks optimized analysis workflows for custom targeted
sequencing panels. Alternative solutions that involve custom bioinformatics pipelines involve the
sequential execution of software tools with numerous parameters, leading to poor reproducibility and
portability. We describe PipeIT, a stand-alone Singularity container of a somatic mutation calling and
filtering pipeline for matched tumor-normal Ion Torrent sequencing data. PipeIT is able to identify
pathogenic variants in BRAF, KRAS, PIK3CA, CTNNB1, TP53, and other cancer genes that the clinical-
grade Oncomine workflow identified. In addition, PipeIT analysis of tumor-normal paired data gener-
ated on a custom targeted sequencing panel achieved 100% positive predictive value and 99%
sensitivity compared with the 68% to 80% positive predictive value and 92% to 96% sensitivity using
the default tumor-normal paired Ion Reporter workflow, substantially reducing the need for manual
curation of the results. PipeIT can be rapidly deployed to and ensures reproducible results in any
laboratory and can be executed with a single command with minimal input files from the users.
(J Mol Diagn 2019, 21: 884e894; https://doi.org/10.1016/j.jmoldx.2019.05.001)
The significant breakthrough in next-generation sequencing
(NGS) of the last decade has provided an unprecedented
opportunity to investigate human genetic variation and its
role in health and disease. Spearheading these international,
large-scale efforts are The Cancer Genome Atlas and the
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International Cancer Genome Consortium. The efforts by
these two consortia have led to a comprehensive molecular
portrait of human cancers and their molecular pathogen-
esis.1,2 Among the major findings is the unbiased discovery
of genes mutated at rates significantly higher than the
expected background level,3 forming a significant group of
the so-called driver genes. The discovery of these driver
genes has provided the essential background knowledge for
the design of cost-effective genomic assays that form the
critical foundations of cancer diagnostics, therapeutics,
clinical trial design, and selection of rational combination
therapies. The accurate identification of somatic mutations
has become a pivotal component of tumor profiling and
precision medicine.
For tumor profiling in the research setting, the Illumina
sequencing technology is by far the most commonly used.
As a result, most of the research on error modeling, error
correction, and the accurate calling of somatic mutations has
been performed on the Illumina platform. There is a general
consensus on the best practices for Illumina sequencing data
analysis. In the diagnostic setting, however, the Ion Torrent
technology is often used because of its relatively low costs,
its fast turnaround time, and the availability of sequencing
panels that require little DNA or RNA input. Ion Torrent
sequencers are most frequently used for surveying cancer
mutation hotspots and/or a limited number of cancer genes
in molecular diagnostics laboratories. However, there is a
lack of consensus on how to perform somatic mutation
analysis for Ion Torrent data.4,5
A typical approach to perform somatic mutation calling
on the Ion Torrent platform is through the proprietary
browser-based Ion Reporter (IR) interface. The underlying
variant calling engine of the IR is the Torrent Variant Caller
(TVC), which generally achieves better specificity than
tools not designed to consider the Ion Torrentespecific flow
space.4 However, the IR has several notable shortcomings.
First, a recent comparison of variant calling methods re-
ported that although the IR was the preferred solution, it
suffered from an approximately 50% false-positive (FP)
rate.5 The high FP rate mandates lengthy and careful expert
manual review of the results, thus introducing human-
induced variability. Second, given the diversity in the
landscape of somatic alterations among tumor types,6 mo-
lecular diagnostics laboratories and researchers are
increasingly creating customized targeted sequencing panels
to address specific questions or tasks. However, IR analysis
support for assays (ie, targeted sequencing panels and
associated analysis procedures) other than the commercially
released Ion Torrent assays is limited.
The importance of properly developed and maintained
NGS bioinformatics pipelines in patient care cannot be
understated.7 NGS analysis pipelines typically involve the
consecutive execution of tools.8 Ensuring reproducible an-
alyses and validating analysis pipelines would require the
execution of multiple tools while locking down software
versions and configurations.7 In addition, many software
tools have complex prerequisites (eg, the stand-alone
version of TVC), adding time for software installation,
maintenance, and testing to ensure compatibility. To ensure
reproducibility and to ease software deployment, container
technologies are being adopted by the bioinformatics com-
munity as prebuilt packages in which the necessary software
is already installed, tested, and ready to be executed. In the
context of NGS analysis pipelines in the diagnostic setting,
container technology facilitates pipeline validation when
transferred from one laboratory to another because a
containerized pipeline gives the same results regardless of
the hardware configurations and operating systems. Docker,
firstly released in 2013, is the gold standard of container
technologies, and today one can find Docker containers for
many commonly used bioinformatics tools. For instance, the
Genome Analysis Toolkit (GATK; Broad Institute, Cam-
bridge, MA),9 one of the most well-maintained NGS anal-
ysis packages, has been releasing Docker images since
2016. However, Docker images usually require root privi-
leges to be executed, making them impractical for regular
users in shared high-performance computing clusters. To
overcome this limitation, Singularity10 was created as an
alternative for distributed environments.
We recently reported on a diagnostic targeted sequencing
assay designed for hepatocellular carcinoma (HCC) with
results benchmarked against whole-exome sequencing
(WES) on an orthogonal sequencing platform.11 We present
the analysis pipeline as PipeIT, a Singularity container
image that can be rapidly deployed and executed from end-
to-end using a single command, from aligned Binary
Alignment Map (BAM) files automatically generated by the
Torrent Server to the final list of somatic mutations with
high sensitivity and specificity.
Materials and Methods
Tissue Samples, Library Preparation, and Sequencing
Fifteen formalin-fixed, paraffin-embedded (FFPE) colon
adenomas were obtained from the archive at the Institute of
Pathology, University Hospital Basel, Basel, Switzerland.
The adenoma tissue and matched germline control were
microdissected separately from the same slide, and DNA
was extracted as previously described.12 DNA was quanti-
fied using the Qubit Fluorometer (Thermo Fisher Scientific,
Waltham, MA). Approval for the use of these samples has
been granted from the local ethics committee. Library
preparation for the colon adenomas and their matched
germline controls was performed using the Ion Torrent
DNA Oncomine Comprehensive Panel v3M (Thermo Fisher
Scientific) as previously described.11,13 Quantification was
performed using the Ion Library TaqMan Quantitation Kit
(Thermo Fisher Scientific), and sequencing was performed
on an Ion S5XL system (Thermo Fisher Scientific).
Sequencing data for 10 frozen samples of HCC with
matched germline sequenced using a custom AmpliSeq
PipeIT: Somatic Variants Pipeline
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targeted sequencing panel (Thermo Fisher Scientific)
designed to focus on the most frequently altered genes in
HCC were obtained from our previously published
study.11 The custom HCC panel includes 33 complete
coding genes, two long noncoding RNA genes, four gene
promoter regions, and mutation hotspots in seven genes,
covering genomic regions of approximately 203 kb.11
Sequencing was performed on an Ion S5XL system
(Thermo Fisher Scientific). These samples had previously
been subjected to WES using the SureSelectXT Clinical
Research Exome (Agilent, Santa Clara, CA) platform and
sequenced on an Illumina HiSeq2500 (Illumina, San
Diego, CA).11
The PipeIT Workflow
As mandatory input files, BAM14 files for the tumor and the
matched germline samples, and a Browser Extensible Data
(BED)15 file specifying the target regions are required
(Figure 1). The BAM files consist of sequencing reads
aligned to the reference genome using the TMAP aligner
and are generated as part of the standard automated data
processing on the Torrent Server as sequencing data are
generated. The BED file specifies the design of the targeted
sequencing panel and comes with every panel design. A
second BED file of the unmerged detailed version of the
design BED file may be provided. If this file is not provided,
PipeIT will create it automatically. The PipeIT workflow
comprises the following steps: i) variant calling, ii) post-
processing variants, iii) variant filtering, and iv) variant
annotation (Figure 1).
The variant calling step (step 1) is performed using TVC
version 5.0.3 (Thermo Fisher Scientific) as the variant calling
engine, using a set of parameters modified from the set of
default somatic, low-stringency parameters for AmpliSeq
panels sequenced on the Personal GenomeMachine (Thermo
Fisher Scientific). Some of the most important modifications
include a quality threshold of 6.5, a minimum variant score of
10, a minimum coverage of 8 and 15 for somatic nucleotide
variants (SNVs) and small insertion/deletions (indels),
respectively, and a minimum variant count of 4 and variant
allele frequency (VAF) of 5% for long assembled indels. The
modifications were made on the basis of the values recom-
mended in IR. As with the original set of parameters for so-
matic analysis for AmpliSeq panels, SNVs, indels, and
multinucleotide variants are reported, whereas complex var-
iants are not reported. These parameters were used in a
benchmarking study11 and in another study in which variant
detection was performed in cell-free DNA in patients with
HCC.13 The JSON file containing the benchmarked parame-
ters is packaged within the container, but PipeIT also allows
user-specified TVC parameters provided as a JSON file.
The postprocessing step (step 2) is performed to facilitate
downstream filtering and annotation. This step is only
required for multiallelic variants and consists of two parts.



































Figure 1 Overview of the PipeIT container. Flowchart showing the
execution of PipeIT where the users need to provide only three files [Binary
Alignment Map (BAM) files for tumor and normal samples and the target
Browser Extensible Data (BED) file]. Variant calling is then performed using the
Torrent Variant Caller with the packaged parameters file. The filtered and an-
notated mutations are then returned as output Variant Call Format (VCF) files.
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using the BCFtools norm function. Second, each monoallelic
variant is then left-aligned using the GATK Left-
AlignAndTrimVariants tool. Multiallelic variants are there-
fore treated as individualmonoallelic variants for downstream
analysis and filtering. These postprocessing steps are partic-
ularly important for indels because TVC frequently reports
several indels at a given locus, including ones that are not
actually detected, within homopolymer or repeated regions.16
The variant filtering step (step 3) is implemented using
VariantFiltration in GATK. Variants outside the target re-
gions are removed. Hotspot variants17,18 are then white-
listed. Variants covered by fewer than the specified number
of reads (default to 10) in either the tumor or the matched
normal sample or supported by fewer than the specified
number of reads (default to 8) are removed. Furthermore,
variants not likely to be somatic based on the ratio of VAF
between tumor and normal (default to minimum 10:1) are
also removed. PipeIT also allows user-specified values for
the above filters. Given the clinical significance of many
hotspot mutations, hotspot mutations were whitelisted even
if they did not pass all read count and/or VAF filters.
Reviewing the whitelisted hotspot variants that did not pass
the above read count and/or VAF filters is recommended.
Finally, variants passing the filters are annotated using the
ann command of SnpEff19 (step 4) using the canonical
transcripts (defined as the longest protein coding transcript)
from the genome version GRCh37.75. The final output is a
Variant Call Format (VCF) file, with gene, transcript, and
amino acid annotations in the INFO field.
Building the PipeIT Singularity Container Image
The PipeIT somatic variant detection workflow described
abovewas implemented in a Singularity container10 in the form
of a compressed, read-only squashfs file system. Using a
CentOS7 Docker image as a base, the software and tools
required to execute the PipeIT workflow, including the stand-
alone version of TVC and its dependencies for variant calling
(step 1), BAMtools, SAMools, BCFtools, IGVtools, GATK,
Tabix, and SnpSift for VCF file manipulation (steps 2 and 3),
and SnpEff for variant annotation (step 4) (Figure 1 and
Table 1)were installed and configured. The installation process
defines the environment variables to ensure that the tools can be
executed seamlessly. The JSON parameters file for TVC and
the human hg19 reference genome compatiblewith the version
used by the Torrent Server for alignment were added to the
PipeIT container. Finally, a script that executes all the steps in
the workflow described above was included to streamline the
entire workflow into a single command.
Sequencing Data Analysis by the IR
Sequence reads were aligned to the human reference
genome hg19 using TMAP within the Torrent Suite Soft-
ware version 5.4 (Thermo Fisher Scientific) for the Ion
S5XL system. Aligned BAM files were uploaded to the IR
version 5.6 (Thermo Fisher Scientific) for analysis. For the
analysis of the Oncomine Comprehensive Panel, the anal-
ysis was performed using the recommended workflow for
the Oncomine Comprehensive Panel v3 (Oncomine
Comprehensive v3 - w3.1.1 - DNA - Single Sample work-
flow, hereafter IR-Oncomine). Specifically, this tumor-only
DNA analysis workflow uses the Oncomine Comprehen-
sive DNA v3 Regions v1.0 file and the Oncomine
Comprehensive DNA v3 Hotspots v1.0 file as target and
hotspot regions, respectively, and hg19 as the reference
genome. Default variant calling parameters, all annotation
sets, no report template, and the Oncomine Variants v5.6
filter chain were used. The analysis was also performed
using IR in a tumor-normal DNA analysis workflow
(IR-TN), using the Oncomine Comprehensive DNA v3
Regions v1.0 file and the Oncomine Comprehensive DNA
v3 Hotspots v1.1 file as target and hotspot regions,
respectively, and hg19 as the reference genome. Further-
more, the default variant calling parameters, all annotation
sets, the Default Variants View v5.6 filter chain, and no
report template were used.
For the analysis of the HCC-targeted sequencing panel,
two IR tumor-normal DNA analysis workflows were
generated using the design BED file as the target regions
and hg19 as the reference genome. In the first workflow
(IR-default), the default variant calling parameters were
used. In the second workflow (IR-custom), the set of custom
parameters included in PipeIT (see above) was used and a
Table 1 Software Installed within the PipeIT Container, Including the Main Tools Used by the PipeIT Pipeline and the Dependencies
Needed by the Main Tools
Main software TVC version 5.0.3 (Thermo Fisher Scientific, Waltham, MA)
BAMtools version 2.4.0 (https://github.com/pezmaster31/bamtools)
SAMtools version 1.3.1 (http://www.htslib.org)14
BCFtools version 1.5 (http://www.htslib.org)
IGVtools version 2.3.60 (https://software.broadinstitute.org/software/igv/igvtools)20
VCFtools version 0.1.14 (https://vcftools.github.io)21
GATK version 3.6 (https://software.broadinstitute.org/gatk)
SnpEff and SnpSift version 4.1l (http://snpeff.sourceforge.net)19
HTSlib version 1.3.1 (http://www.htslib.org)14
Additional dependencies armadillo, atlas, autoconf, automake, blas, boost, bzip2, cmake, epel, gcc, gcc-cþþ, git, igvtools,
java, kernel-debug, lapack, libbz2, libopenblas, make, ncurses, openblas, unzip, wget, xz, zlib
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BED file that covered the mutation hotspots17,18 within the
target regions was included as the hotspot regions. For both
workflows, all annotation sets, no report template, and the
Default Variants View v5.6 filter chain were used.
The analyses for the 15 colon adenomaenormal pairs
and the 10 HCC tumor-normal pairs were set up manually
and sequentially. The filtered results of each analysis were
downloaded as TSV files. For clarity, mutations not
marked as Non-confident by the IR in tumor-normal DNA
workflows (ie, IR-TN for the Comprehensive Cancer Panel
and IR-default and IR-custom for the HCC targeted
sequencing panel) were considered high confidence (HC)
in this study.
Sanger Sequencing
To validate selected discordant variants among the mutation
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Figure 2 Comparison of mutation calls from PipeIT,
Ion Reporter (IR) Oncomine Comprehensive Panel work-
flow (IR-Oncomine), and IR in a tumor-normal DNA anal-
ysis workflow (IR-TN) in 15 colon adenomas sequenced
using the commercial Oncomine Comprehensive Panel v3.
A: Venn diagrams showing the overlap of the mutation
calls among PipeIT, IR-Oncomine, and IR-TN (left panel)
and among PipeIT, IR-Oncomine, and IR-TN (high confi-
dence; right panel). B: Scatterplots illustrating the
variant allele fractions against read depth of the putative
mutations identified by the three workflows. Mutations
that were confirmed to be present by Sanger sequencing
are colored in purple, and mutations that could not be
confirmed by Sanger sequencing are colored in red. Mu-
tations marked as non-confident by IR-TN analysis are
indicated with crosses. Mutations in IR (both IR-Oncomine
and IR-TN) appeared to have lower overall depth than
PipeIT because the downsampling of the reads during
variant calling.
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sets were designed as previously described12 and reported in
Table 2. PCR amplification of 5 ng of genomic DNA was
performed with the AmpliTaq 360 Master Mix Kit (Thermo
Fisher Scientific) on a Veriti Thermal Cycler (Thermo
Fisher Scientific) as previously described.12 PCR fragments
were purified with ExoSAP-IT (Thermo Fisher Scientific).
Sequencing reactions were performed on a 3500 Series
Genetic Analyzer instrument by using the ABI BigDye
Terminator chemistry version 3.1 (Thermo Fisher Scientific)
according to the manufacturer’s instructions. All analyses
were performed in duplicate. Sequences of the forward and
reverse strands were analyzed with SnapGene Viewer
software version 4.0.2 (GSL Biotech LLC, Chicago, IL).
Evaluation of PipeIT and IR Results against WES
The somatic mutations identified in the HCC samples by
PipeIT, IR-default, and IR-custom were compared with
those identified by WES.11 To account for the possibility
that variants identified by PipeIT, IR-default, and IR-custom
but not WES might have been detected but were not called
in the WES analysis, discordant variants were reevaluated
and interrogated for their presence in the WES data using
the GATK version 3.6 UnifiedGenotyper by using the
GENOTYPE_GIVEN_ALLELES mode. Mutations
concordant with WES were considered true-positive (TP)
results, mutations not found by WES were considered FP
results, and mutations called in the WES analysis but not by
PipeIT, IR-default, or IR-custom were considered false-
negative (FN) results. Evaluation of performance of
PipeIT and IR was then performed by computing positive
predictive value (PPV, also known as precision), defined as
TP/(TP þ FP), and sensitivity, defined as TP/(TP þ FN).
Software Availability
The PipeIT pipeline is freely available from Oncogenomics
Laboratory (Basel, Switzerland; http://oncogenomicslab.
org/software-downloads, last accessed December 12, 2018).
Figure 3 Validation of selected somatic mutations using Sanger sequencing. Sanger sequencing chromatograms of selected mutations being validated.
Red arrows indicate the specific nucleotide investigated for the presence or absence of a specific somatic mutation. Asterisks indicate BRAF V600E mutations
identified by PipeIT, Ion Reporter (IR) Oncomine Comprehensive Panel workflow (IR-Oncomine), and IR in a tumor-normal DNA analysis workflow (IR-TN).
Daggers indicate putative mutations identified by IR-TN.
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Results
To streamline the somatic mutation analysis for matched
tumor-germline DNA sequencing data generated on the
Ion Torrent platform, PipeIT was built, implementing the
workflow previously used in our diagnostic HCC assay
(Figure 1).11 This workflow has been benchmarked in
samples sequenced from approximately 200" to approx-
imately 1600" depth in both fresh-frozen and FFPE
samples against results from WES on an orthogonal
sequencing platform and were shown to be highly
concordant.11
PipeIT was built as a Singularity container image that can
be executed in a single command, eliminating the need for
the individual execution of variant calling, postprocessing
steps, filtering, and annotation (Figure 1). Importantly, as a
container image, PipeIT is easily portable to any laboratory
and always produces the same results. To execute the
complete somatic mutation calling workflow of PipeIT, the
single command singularity run PipeIT.img -t path/to/
tumor.bam -n path/to/normal.bam -e path/to/region.bed is
needed. Additional optional parameters, such as TVC pa-
rameters and thresholds for variant filtering, may also be
specified, allowing individual laboratories to customize their
own analyses. Since Singularity is high-performance
computing compatible, PipeIT can be used to execute
many analyses in parallel without cumbersome and labor-
intensive analysis setup.
PipeIT was tested on 15 colon adenomas and 10 HCCs.
The 15 colon adenomas consisted of adenoma-normal pairs
of FFPE colon adenoma sequenced using the Oncomine
Comprehensive Panel v3, covering approximately 349 kb
to a median depth of 569" (range, 301" to 834"),
whereas the 10 HCCs consisted of the previously pub-
lished 10 tumor-normal pairs of fresh-frozen HCCs
sequenced using a custom HCC targeted sequencing panel
covering approximately 203 kb to a median depth of
1495" (range, 1026" to 1855").11 On a machine with
Intel Xeon 2.6 Hz processor with four threads and 32 GB
of memory, the PipeIT analysis took a mean of approxi-
mately 15 minutes for each colon adenoma-normal pair
and a mean of approximately 45 minutes for each HCC
tumor-normal pair.
PipeIT Identifies Pathogenic Somatic Mutations on the
Commercial Oncomine Comprehensive Panel
To compare PipeIT to the IR, the routinely used interface for
mutation calling in clinical diagnostic laboratories, PipeIT
was first evaluated on the 15 colon adenomas sequenced on
the commercially available Oncomine Comprehensive Panel
v3. PipeIT was first compared to the IR out-of-the-box
tumor-only workflow optimized for the Oncomine
Comprehensive Panel v3 for diagnostic use (IR-Oncomine).
PipeIT and IR-Oncomine identified 48 and 33 mutations,
respectively (Figure 2A), with a median of 3 (range, 1 to 6
somatic mutations) and 2 (range, 0 to 5 somatic mutations)
per sample, respectively. Both PipeIT and IR-Oncomine
identified bona fide pathogenic variants, including BRAF
V600E mutation in 10 cases, all of which were confirmed by
Sanger sequencing (Figure 3, Table 2, and Supplemental
Figure S1A). Furthermore, PipeIT identified the additional
pathogenic variants that IR-Oncomine found, including
NRAS Q61K, KRAS G12C, and Q61K; PIK3CA C420R,
CTNNB1 T41A, and S45A; and TP53 C275Y, ARID1A
Y815fs, and CDKN1B R152fs mutations (Supplemental
Table S1). Of note, two of the BRAF V600E mutations
were flagged for review by PipeIT because of the presence
of small number of variant reads (ie, the presence of some
adenoma cells) in the matched germline samples (Table 2
and Supplemental Figure S1A).
On the other hand, 13 variants were found only by
IR-Oncomine but not PipeIT (Figure 2A). On inspection of
the variants and the sequence reads, two were found to be
germline heterozygous variants (BRCA2 K3326* and MET
R988C, both with minor allele frequency >0.1% in the
general population),22 nine were present at low VAF in
matched tumor and normal samples, and one was in a poorly
aligned region, highlighting the advantage of performing
matched tumor-normal analysis as opposed to tumor-only
analysis in removing germline variants and systematic arti-
facts. Lastly, an RNF43 large frameshift deletion found only
by IR-Oncomine but not PipeIT was shown to be FP by
Sanger sequencing (Table 2 and Supplemental Figure S1B).
However, the tumor-only IR-Oncomine workflow only
conservatively reports the subset of mutations cataloged in
its internal database as likely somatic, therefore likely
Table 2 Primer Sets Used to Perform Sanger Sequencing Validation of Selected Mutations
Gene Mutation Forward Reverse
BRAF p.Val600Glu 50-AGCCTCAATTCTTACCATCCACA-30 50-ACTGTTTTCCTTTACTTACTACACCT-30
RNF43 p.Thr20fs 50-GGTCCATTTTCAAGGGGATCAC-30 50-ATGGTTGAAGTGCATTGCTG-30
MYC p.Val421Gly 50-GTGACCAGATCCCGGAGTTG-30 50-CGCACAAGAGTTCCGTAGCT-30
CREBBP p.Ala346Thr 50-GCTTGCTCTCGTCTCTGACA-30 50-CTTGGAACTCTGAGAGGTTAAAGT-30
BRCA2 p.Thr226Ala 50-TGCATTCTAGTGATAATATACAATACACA-30 50-TGTAAGATAAATAATTTAACAAGGCATTCC-30
NOTCH1 p.Ala2425Asp 50-GCTCTCCTGGGGCAGAATAG-30 50-CAGCAAACATCCAGCAGCAG-30
NOTCH1 p.Pro498Arg 50-GCCAGGGTGCAGACGACC-30 50-CCCTCACTGTTGCCCCAC-30
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Figure 4 Comparison of mutation calls from PipeIT, IR analysis using the default parameters (IR-default), and IR analysis using the custom set of variant
calling parameters used in PipeIT (IR-custom) in 10 hepatocellular carcinomas sequenced using a custom AmpliSeq panel. A: Bar plot shows the number of
putative somatic mutations (including all protein-coding and noncoding mutations). B: The positive predictive values and the sensitivity are plotted for each
analysis pipelines. C: UpSet21 plots show the number of protein-coding and splice site mutations identified by each of PipeIT, IR-default, or IR-custom
compared with whole-exome sequencing (WES). Vertical bars represent, from the leftmost to the rightmost, the numbers of mutations at the intersection,
the ones called by PipeIT, IR-default or IR-custom only, and the ones called in the WES only. Horizontal bars represent the total number of mutations called by
PipeIT, IR-default, or IR-custom or in WES. For IR-default and IR-custom, two plots were made, one with all the variants called and one with the subset of
high-confidence (HC) mutations.
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omitting genuine but rare somatic variants, in particular
those in tumor suppressor genes. For instance, an RNF43
splice site mutation at 35% VAF was reported by PipeIT but
not IR-Oncomine.
Given that the tumor-only IR-Oncomine identified a
number of germline variants and false variants that could have
been removed using a tumor-normal approach, PipeIT was
further evaluated against an IR matched tumor-normal (IR-
TN) workflow. The IR-TN workflow identified 906 (of which
398 were HC) mutations, with a median of 52 (range, 36 to
114; or median, 18; range, 6 to 65 for HC mutations) muta-
tions per sample (Figure 2A and Supplemental Table S1). IR-
TN identified 861 putative variants (or 364 counting only HC
variants) that were not detected by PipeIT or IR-Oncomine
(Figure 2A). Five of these IR-TNespecific mutations with
VAF >5% were randomly selected for validation by Sanger
sequencing, including four mutations that were considered to
be HC. All five mutations in MYC, CREBBP, BRCA2, and
NOTCH1 were absent by Sanger sequencing (Figure 3 and
Table 2), indicating that these were not variants that were
missed by PipeIT. Compared with PipeIT and IR-Oncomine,
IR-TN identified many more mutations with low VAF and/or
low depth (Figure 2B). Many of the IR-TN variants were
flagged as non-confident, primarily because they were
detected at low VAF in both the tumor and the corresponding
normal samples. Among the 508 non-confident variants
called by IR-TN were three BRAF V600E mutations, high-
lighting the need for careful manual curation of the non-
confident IR-TN results. Taken together, these results indicate
that PipeIT was able to identify pathogenic variants that were
detected using the IR-Oncomine as would have been done in
the diagnostic setting.
PipeIT Accurately Identifies Somatic Mutations on a
Custom AmpliSeq Panel
For custom sequencing panels, IR does not provide opti-
mized analysis workflows. For the 10 HCCs sequenced on a
custom AmpliSeq panel, PipeIT was first evaluated against
an IR tumor-normal analysis workflow using default pa-
rameters and default variants filter chain (IR-default)
(Materials and Methods). In addition, a second workflow
that used the custom variant calling parameter set used in
PipeIT and hotspot regions17,18 curated from the literature
(IR-custom) was generated to mimic the setup of PipeIT.
Across the 10 HCCs, PipeIT, IR-default, and IR-custom
identified 139, 346 (of which 217 were HC), and 256 (of
which 137 were HC) somatic mutations, respectively, with
134 (128 counting only HC mutations from IR-default and
IR-custom) identified by all three analyses (Figure 4A,23
Supplemental Figure S2, and Supplemental Table S2).
PipeIT, IR-default, and IR-custom identified a median of 2.5
(range, 0 to 112), 25 (range, 16 to 137; or median, 11.5;
range, 6 to 117 for HC mutations), and 13.5 (range, 7 to
130; or median, 3; range, 0 to 109 for HC mutations) so-
matic mutations, respectively, per sample. As previously
reported,11 one of the cases displayed a hypermutator
phenotype with >50% of all mutations coming from this
single case (HPU207T). IR (IR-default and IR-custom) did
not appear to recognize the noncoding gene NEAT1
(Supplemental Table S2).
The exonic mutations (in protein coding genes, including
splice site mutations) calls obtained from PipeIT, IR-default,
and IR-customwere comparedwith those obtained fromWES
on the Illumina platform.11 All 68 exonic mutations identified
by PipeIT were confirmed to be present and somatic byWES,
giving a PPV of 100% (Figure 4, B andC), including twowith
<5% VAF and 14 with<10% VAF. Compared with PipeIT,
IR-default identified more putative exonic mutations
(nZ 108, of which 82 were HC) but with a far inferior PPV
(68%, or 80% counting only HC variants). On the other hand,
IR-custom identified 82 (of which 64wereHC) but had a PPV
more similar to PipeIT (84%, or 100% counting only HC
variants). Compared with the variability in PPV among the
variousworkflows, all workflows achieved>92% sensitivity,
with 99% sensitivity for PipeIT outperforming all other
workflows (93% to 96%) (Figure 4B).
Taken together, benchmarked against the mutations
identified from WES and compared with the IR, PipeIT
identified more known mutations while maintaining excel-
lent PPV, including mutations at low VAF. Of note,
customizing the variant calling parameters alone in the IR
(as in IR-custom) raised the PPV substantially compared
with the default tumor-normal DNA analysis parameters in
IR-default.
Discussion
Modern clinical molecular diagnostics are becoming
increasingly reliant on the identification of somatic genetic
alterations using NGS. Owing to its relative low costs and
fast turnaround, the Ion Torrent platform is one of the
main sequencing platforms used in the clinical setting.
Although the workflow for sample and library preparation,
as well as for sequencing, is well standardized and
streamlined, data analysis remains cumbersome, and it is
difficult to obtain consistent and reliable results. A prop-
erly developed analysis pipeline is critical to ensuring
adequate patient care.7 The most common approach to
analyzing Ion Torrent sequencing data is to use Thermo
Fisher Scientific’s proprietary IR software interface. The
IR is highly customizable but also suffers from a number
of drawbacks. Although optimized tumor-only analysis
parameters for clinical-grade Oncomine panels are avail-
able out of the box, the default solutions for custom panels
suffer from a high FP rate, requiring tuning of variant
calling parameters, defining optimized filters, and/or
extensive manual post-IR filtering.
To overcome these limits, PipeIT, a Singularity container
for diagnostic somatic variant calling on the Ion Torrent
platform, applicable for both Oncomine and custom targeted
Garofoli et al
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sequencing panels, was developed. The pipeline was
designed to account for the requirements of somatic variant
calling analysis in a diagnostic setting. First, sensitivity and
PPV are both important. In particular, a high PPV would
reduce the workload in curating the results and increase
reproducibility by minimizing variability associated with
manual review of the results. Second, the ability of high-
throughput analysis of many tumor-normal sample pairs by
executing a single shell command, either on a desktop
computer or in parallel in a high-performance computing
environment, is desirable. Third, although the PipeIT
workflow was designed to be run from start to finish, it is
also possible to execute individual components (Table 1)
instead of the complete PipeIT workflow. Fourth, repro-
ducibility and portability are enabled by the use of the
Singularity container technology, thus removing the hassle
of complex software setup and ensuring that results are
reproducible in any hardware and operating system config-
uration. This in turn facilitates the pipeline validation pro-
cess that is necessary when pipelines are deployed in a new
laboratory.7 The read-only nature of a Singularity container
also prevents unintentional alterations of the software setup
by the users.
The performance of PipeIT was demonstrated using two
data sets. In the first set of 15 FFPE colon adenomas
sequenced using the Oncomine Comprehensive Panel,
PipeIT was able to identify the bona fide pathogenic mu-
tations identified by IR-Oncomine, the optimized IR work-
flow for diagnostic use. PipeIT did not identify a number of
germline variants called by IR-Oncomine and the many IR-
TNespecific variants enriched for low VAF and/or low
depth, many of which are likely to have been fixation arti-
facts or are otherwise FP results, as shown by the enrich-
ment of C>T mutations at the low VAF range
(Supplemental Figure S3).24 In 10 fresh-frozen HCCs
sequenced using a custom AmpliSeq panel, PipeIT has
excellent PPV compared with IR solutions. Benchmarked
against the mutations identified by WES of the HCCs,
PipeIT identified the most known mutations while main-
taining excellent PPV compared with both IR-default and
IR-custom, including variants at low VAF. Interestingly,
although IR-default (HC) suffered from poor PPV of <80%,
IR-custom (HC) had 100% PPV, and its performance was
comparable to PipeIT. This observation underlines the ne-
cessity of molecular diagnostics laboratories to customize
their own analysis parameters and filters; PipeIT provides a
tested and easy-to-implement solution.
In conclusion, PipeIT offers a fully automated, self-
contained pipeline for somatic variant calling for Ion
Torrent sequencing, with minimal input requirements. The
excellent PPV of PipeIT significantly reduces the need for
extensive expert manual review. PipeIT is a useful addition
to molecular diagnostics laboratories, especially for custom
targeted sequencing panels, as well as for researchers
seeking a workflow to analyze somatic mutations from Ion
Torrent data.
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3.2- Chapter II  
Identification of HMGA1 molecular 




HMGA1 is a protein known as an architectural transcription factor because it can bind to and 
modify the DNA. Even if it does not have transcriptional activity per se, it can assemble functional 
transcription units and by that can affect transcription 108,109. HMGA1 is known to be involved in 
several cellular processes implicated in cancer development and tumour progression. It has also 
been found to be highly expressed in a broad range of tumours whilst it is not or lowly expressed 
in normal tissue. Even if the mechanisms of action are quite well studied for some of its targets, 
a broad characterisation of its molecular interactors and its specific role with them is not yet 
discovered, especially in the context of HCC. After our previous study showing an overexpression 
of HMGA1 in more than 50% of HCC patients in both transcription and protein levels 121, we 
decided to focus our attention on the role of HMGA1 in HCC and to elucidate its molecular targets.  
 
This chapter contains my experimental work performed on HMGA1 on in vitro HCC models to 
explore more in depth the general role of this protein and, above all, to highlight its molecular 
targets of potential clinical utility.         
 
Our first aim was to investigate the binding landscape of HMGA1 at the DNA level by performing 
chromatin immunoprecipitation sequencing (ChIP-seq) on endogenous levels of HMGA1 in HCC 
cells. The second aim was to define a gene and protein expression signature of HMGA1 
deregulation. We performed RNA-sequencing on HCC cell lines after overexpression and 
silencing of HMGA1 and mass spectrometry after silencing of HMGA1. The third aim was to 




Materials and Methods 
Cell lines 
All HCC-derived cell lines were maintained in a 5% CO2-humidified atmosphere at 37°C and 
cultured in DMEM supplemented with 10% FBS, 1% Pen/Strep (Bio-Concept) and 1% MEM-
NEAA (MEM non-essential amino acids, Thermo Fisher Scientific). All cell lines were confirmed 
negative for mycoplasma infection using the PCR-based Universal Mycoplasma Detection kit 
(American Type Culture Collection) according to standard protocol. 
Plasmids and transfection 
The vector for the overexpression of HMGA1 was designed and ordered on GenScript Biotech 
(Figure 3.2.1). As empty control vector was used pCMV-mir EGFP. 2x105 cells per 6-well were 
plated 24h before transfection. The expression vectors were transfected using the jetPRIME 
transfection reagent (Polyplus) following the manufacturer’s instructions. Briefly, 2µg of plasmid 
were added in 200µl of jetPRIME buffer. Successively, 4µl of jetPRIME reagent were added. The 
transfection mix was then properly mixed and was incubated at room temperature for 10 minutes. 
The transfection mix was added dropwise onto the cells and distributed evenly. To avoid 
cytotoxicity, the transfection medium was replaced after 4 hours by complete medium. The 
expression of the plasmids was evaluated by western blot and qRT-PCR analysis 48h after 
transfection.  
 




siRNA and transfection 
The silencing of HMGA1 was performed using ON-TARGET plus siRNA transfection. ON-
TARGET plus SMARTpool siRNAs against human HMGA1 and ON-TARGET plus SMARTpool 
non-targeting control and DharmaFECT transfection reagent were all purchased from GE 
Dharmacon. 
Catalog ID for ON-TARGET plus SMARTpool siRNAs against human HMGA1: L-004597-00-0005  
Catalog ID for ON-TARGET plus SMARTpool non-targeting control: D-001810-10-05 
Transfection was performed according to the manufacturer’s protocol. Briefly, HCC cancer cells 
were seeded at approximately 60% confluence. Because residual serum affects the knockdown 
efficiency of ON-TARGET plus siRNAs, growth medium was removed as much as possible and 
replaced by serum-free medium (Opti-MEM). siRNAs were added to a final concentration of 
25nM. Cells were incubated at 37°C in 5% CO2 for 48 hours or for 48 and 72 hours (for western 
blotting after subcellular fractionation). To avoid cytotoxicity, the transfection medium was 
replaced with a complete medium after 24 hours. 
RNA extraction and qRT-PCR 
RNA extraction was performed using the TRIzol Reagent (ThermoFisher) followed by an 
additional DNase treatment using DNA-free DNA Removal Kit (ThermoFisher) according to the 
manufacturer’s specifications. RNA concentrations were quantified using Qubit Fluorometer (Life 
Technologies).  
1µg of RNA was retro-transcribed using the SuperScript VILO cDNA synthesis kit (Thermo Fisher 
Scientific). Quantitative real-time PCR for the expression levels of HMGA1 was performed with 
Sybr Green method. When GAPDH was used as a housekeeping gene, the fold changes in gene 
expression were calculated using the standard ΔΔCt method 153. To quantitate HMGA1 transcript 
levels, dilutions of the HMGA1 vector  were used as standard curves (dilutions ranged from 2.5 
to 1 million copies of plasmid).  





GAPDH primers:  
Forward: AGGTGAAGGTCGGAGTCAACG 
Reverse: TGGAAGATGGTGATGGGATTT 
Protein extraction and Western Blot 
Proteins were extracted using Co-IP buffer (100mmol/L NaCl, 50mmol/L Tris pH 7.5, 1mmol/L 
EDTA, 0.1% Triton X-100) supplemented with 1x protease inhibitors (cOmplete Mini, EDTA-free 
Protease Inhibitor Cocktail, Roche) and 1x phosphatase inhibitors (PhosSTOP, Merck) at 4°C for 
30 minutes. Cell lysates were quantified by the Bradford protein assay (Bio-Rad) using Bovine 
Serum Albumin Acetylated (Promega) as standard in seven diluted concentrations. Same 
concentrations of the cell lysates were then treated with 1x reducing agent (NuPAGE Sample 
Reducing Agent, Invitrogen), 1x loading buffer (NuPAGE LDS Sample Buffer, Invitrogen), boiled 
at 70°C for 10 minutes and loaded into neutral pH, pre-cast, discontinuous SDS-PAGE mini-gel 
system (NuPAGE 4-12% Bis-Tris Protein Gels, Thermo Fisher). The proteins were then 
transferred to nitrocellulose membranes using the Trans-Blot Turbo Transfer System (Bio-Rad). 
The membranes were blocked for 1 hour with 3% Sure Block (Lubio science) and then probed 
with primary antibodies overnight at 4°C. Next day, the membranes were incubated for 1 hour at 
room temperature with fluorescent secondary goat anti-mouse (IRDye 680) or anti-rabbit (IRDye 
800) antibodies (both from LI-COR Biosciences). Blots were scanned using the Odyssey Infrared 
Imaging System (LICOR Biosciences) and band intensity was quantified using ImageJ software. 
The ratio of proteins of interest/loading control in treated samples were normalised to their 
counterparts in control cells. 
Antibodies 
 
Antibody Company Catalog 
number 
Application Dilution / 
Concentration 
HMGA1 abcam ab4078 ChIP-seq 5 µg 
HMGA1 Cell Signaling D6A4 – 7777 WB, IHC, IP 1:1000, 1:500,  
4 µg 
Alyref abcam ab202894 WB, IP 1:2000, 4 µg 
64 
 
Rabbit IgG Cell Signaling 2729 IP 4 µg 
β-actin Sigma Aldrich A5441 WB 1:5000 
MEK1/2 Cell Signaling D145 – 8727 WB 1:1000 
AIF Cell Signaling D39D2 – 5318 WB 1:1000 
Vimentin Cell Signaling D21H3 – 5741 WB 1:1000 
Histone H3 Cell Signaling D1H2 – 4499 WB 1:1000 
 
Chromatin Immunoprecipitation (ChIP) – sequencing 
In collaboration with Song Shuang and Prof. Patrick Matthias from the Friedrich Miescher Institute 
for Biomedical Research, and Dr. Fengyuan Tang from the Department of Biomedicine in Basel, 
we established a protocol to perform the ChIP-seq for HMGA1. In brief, more than 50 million cells 
per sample were crosslinked and subjected to sonication to obtain DNA fragments of 
approximately 300 bp. Chromatin was immunoprecipitated using a new ChIP-grade anti-HMGA1 
antibody (Abcam). Library construction from immunoprecipitated DNA and the input (50ng each) 
was performed using NEBNext Ultra II DNA Library preparation kit (New England BioLabs) 
according to the standard protocol. Massively parallel sequencing was performed on an Illumina 
NextSeq 550 in our institute according to manufacturer’s instructions. We obtained ~30 million 
reads per sample. The study was performed on 2 biological replicates for each cell line.  
Analysis of ChIP-seq 
ChIP-seq analysis was performed by the bioinformaticians in our group, in particular Dr. Gallon 
and Dr. De Filippo. ChIP-seq reads were aligned to the human reference genome hg19 using the 
BWA aligner. Peaks were called using MACS2 154 and subsequently combined across replicates, 
into consensus peak lists, using MSPC 155. A second analysis for identification of enriched regions 
was done by counting reads overlapping regions using countOverlaps from the GenomicRanges 
package in R. Pathway analysis was carried out on consensus peak lists for each cell line whereby 
peaks were annotated using the ChIPseeker package, before KEGG pathway analysis was 




Extracted RNA from cells was subjected to quality control before library preparation. The RNA 
integrity number was > 9 for all the samples. 100ng RNA were used for each sample for the 
construction of libraries, according to the poly-A tail selection TruSeq Stranded mRNA protocol 
(Illumina). The libraries were prepared and sequenced on an Illumina NovaSeq 6000 by CeGaT 
GmbH. We obtained > 30 million reads for each sample. The study was performed on 2 biological 
replicates for each cell line. 
 
Analysis of RNA-seq 
RNA-seq analysis was performed by Dr. Gallon. Sequencing reads generated were aligned to 
hg19 and assigned to genes using STAR 2.5 156. Analysis of differential gene expression between 
HMGA1 dysregulated and control samples was performed using DESeq2 157 and Gene Set 
Enrichment Analysis was then carried out using the moderated T statistics from this analysis to 
detect differential expression of gene sets defined in the MsigDB database, using the ‘fgsea’ 
package in R 158.  
Mass-spectrometry (MS) 
Extracted proteins from whole cells (2.5x108 per sample) were lysed in 50µL of lysis buffer (1% 
Sodium deoxycholate (SDC), 10mM TCEP, 100mM Tris pH=8.5) using 10 cycles of sonication 
(30 seconds on, 30 seconds off per cycle) on a Bioruptor (Dianode). Following sonication, proteins 
in the cell lysates were reduced by TCEP at 95°C for 10 minutes. Proteins were then alkylated 
using 15mM chloroacetamide at 37°C for 30 minutes and further digested using sequencing-
grade modified trypsin (1/50, w/w, trypsin/protein; Promega) at 37°C overnight. After digestion, 
the samples were acidified with TFA to a final concentration of 1%. Peptide Desalting was 
performed using iST cartridges (PreOmics) following the manufacturer’s instructions. Peptides 
were dried under vacuum. Sample aliquots comprising 12.5µg of peptides were resuspended in 
10µl labelling buffer (2M urea, 0.2 M HEPES pH 8.3) by sonication and labelled with isobaric 
tandem mass tags (TMTpro 16-plex, Thermo Fisher Scientific). For that, 2.5µL of each TMT 
reagent were added to the individual peptide samples followed by a 1 hour incubation at 25°C 
shaking at 500 rpm. To control for ratio distortion during quantification, a peptide calibration 
mixture consisting of six digested standard proteins mixed in different amounts was added to each 
sample before TMT labelling (for details see 159). To quench the labelling reaction, 0.75µL 
aqueous 1.5M hydroxylamine solution was added and samples were incubated for 5 minutes at 
25°C shaking at 500 rpm followed by pooling of all samples. The pH of the sample pool was 
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increased to 11.9 by addition of 1M phosphate buffer (pH 12) and incubated for 20 minutes at 
25°C shaking at 500 rpm to remove TMT labels linked to peptide hydroxyl groups. Subsequently, 
the reaction was stopped by addition of 2M hydrochloric acid until a pH < 2 was reached. Peptide 
samples were further acidified using 5% TFA and desalted using BioPureSPN Macro spin 
columns (The Nest Group) according to the manufacturer’s instructions and dried under vacuum. 
 
TMT-labelled peptides were fractionated by high-pH reversed phase separation using a Xbridge 
Peptide BEH C18 column (3.5µm, 130Å, 1mm x 150mm, Waters) on an Agilent 1260 Infinity 
HPLC system. Peptides were loaded on column in buffer A (20mM ammonium formate in water, 
pH 10) and eluted using a two-step linear gradient from 2% to 10% in 5 minutes and then to 50% 
buffer B (20mM ammonium formate in 90% acetonitrile, pH 10) over 55 minutes at a flow rate of 
42 µl/min. Elution of peptides was monitored with a UV detector (215nm, 254nm) and a total of 
36 fractions were collected, pooled into 12 fractions using a post-concatenation strategy as 
previously described (Ahrné et al. 2016) and dried under vacuum. Dried peptides were 
resuspended in 0.1% aqueous formic acid and subjected to LC–MS/MS analysis by the team of 
Proteomics Core Facility, Biozentrum, University of Basel, using a Q Exactive HF Mass 
Spectrometer fitted with an EASY-nLC 1000 (both Thermo Fisher Scientific) and a custom-made 
column heater set to 60°C.  
Analysis of Mass-spectrometry (MS) 
The acquired MS raw-files were analysed by the team of Proteomics Core Facility, Biozentrum, 
University of Basel, using the SpectroMine software (Biognosis AG). Spectra were searched 
against a human database consisting of 20767 protein sequences (downloaded from Uniprot on 
20190307) including commonly observed contaminants. Standard Pulsar search settings for TMT 
16 pro (“TMTpro_Quantification”) were used and resulting identifications and corresponding 
quantitative values were exported on the PSM level using the “Export Report” function. Acquired 
reporter ion intensities in the experiments were employed for automated quantification and 
statistical analysis using an in-house developed SafeQuant R script (v2.3 159). This analysis 
included adjustment of reporter ion intensities, global data normalization by equalizing the total 
reporter ion intensity across all channels, summation of reporter ion intensities per protein and 
channel, calculation of protein abundance ratios and testing for differential abundance using 
empirical Bayes moderated t-statistics. Finally, the calculated p-values were corrected for multiple 
testing using the Benjamini−Hochberg method. 
All LC-MS analysis runs were acquired from three independent biological samples. To meet 
additional assumptions (normality and homoscedasticity) underlying the use of linear regression 
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models and Student t-Test MS-intensity signals were transformed from the linear to the log-scale. 
Linear regression was performed using the ordinary least square (OLS) method as implemented 
in the base package of R v.3.1.2 (http://www.R-project.org/). The Proteomics Core Facility 
performed the analysis assuming a within-group MS-signal Coefficient of Variation of 10% in a 
sample size of three biological replicates. They applied a two-sample, two-sided Student t test 
that gives adequate power (80%) to detect protein abundance fold changes higher than 1.65, per 
statistical test. The statistical package used to assess protein abundance changes, SafeQuant, 
employs a moderated t-Test, which has been shown to provide higher power than the Student t-
test.  
Immunoprecipitation (IP)  
Cells from 10cm plates (one for regular IP, four for IP-MS) were lysed with Co-IP buffer 
(100mmol/L NaCl, 50mmol/L Tris pH 7.5, 1mmol/L EDTA, 0.1% Triton X-100) supplemented with 
1x protease inhibitors (cOmplete Mini, EDTA-free Protease Inhibitor Cocktail, Roche) and 1x 
phosphatase inhibitors (PhosSTOP, Merck) at 4°C for 30 minutes. The lysates were first cleared 
by spinning at 16,000g at 4°C for 30 minutes to remove cell debris, pre-cleared using Dynabeads 
Protein G (Thermo Fisher) for 1 hour and then the protein amount was split and used for 
immunoprecipitation with 4µg of either anti-HMGA1 antibody or Rabbit-IgG antibody (for the 
control). The binding of the targets to the antibody occurred at 4°C overnight. Ips were performed 
at 4°C for 1hour and 30 minutes adding Dynabeads Protein G (Thermo Fisher) and then washed 
five times in lysis buffer. The proteins were eluted with SDS sample buffer (NuPAGE LDS Sample 
Buffer, Invitrogen) and heated at 70°C for 10 minutes for regular IP samples and eluted with 
glycine 0.2M ph 2.7 for IP-MS samples. 
Mass spectrometry after Immunoprecipitation (IP-MS) 
Glycine eluted samples after immunoprecipitation were subjected to on-bead digestion (adapted 
from 160) by trypsin (5µg/ml, Promega) in 1.6M urea / 0.1M ammonium bicarbonate buffer at 27°C 
for 30 minutes. Supernatant eluates containing active trypsin were further incubated with 10mM 
TCEP and 15mM Chloroacetamide at 37°C overnight in order to achieve complete digestion and 
carbamidomethylation of cysteines. The tryptic digest was acidified (pH < 3) using TFA and 
desalted using C18 reversed phase spin columns (Harvard Apparatus) according to the protocol 
of the manufacturer. Dried peptides were dissolved in 0.1% aqueous formic acid solution at a 
concentration of 0.2mg/ml prior to injection into the mass spectrometer. Aliquots of 0.4µg of total 
peptides (in 0.1% aqueous formic acid) were subjected to LC-MS analysis again by the team of 
Proteomics Core Facility, Biozentrum, University of Basel, using a dual pressure LTQ-Orbitrap 
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Elite mass spectrometer connected to an electrospray ion source (both Thermo Fisher Scientific) 
and a custom-made column heater set to 60°C. 
Analysis of IP-MS 
The acquired MS raw-files were imported into the Progenesis QI software (v2.0, Nonlinear 
Dynamics Limited), which was used to extract peptide precursor ion intensities across all samples 
applying the default parameters, and analysed by the team of Proteomics Core Facility, 
Biozentrum, University of Basel. The generated mgf files were searched using MASCOT against 
a decoy database containing normal and reverse sequences of the concatenated Homo sapiens 
(UniProt, May 2018) proteome including commonly observed contaminants (in total 41534 
sequences) generated using the SequenceReverser tool from the MaxQuant software (Version 
1.0.13.13). The following search criteria were used: full tryptic specificity was required (cleavage 
after lysine or arginine residues, unless followed by proline); 3 missed cleavages were allowed; 
carbamidomethylation I was set as fixed modification; oxidation (M) and protein N-terminal 
acetylation were applied as variable modifications; mass tolerance of 10ppm (precursor) and 
0.6Da (fragments) was set. The database search results were filtered using the ion score to set 
the false discovery rate (FDR) to 1% on the peptide and protein level, respectively, based on the 
number of reverse protein sequence hits in the datasets. Quantitative analysis results from label-
free quantification were normalised and statically analysed using the SafeQuant R package 
v.2.3.4 (https://github.com/eahrne/SafeQuant/; 159) to obtain relative protein  abundances. This 
analysis included summation of peak areas per protein and LC MS/MS run followed by calculation 
of protein abundance ratios. Only isoform specific peptide ion signals were considered for 
quantification. The summarised protein expression values were used for statistical testing of 
differentially abundant proteins between conditions. Empirical Bayes moderated T-tests were 
applied, as implemented in the R/Bioconductor limma package 
(http://bioconductor.org/packages/release/bioc/html/limma.html). The resulting p-values were 
adjusted for multiple testing using the Benjamini-Hochberg method. 
g:Profiler 
Pathway enrichment analysis was performed on g:Profiler using the KEGG and the Gene 
Ontology (GO) datasets. Enriched pathways were used for the screening of the molecular 




For immunocytochemistry, cultured cells were washed with PBS and fixed in 4% 
paraformaldehyde overnight at 4°C. After fixation and further washing, cells were encapsulated 
in a drop of Richard-Allan Scientific HistoGel (Thermo Fisher), histoprocessed and embedded. 
The FFPE block was then cut and dried on glass slides. Antigen retrieval and 
immunohistochemical staining were performed on the glass slides on an automated Benchmark 
Leica Bond III immunohistochemistry staining system (Leica Biosystems) using a BOND polymer 
refine detection kit (Leica Biosystems). Heat-induced epitope retrieval (HIER) was performed on 
all slides in Bond Epitope Retrieval Solution 1, pH 6 (Leica Biosystems) for 20 minutes. As a 
primary antibody, anti-HMGA1 (Cell Signaling) was applied and incubated for 20 minutes at room 
temperature at 1:500 dilution. Images were acquired using an Olympus BX46 microscope. 
Subcellular fractionation 
The isolation of different cellular compartments was performed using 2.5x106 cells per sample 
following the manufacturer’s instructions of Cell Fractionation Kit (Cell Signaling). All steps were 
performed at 4°C. 30µl of all fractions were then treated with 1x loading buffer (NuPAGE LDS 
Sample Buffer, Invitrogen), boiled at 70°C for 10 minutes and loaded into a SDS-PAGE mini-gel 






I. HMGA1 genome-wide DNA-binding landscape in HCC 
As previously stated, the exact role of HMGA1 is only partially known. One of its main roles is 
acting as an architectural transcription factor, however, its binding sites have not yet been 
systematically investigated. For this reason our first aim was to explore HMGA1 binding 
landscape at the DNA level in an in vitro model of HCC. To achieve this goal, we performed 
chromatin immunoprecipitation sequencing (ChIP-seq). Between a panel of six HCC cell lines 
available in the laboratory we selected three (Hep3B, HUH7, SNU449) with different 
characteristics (HBV positive and negative, different tumour grades, different patient’s age and 
different HMGA1 endogenous levels) to represent the disease (Figure 3.2.2). The ChIP-seq 
experiments were run in duplicate for each cell line.  
 
Figure 3.2.2: HMGA1 screening and characteristic of the chosen HCC cell lines. A) Six HCC cell lines are shown to 
represent the endogenous amount of HMGA1 at the protein (upper part) and mRNA levels (lower part). In oblique lines 
pattern the cell lines used for the ChIP-seq analysis (HUH7, Hep3B, SNU449). B) A table showing the characteristics 





















HUH7 Hep3B SNU449 SNU182 HepG2 HLE
HUH7 Hep3B SNU449
HBV infection no yes yes
Tumour grade II II III/IV




HMGA1 is a DNA-binding protein with low complexity motif (AT-rich regions); it might bind to any 
open region in the chromatin containing an enrichment of AT bases. Our results indeed confirmed 
the binding of HMGA1 protein on distinctive genomic regions in dependency of a specific DNA-
binding pattern. ChIP-seq analysis revealed on average high occupancy of HMGA1 protein 
toward the entire AT-rich DNA (average of 60% binding in AT regions, Table 3.2.1), in accordance 
with a recent study (D. F. Colombo et al. 2017). Broad regions with high enrichment of HMGA1 
binding sites had high AT content and they were consistent between replicates. This consistency 
provided direct support for the specificity of HMGA1-binding for AT-regions independently of the 
function of DNA domains. In addition to this, we found similar percentages of AT content through 
HMGA1 binding sites between cell lines. The difference of total AT content between cell lines, 
despite not being significant, suggested a correlation with the amount of endogenous HMGA1. 
Sample Mean AT 
content 
 (%) 
SD of AT content 
 
HUH7_1 73.60 0.0932 
HUH7_2 69.27 0.1179 
Hep3B_1 66.28 0.0987 
Hep3B_2 66.26 0.0901 
SNU449_1 60.62 0.1181 
SNU449_2 63.37 0.1313 
Table 3.2.1 AT content mean and standard deviation (SD) of binding sites from input normalised data from all samples 
and their replicates obtained by ChIP-seq analysis.  
With the exploration of the DNA domains of the HMGA1 bindings, we found that the majority of 
the peaks were in introns and distal intergenic regions and fewer than 20% of the peaks were in 
promoter regions, while 10% were found in the first intron, only 0.6% were found in exons (Figure 
3.2.3A). Furthermore, 14% of the peaks were located in the 6Kb spanning promoters (Figure 
3.2.3B). Notable also between the cell lines were differences in the distribution of HMGA1 binding 
sites. Hep3B showed the greatest proportion of peaks binding close to transcription start sites 
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(TSS’), with 15% of HMGA1 falling within 6 Kb of promoters, while only 12.6% of HMGA1 peaks 
were within this distance of promoters in the SNU449 line. This is also demonstrated by a greater 
percentage of Hep3B HMGA1 peaks as being nearer TSS’ than in either SNU449 or HUH7 cells. 
This finding was identified again in the level of HMGA1 ChIP-seq coverage around TSS’ in Hep3B 
compared to SNU449, with Hep3B showing greater normalised coverage around TSS’ than both 
SNU449 and HUH7 (Figure 3.2.3C). It is interesting to note that there appears to be a substantial 
drop in HMGA1 coverage around TSS’ in both Hep3B and HUH7, while this was less evident in 
SNU449. Taken together the mapping results of the ChIP sequencing suggests a non-
conventional role of this protein as transcription factors. 
To gain insight into the signalling pathways that may be regulated by HMGA1 at the transcriptional 
level, we performed a KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathway analysis 
using the genes nearest to the called peaks in each cell line (Figure 3.2.4). Although Hep3B did 
not show enrichment for any pathways in its peak distribution, in the two HCC cell lines HUH7 
and SNU449 there was an enrichment of binding sites for HMGA1 in proximity to non-canonical 
genes involved in the epithelial to mesenchymal transition (EMT) such as CLDN3, CDH26, EZH2. 
For example, the “Axon guidance” pathway includes Rho GTPases and cyclines (such as Cycline 
A2) that are involved in the microtubule and cytoskeletal organization 162-164. Furthermore, both 
cell lines showed enrichment in the “Rap1 signalling pathway”, implicated in cell-adhesion in 
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Figure 3.2.3: Characterisation of HMGA1 DNA binding. A) Proportionate distribution of MACS2 called HMGA1 peaks, in 
each of the cell lines analysed, according to the nearest genomic feature. B) Distribution of HMGA1 peaks relative to 
transcription start sites (TSS’), defined by the UCSC database. C) HMGA1 ChIP-seq coverage, normalised against input, 
in 3 Kb region around TSS’, for each cell line analysed. 
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SNU449 also showed an enrichment of peaks closed to genes connected to adherens junctions 
while in HUH7 there was significant enrichment for genes related to gap junctions. 
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Figure 3.2.4: KEGG pathway enrichment analysis on normalised data peaks obtained by ChIP-seq in each of the 
cell lines analysed. Hep3B did not show any enriched pathway. Points are coloured according to -log10 (Benjamini 
Hochberg adjusted P value). 
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II. HMGA1 expression signature in HCC 
To identify the “direct” (i.e. directly bound to HMGA1) and “indirect” (i.e. not bound to HMGA1) 
targets of HMGA1, we performed RNA-seq on HCC cell lines after dysregulation of HMGA1. We 
screened the above mentioned panel of liver cancer cell lines and we selected two with the lowest 
endogenous level of HMGA1, HUH7 and Hep3B, for protein overexpression, and three with high 
endogenous levels, SNU182, HLE and SNU449, for silencing (Figure 3.2.5A). RNA-seq was 
performed on the chosen 5 HCC cell lines, the dysregulation of HMGA1 in all samples was 
confirmed using both western blot analysis and quantitative real-time PCR (qRT-PCR) (Figure 
3.2.5B-F). The RNA-seq was executed in collaboration with CeGaT facility. 
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Figure 3.2.5: HCC cell lines screening and expression level of HMGA1 after overexpression and silencing. A) The 
same data as in Figure 3.2.2A. Six HCC cell lines are shown to represent the endogenous amount of HMGA1 at the 
protein (upper part) and mRNA levels (lower part). In checkered pattern the cell lines used for HMGA1 overexpression 
(HUH7, Hep3B), in striped pattern the ones for silencing (SNU449, SNU182, HLE) B) Expression of HMGA1 in HUH7 
wild type (wt), in HUH7 after transfection with the plasmid control (HA) and with the HMGA1-overexpressing plasmid 
(HMGA1) at the protein and mRNA levels. C) Expression of HMGA1 in Hep3B wild type (wt), in Hep3B after transfection 
with the plasmid control (HA) and with the HMGA1-overexpressing plasmid (HMGA1) at the protein and mRNA levels. 
D) Expression of HMGA1 in SNU449 wild type (wt) and SNU449 after transfection with the control pool of siRNA 



































































































1 0 1 0




















































































1 0 1 0
1 0 1 5
S N U 182
HMGA1
















































































1 0 1 0
1 0 1 5
H LE
HMGA1













































































1 0 1 0
1 0 1 5
















































































1 0 1 0
1 0 1 5
S N U 449
HMGA1
1 1.3 0.31 1.2 0.7
β-actin
wt siCNTRL siHMGA1wt siCNTRL siHMGA1
76 
 
wild type (wt) and SNU182 after transfection with the control pool of siRNA (siCNTRL) and the HMGA1 pool of siRNA 
(siHMGA1) at protein and mRNA level. F) Expression of HMGA1 in HLE wild type (wt) and HLE after transfection with 
the control pool of siRNA (siCNTRL) and the HMGA1 pool of siRNA (siHMGA1) at the protein and mRNA levels. Each 
experiment was repeated twice and both replicates are shown for each cell line.  
 
Unexpectedly, there was not a substantial effect on gene expression level between the HMGA1 
dysregulated vs control samples, as shown in the volcano plots (Figure 3.2.6). It is although 
noticeable that HMGA1 is the most significant upregulated/downregulated gene in each cell line 
compared to control cells, with a log2 fold change in expression of -4.41, -4.33 and -3.37 when 
silenced in SNU449, SNU182 and HLE respectively, and 5.00 and 6.26 when overexpressed in 
Hep3B and HUH7 respectively. 
To have a broader overview on the effect of HMGA1 dysregulation, we also examined the 
changes in response to HMGA1 alteration at the protein level. We performed mass spectrometry 
analysis on the three transiently silenced HCC cell lines. Consistent with the results obtained by 
RNA-seq, no substantial effect was observed at the protein level between the control and the 
silenced conditions (Figure 3.2.7). HMGA1 was significantly downregulated in the three cell lines; 
especially SNU449 and HLE showed substantial differences compared to the endogenous levels. 
In the SNU182 the low adjusted p value (Q value) showed that there was a consistent decrease 
in HMGA1 expression, but the magnitude of this change was just less than the stringent threshold 
of a log2FC ≥ 1 which was applied (-0.9). However, none of these results were able to unveil the 
role of HMGA1 in the context of HCC, so we decided to focus our attention on the molecular 





Figure 3.2.6: Differential gene expression on overexpression and silencing of HMGA1. Volcano plots showing -log10 (FDR, 
false discovery rate) against log2FC (fold change) in gene expression for all genes analysed. Genes showing significantly 
different expression (log2FC > ± 1 and FDR < 0.05) are labelled in red in the analysis in the cell lines designed for the 
overexpression (A) HUH7, B) Hep3B), in blue for the silencing (C) SNU449, D) SNU182, E) HLE). HMGA1 is the most 




Figure 3.2.7: Response of cell lines (SNU449, SNU182, HLE) on protein level after HMGA1 silencing, compared to 
control. A) Expression of HMGA1 in SNU449 wild type (wt) and SNU449 after transfection with the control pool of 
siRNA (siCNTRL) and the HMGA1 pool of siRNA (siHMGA1) at protein level (upper part). Volcano plot of Benjamini-
Hochberg adjusted P value (Q-value, -log10scale) vs fold-change (log2scale) generated for HMGA1 silenced cells vs 
control. Each dot represents a protein element. Dashed lines represent the thresholds used and only significant 
elements are labelled and coloured (lower part). B) Expression of HMGA1 in SNU182 wild type (wt) and SNU182 after 
transfection with the control pool of siRNA (siCNTRL) and the HMGA1 pool of siRNA (siHMGA1) at protein level (upper 
part). Volcano plot of Benjamini-Hochberg adjusted P value (Q-value, -log10scale) vs fold-change (log2scale) 
generated for HMGA1 silenced cells vs control. Each dot represents a protein element. Dashed lines represent the 
thresholds used and only significant elements are labelled and coloured (lower part). C) Expression of HMGA1 in HLE 
wild type (wt) and HLE after transfection with the control pool of siRNA (siCNTRL) and the HMGA1 pool of siRNA 
(siHMGA1) at protein level (upper part). Volcano plot of Benjamini-Hochberg adjusted P value (Q-value, -log10scale) 
vs fold-change (log2scale) generated for HMGA1 silenced cells vs control. Each dot represents a protein element. 




III. Identification of molecular partners of HMGA1 
For an accurate molecular characterisation of biological systems, it is critical to decipher the 
dynamics of protein interactions in complex networks. To elucidate the role of HMGA1, we used 
HMGA1 immunoprecipitation followed by mass-spectrometry (IP-MS) to reveal its interacting 
partners. The immunoprecipitation was performed on three HCC cell lines with high levels of 
endogenous HMGA1 (SNU449, SNU182, HLE) and these samples underwent MS analysis 
(Figure 3.2.8A). We performed three independent replicates and an equal number of matched 
IgG control samples were prepared. The IP-MS method identified 95 proteins in the SNU449, 189 
in the SNU182 and 166 in the HLE cell line with positive enrichment at q-value of 0.01. HMGA1 
was one of the two most significantly enriched proteins in all three cell lines identified with 12 
unique peptides. The portion of proteotypic peptides associated with each protein that are 
observed by MS analysis are indicators of the accuracy of the prediction. HMGA1 protein, with its 
~100 aa, was detected with high accuracy without distinction between its isoforms. We found the 
known co-regulators (NPM1 167 and several members of the histone H1 family 168,169) and several 
new binding factors with significant enrichment in the HMGA1 IP samples compared to the 
controls (Figure 3.2.8B). We identified 71 proteins in common between the three cell lines (Table 
3.2.2). Notably 41% (n= 29) were ribosomal proteins, 11% (n=8) were histone proteins and the 
remaining ones were mostly nuclear proteins involved in different networks, such as RNA binding 
or maturation of ribosomes. The KEGG pathway analysis and the Gene Ontology enrichment 
analysis performed on the common set of HMGA1 binding proteins reveal a putative function of 
HMGA1 in protein translation, showing also the highest enrichment for RNA and rRNA binding in 









Figure 3.2.8: Identification of interaction partners of HMGA1 by IP-MS. A) Immunoprecipitation of endogenous 
HMGA1 in the 3 cell lines (SNU449, SNU182, HLE). Immunoprecipitation with HMGA1 antibody or IgG was 
performed. IgG pull-down was used for IP control. Inputs and Flow-Through (FT) were investigated in parallel. The 
inputs, IP and FT fractions were immunoblotted with HMGA1 antibody. B) Volcano plot of Benajmini-Hochberg 
adjusted P value (Q-value, log10scale) vs fold-change (log2scale) generated for IP with HMGA1 antibody vs control 
(IP with IgG) in SNU449, SNU182 and HLE, respectively, showing the quantitative results of the IP-MS. HMGA1 
and nine of its most significantly enriched interactors are labelled. The colour gradient (Max Int: maximum intensity) 
refers to an intensity ranking of the displayed proteins, from the blue ones with highest and the yellow ones with 
lowest intensity in the experiment. More than 50% of the quantified features imputed, not based on a real 
measurement due to missing values (NA Features), are represented with an up-pointing triangle for the control 
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IV. HMGA1 and the translational regulation 
We decided then to focus our attention on these intriguing results about HMGA1 interaction 
proteins involved in translational processes. We noticed that there were only 9 proteins in 
common between the three cell lines if isolating the most significantly enriched 50 proteins in the 
IP-MS analysis. These common results are histone and ribosomal proteins, with the exception of 
Alyref. Alyref is a protein involved in the control of the transcription and in mRNA transport and 
stabilization 170-173. It has been shown that Alyref binds RNAs because it is able to recognise their 
5-methylcytosine (m5C) modifications 174. This m5C modification, as the other post-transcriptional 
RNA modifications discovered, can affect mRNA metabolism 175-178. m5C was first identified in 
stable and highly abundant tRNAs and rRNAs, but in the last decades many other sites on coding 
and non-coding RNAs have been discovered 179-181. m5C promotes mRNA export thanks to the 
regulatory proteins NSUN2 (“writer”, methyltransferase) and Alyref (“reader”, RNA binding and 
chaperone protein) 174. The idea that HMGA1 could be involved in the translation and mRNA 
binding is entirely new, but it was supported by the finding as common interaction partners in the 
three cell lines of other translational regulators: CHTOP - a paralog of Alyref part of the TREX 
Figure 3.2.9: Identification of relations between the common set of HMGA1 binding proteins and their activity. The 
molecular function by Gene Ontology (GO:MF; upper panel) shows the activities at molecular level performed by the 
binding partners of HMGA1 in common between the 3 HCC cell lines. KEGG pathway enrichment analysis (bottom 
panel) shows the interaction networks between the common binding partners of HMGA1. Image obtained with g:Profiler. 
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complex 174,182, YBX3 - a RNA-binding protein that regulates transport and abundance of mRNAs 
183, and HNRNPA0 - another RNA-binding protein involved in mRNA metabolism and transport 
184,185. Furthermore, both YBX and hnRNP families consist of “readers” of RNA modifications; 
YBX1 is another m5C reader 186, while HNRNPG interacts with m6A modified RNAs 187. After 
verification by IP of the direct binding between HMGA1 and Alyref (Figure 3.2.10A), we 
considered the possibility that HMGA1 could be involved in the coordination of the processing of 
mRNAs into mature proteins as a consequence of export regulation when binding Alyref. This 
could also imply that HMGA1 might be partially cytoplasmic. Therefore, we first investigated 
HMGA1 expression in the nucleus and in the cytoplasm by immunoblotting of subcellular fractions 
and immunohistochemistry (IHC) (Figure 3.2.10B, C). In contrast to previous reports, we found 
evidence of the presence of HMGA1 in the cytoplasm. Additionally, HMGA1 cytoplasmic 
expression differences between cell lines found by immunoblotting matched with the levels shown 





Figure 3.2.10: Cytoplasmic presence of HMGA1 A) Immunoprecipitation (IP) of endogenous HMGA1 and Alyref in the 
3 HCC cell lines (SNU449, SNU182, HLE) with HMGA1 or Alyref pull-down. IgG pull-down was used for control IP. The 
IP fractions and inputs were immunoblotted with HMGA1 and Alyref antibodies. B) Western blot analysis of cell fractions 
in the 3 cell lines showing cytoplasmic (C), membrane/organellular (M) and nuclear/cytoskeletal (N) localization. Whole 
cell lysates (WCS) were used to represent total protein abundance. In addition to HMGA1 and Alyref, Mek1/2, AIF and 
Vimentin antibodies were used as markers for cytoplasm, mitochondria and cytoskeleton, respectively. C) 
Immunohistochemistry of HMGA1 on 4 HCC cell lines (SNU449, SNU182, HLE and HUH7, as control). Nuclear staining 
is high in all cell lines but HUH7, cytoplasmic presence of HMGA1 is noticeable in the SNU449, and to a smaller extent 
in the other cell lines. 
V. Alyref and HMGA1 
At this point we were evaluating the possibility to examine a new putative role of HMGA1 that, 
while binding Alyref, might regulate comprehensively the activation of oncogenes in HCC cell lines 
involved in a mechanism of m5C-mediated export (Figure 3.2.11A). A second hypothesis 
considers the idea that only the binding with some specific common targets could be better 
stabilised when HMGA1 binds Alyref; HMGA1 is therefore involved in a target specific regulation 
(Figure 3.2.11B). These hypotheses open a new panel of questions to be answered. First of all, 























































be interesting to explore if the binding of Alyref on m5C is HMGA1-dependent and thus if HMGA1 
is involved in m5C mRNA export regulation. We already started investigating our hypothesis 
checking the role of HMGA1 in the regulation of the nuclear-cytoplasmic shuttling of Alyref. We 
compared the expressions of both proteins at the nuclear and cytoplasmic levels in endogenous 
conditions and after HMGA1 silencing in each of the three HCC cell lines used for the previous 
analysis (SNU449, SNU182, HLE) (Figure 3.2.12). Despite the substantial efficiency of HMGA1 
downregulation, we did not find considerable differences in Alyref cellular distribution when 
HMGA1 was silenced for 48 and 72h. This led us to be more inclined in our second hypothesis: 
HMGA1 could stabilise only a few mRNA targets of Alyref involved in the tumourigenesis. To 
verify this hypothesis, omics techniques are needed. The next steps foresee a RNA bisulfite 
sequencing analysis (RNA-BisSeq), to analyse Alyref mRNA targets showing a significant 
decrease in m5C methylation following HMGA1 silencing, and/or RNA immunoprecipitation 




Figure 3.2.11: HMGA1 and Alyref interactions hypothesis A) Broad regulation of HMGA1 on Alyref targets. 
HMGA1 regulates nuclear-cytoplasmic shuttling and m5C mediated RNA-binding ability of Alyref. This 
promotes the translation of oncogenes and their consecutive activation. B) Alyref targets’ specific regulation 
of HMGA1. HMGA1 stabilises specific m5C-mRNAs targets of Alyref to promote their translation and 
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Figure 3.2.12: HMGA1 and Alyref localization in HCC cells. Western blot analysis of cell fractions in the 3 cell lines 
(SNU449 A), SNU182 B), HLE C)) showing cytoplasmic (C) and nuclear/cytoskeletal (N) localization after 
transfection with the control pool of siRNA (siCNTR) and the HMGA1 pool of siRNA (siHMGA1). Whole cell lysates 
(WCS) were used to represent total protein abundance. In addition to HMGA1 and Alyref, Mek1/2 and Histone H3 
antibodies were used as markers for cytoplasm and nucleus, respectively. The analysis was performed at 48h and 




Although most patients with HCC present high expression levels of HMGA1 that correlate with 
advanced disease, tumour progression and invasion, the mechanistic explanations of its role in 
tumourigenesis are poorly understood. In this study, we examined the binding profile of this 
architectural transcription factor along the genome and its expression signature in both RNA and 
protein levels in HCC in vitro models using several omics techniques (ChIP-seq, RNA-seq, MS). 
The AT-dependence in the binding of HMGA1 on the DNA revealed a high abundance of detected 
peaks all over the genome, not only close to transcription start sites, and explains the overall lack 
of focal binding. However, the KEGG pathway analysis on the genes nearest to HMGA1 peaks 
revealed an overall enrichment of binding sites for HMGA1 in proximity to unconventional genes 
involved in the EMT. The role of HMGA1 in this process has already been established in the 
literature in vitro and in vivo in other types of cancer 188,189.  
 
We also evaluated the expression signature of deregulated HMGA1 in HCC cell lines at the 
transcription and translation levels. We found few significant changes in the altered conditions vs 
the control. One of the explanations could be due to the limitations of the model used. With 
transient transfections we can identify molecular changes happening in a short range of time. In 
case of complex mechanisms to study, as the examination of dysregulated HMGA1 expression 
signatures, a stable transfection might have been a more appropriate method to capture the 
overall changes. At the beginning of this project we indeed planned to carry our study using 
HMGA1 stable clones. The overexpressing cell lines, chosen after four weeks of genetic selection 
with Geneticin antibiotic, presented a higher level of HMGA1 but only for a few passages. A stable 
overexpression of HMGA1 in HCC cell lines induced stress responses and the cells were dying 
not long after. We tried to optimise the generation of stable cell lines with changes of the 
concentration levels of the antibiotic, medium conditions and transfection methods. Nonetheless, 
we always observed the same ending point. We concluded that overexpression of HMGA1 for a 
long period is not feasible for the survival of these HCC cell lines. We also tried to generate stable 
clones with knock-down of HMGA1 using a well-known short hairpin RNA construct, already 
present in the literature for HMGA1 silencing in glioblastoma and colon cancer cell lines 143,190,191. 
Despite several attempts, HMGA1 was not silenced successfully and we hypothesised that this 
kind of construct used for RNA interference is not functional in HCC cell lines. For this reason we 
proceeded with a transient transfection of HMGA1 in all previous experiments, well aware of the 
limitations of the method.  
 
Consequently, we also cannot exclude the possibility that the few molecular changes detected by 
RNA-seq and MS between different conditions could not be a reflection of the reality. It might be 
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possible that other molecular changes could be detected past the investigated time points. In our 
experiments we proceeded with the analysis of the expression signature after 48 hours of 
dysregulated HMGA1. This was the first of the investigated time points where we obtained ~50% 
either increase or decrease in the amount of HMGA1 compared to its endogenous levels.  
 
Our last examination was on the molecular partners binding HMGA1. The relevance of our study 
is underlined by the discovery of Alyref and other direct targets of HMGA1 involved in the 
regulation of the translation and the RNA binding. Alyref is a m5C reader that promotes mRNA 
export 174 and allows the translation of its targets. This could lead to a new putative role of HMGA1 
in the post-transcriptional RNA modification mechanisms that affect mRNA metabolism. 
Furthermore, most of the studies on HMGA1 have focused on its nuclear accumulation and 
therefore its role in the nucleus. Our results, instead, showed how HMGA1 is also present in the 
cytoplasm of HCC cell lines. The implications of the presence and the role of HMGA1 in other 
compartments of the cells, aside from the nucleus, have been investigated in recent years. 
HMGA1 has been found to be extracellular in breast tumour invasive cells 192. The extracellular 
fraction of HMGA1 has been found to be secreted through non-canonical secretion and mediates 
migration and invasion in the extracellular space with the activation of pERK signaling pathway. 
The novelty of this kind of research makes us realise how much is still undiscovered about the 
HMGA1 mechanistic process in tumourigenesis.  
Our future goals would be to identify HMGA1-Alyref targets and to examine the molecular 
mechanism used by this complex to mediate mRNA export in the cytoplasmic space to stabilise 




4- Discussions and Outlook 
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The death rate of hepatocellular carcinoma (HCC) is rising faster both in European and American 
countries in the last decades and is already a burden for Asian countries 79. Surgery, 
radiofrequency ablation and radiation therapy are the most common strategies used in case of a 
diagnosis of an early stage HCC. Today, targeted therapies for HCC are used when cancer is in 
a late stage, and they are mostly adopted to improve patients’ lives. The goal of new treatments 
is to focus on slowing the growth and relieving symptoms to improve quality of life. Few targeted 
therapies that demonstrated a survival benefit are currently in use in the clinic, including 
regorafenib, cabozantinib, and ramucirumab alongside the most investigated protein kinase 
inhibitor, the drug sorafenib, but the results remain modest 76. One of the reasons is that only 
parts of the molecular mechanisms responsible for the HCC tumourigenesis are well known. 
Despite some of these processes share genetic and molecular features with other types of 
tumours, there are some characteristics that are specific for this organ, as the transformation of 
hepatocytes. The screening for genes with specific HCC alterations can increase the survival rate 
in HCC patients; not only because of tumour surveillance but also because it can facilitate the 
discovery of new molecular biomarkers. The exploration and characterisation of putative 
biomarkers are the major answers for our urgent need to improve our current treatment 
possibilities for HCC patients.  
 
I. Clinical screening of mutations in HCC: Considerations 
As already discussed, at the moment the best way to increase the survival rate in patients with 
HCC is the surveillance. However, the effectiveness of HCC surveillance in clinical practice is 
limited also by poor HCC specificity of existing commercial sequencing panels. We designed an 
amplicon-based sequencing panel specifically to screen for somatic mutations and copy number 
alterations in HCC. The most significant variants in HCC, confirmed through our own study 193, 
included TERT promoter mutation, TP53, CTNNB1, ALB, AXIN1, RB1 and chromatin remodelling 
genes (ARID1A, ARID2, BAP1). All these variants are all included in our panel, as well as those 
not currently covered by commercially available ones. We tested the sequencing panel by using 
biopsies (fresh-frozen, formalin-fixed paraffin-embedded (FFPE) materials) and liquid biopsy 
(plasma-derived cell-free DNA (cfDNA)) to evaluate the feasibility of the panel in routine 
diagnostics. We also designed a somatic mutation calling pipeline, PipeIT, that is practical and 
simple to use and ensures reproducible results in any laboratory. 
 
Among the limitations of the study already discussed in the manuscripts, we need to consider the 
importance of methylation changes on the side of genetic alterations. Epigenetic altered pathways 
may be a consequence of aging process, persistent viral infection and chronic inflammation. They 
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are characterised by three main mechanisms: DNA hypermethylation leading to gene inactivation, 
DNA hypomethylation causing genomic instability, histone modifications affecting chromatin 
conformation 194. DNA methylation occurs in different stages of liver disease (non-cirrhosis, 
cirrhosis and HCC) and both DNA hypomethylation and CpG hypermethylation are the dominant 
event during HCC development and progression 194,195. Therefore, epigenetic changes may serve 
as indicators or biomarkers for screening of patients with an increased risk for HCC and they are 
not possible to be detected with a genetic sequencing panel.  
 
However, we were able to identify somatic mutations from plasma-derived cfDNA, even without 
prior knowledge of the alteration pattern in the HCCs. This is a great outcome considering the 
potential of liquid biopsy. Biopsies in HCCs are rarely carried out. Thus, in patients not eligible for 
tumour resection, meaning patients with high disease burden, tumour materials are usually 
unavailable for molecular profiling. The possibility to capture nearly as many mutations as in 
primary tumour biopsy using only cfDNA profiling may be highly beneficial in the choice of 
therapeutic strategies for HCC patients. 
 
The advantage of the adoption in diagnostic routine analysis of an accessible, cost-effective, 
reliable sequencing panel to use with all kinds of patients’ biopsies is the possibility to accelerate 
the identification and validation of biomarkers to create a more personalised and optimised 
therapy based on putative oncogenic drivers.  
 
II. HMGA1 study: limitations and outlooks 
The increasing interest in identifying new putative biomarkers made relevant the exploration of 
the role of HMGA1 in HCC. HMGA1 is a protein not only highly involved in the chromatin network, 
but also connected with a huge number of other macromolecular complexes with diverse roles. 
These complexes enhance the expression of genes that are involved in several biological 
processes, from embryogenesis to virus integration to neoplastic transformation. HMGA1 protein 
is expressed in embryonic cells and in several tumour tissues but is absent in normal adult tissues 
110,196. Among the tumours with the majority of cases displaying a high expression of HMGA1 there 
is also HCC 91,121,152.The oncogenic mechanism of HMGA1 has been demonstrated to be mostly 
due to its ability to modulate chromatin structure and to bind to different transcription factors, 
facilitating the expression of genes involved in tumour progression and metastasis. However, the 




We investigated the potential oncogenic role of HMGA1 in HCC and we identified its molecular 
targets using in vitro models. Our study has several limitations. The use of cell lines may fail to 
recapitulate key features of HCC, taking into account also interactions between cells, three-
dimensional tumour architecture and cellular heterogeneity. The recent development of organoid 
technology might overcome these limitations. Organoids are superior in maintaining cancer tissue 
architecture and they allow differentiation of tissue stem cells into functional organ-like structures  
197. Tumour organoids from biopsy of HCC patients have been established 198 and the creation of 
an organoids biobank containing patients with high and low levels of HMGA1 in our laboratory is 
one of our outlook. This model might better represent the patients’ features and it might be of 
great interest to analyse the expression signatures and differences, for example possible 
divergent epithelial to mesenchymal transition (EMT) and stemness characteristics. 
 
In my study all the observations were made using transient transfection approaches. This may be 
as well a limitation. In contrast to other types of cancer cell lines, HCC cells are less prone to grow 
and survive with dysregulated levels of HMGA1. Especially for the overexpression, we noticed 
that they do not survive after 3-4 passages. HMGA1 overexpression might result in a saturation 
of the system that does not allow us to observe drastic differences in the functionality of this 
protein. Also the silencing could be sensitive to several constraints and parameters. Changes in 
the availability of HMGA1 only for a certain amount of time could alter the potency of its target, it 
might be that specific conditions of abundance must be met for changes to affect silenced 
HMGA1-mediated targets. For this reason the tumourigenic role of HMGA1 in the hepatocellular 
cells might not be accentuated with the  temporary differential expression of the gene. Also in this 
case the establishment of organoids biobank and the characterisation of HMGA1 in more patients’ 
representative models might help the exploration of the function of the protein in HCC. 
 
As already mentioned before, it has been shown that HCCs harbour a multitude of epigenetic 
aberrations, in conjunction with the genetic ones, involved in the process of liver carcinogenesis  
199,200. Thus, to analyse the epigenomics of hepatocellular cells might also help to have a deeper 
understanding of the genomic targets of HMGA1. We investigated the genome-wide DNA binding 
profile of HMGA1 and we demonstrated the protein preference for AT-rich regions. However, the 
enrichment in a broad range of higher AT content binding sites, and not specifically in regulatory 
regions, did not help to highlight the targets of HMGA1. To acquire information about 
heterochromatic regions compatibility and chromatin modifications across the genome when 
HMGA1 is deregulated, we already started to assess its genome-wide chromatin accessibility. An 
initial test on two HCC cell lines with silenced HMGA1 vs control by ATAC-seq (Assay for 
transposase-accessible chromatin with high-throughput sequencing) is ongoing. We are excited 
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to explore the results and, with a settled preparation protocol, we will proceed with more 
specimens.  
 
Finally, our results highlight the potential relevance of a non-canonical role of HMGA1 binding 
mRNAs. The direct binding with Alyref and other proteins involved in translational regulation 
shows a new aspect of HMGA1. The proteins complex can lead to the stabilization and therefore 
the regulation of specific m5C-mRNAs targets of Alyref to promote their translation and activation, 
ending in promotion of specific tumour features. The concept and the discovery of atypical roles 
of HMGA1 is not completely new. Aside from the study already mentioned showing an 
extracellular role of secreted HMGA1 in triple negative breast cancer cells promoting tumour 
progression 192, another recent research described the binding of HMGA1 with RNAs in breast 
cancer cells 201. This research group showed that HMGA1 is able to increase mRNA level of 
estrogen receptor alpha (ERα) because of its ability to induce exon-skipping. Furthermore, they 
confirm the participation of HMGA1 in alternative splicing because they demonstrated that the 
HMGA1 RNA decoy inhibits ERα46 expression and increases cell viability, sensitises the cells to 
tamoxifen and induces tumour formation in vivo 202. The same group had recently shown the 
aberrant exon-skipping caused by HMGA1-RNA-protein complex on target sites adjacent to 
authentic 5’ splice sites. This causes the overexpression of genes involved in neuronal cells 
degeneration of patients with sporadic Alzheimer’s disease 203. New experiments adequate to 
discover the atypical role of HMGA1-Alyref complex in stabilization of mRNA targets, like RNA 
immunoprecipitation sequencing (RIP-seq), could add another piece in the knowledge of the role 
of HMGA1 in tumourigenesis.  
 
III. Conclusions  
HCC is an aggressive and deadly type of cancer, with an incidence rate increasing every year 
also in western countries 79. A better understanding of the mechanisms underlying the 
development and progression of the tumour could be a great starting point in the development of 
preventive strategies and specific targeted therapies. The main research objective of my project 
was to investigate biomarkers in HCC.  
 
In Chapter I, this aim was followed based on the genetics of the disease. The possibility to screen 
patients’ samples for genetic alterations can give us an overview of the genes dysregulated and 
help us to focus our attention on the appropriate and advantageous targets. We developed a HCC 
specific sequencing panel, with the most common somatic mutations and copy number alterations 
(CNAs) evaluated in HCC. It was tested for different kinds of patients’ biopsies, frozen tissues, 
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FFPEs and also liquid biopsies. We created a somatic variant calling pipeline specific for these 
sequencing data as well, to have a reliable and reproducible analysis in each laboratory.  
 
We also explored the role of one of the biomarkers of prognosis and survival of liver 
carcinogenesis. In Chapter II, we focused on the molecular characterisation of HMGA1 and the 
identification of its targets. We deregulated the protein in a HCC in vitro environment and we 
evaluated the DNA-binding landscape and its expression signature at RNA and protein level. We 
also identified the binding partners of HMGA1 and we recognised several RNA regulators, 
including Alyref. This discovery opens new research possibilities to seek a non-canonical role of 
HMGA1 binding mRNAs and involved in translational regulation.   
 
The steps collected with my study are small but they underline the necessity to keep researching 
on markers in HCC and to define their clinical significance. Furthermore, it is important to create 
a method to evaluate the genetic landscape of a patient’s tumour that may be feasible for 
diagnostic routine practice. This may lead in the nearest future to a deeper knowledge of the 
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Abstract
The aim of this study was to assess the feasibility of cell-free DNA extraction and circulating tumor DNA
sequencing in 30-year-old serum samples of patients with breast cancer. Cell-free DNA extraction was suc-
cessful in 52 of 52 patients, and 24 cancer-specific mutations were found in 22 of 25 samples undergoing
sequencing. This study shows that next-generation sequencing technology is sufficiently robust and specific to
analyze 30-year-old serum.
Introduction: The aim of this study was to assess the feasibility of cell-free DNA (cfDNA) extraction and circulating
tumor DNA sequencing in 30-year-old serum samples.Materials and Methods:We evaluated serum samples from 52
patients with breast cancer, which were collected between 1983 and 1991, with correlating clinicopathologic data.
cfDNA was extracted by using the QIAamp Circulating Nucleic Acid Extraction Kit (Qiagen). Of these 52 cfDNA
samples, 10 were randomly selected and sequenced with the Oncomine Breast cfDNA Assay (A31183). In a second
step, high-depth targeted sequencing of 15 additional cfDNA samples was performed using a custom Ampliseq Ion
Torrent panel targeting breast cancer-related genes. Results: cfDNA extraction was successful in 52 (100%) of 52
patients with a total concentration of 0.2 to 54 ng/uL. A total of 24 cancer-specific mutations were found in 22 (88%) of
the 25 samples undergoing sequencing. Of the 52 patients, 32 (62%) had died from breast cancer after a median
follow-up of 7.9 years (interquartile range, 3.7-15.5 years). Conclusion: The present study shows that current next
generation sequencing technology is sufficiently robust and specific to analyze 30-year-old serum. Therefore,
longitudinal studies can be designed with storage of serum samples over many years, thereby obviating the need for
timely and continuous cfDNA extraction and sequencing. The samples can be pooled and processed at once with the
most modern technology available at the end of the study, when accumulation of events allows correlation of clinical
outcomes with adequate power.
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Introduction
A breakthrough in next-generation sequencing (NGS) in the past
decade provided an unprecedented opportunity to investigate
genetic variations in humans and their roles in health and disease. In
particular, large-scale efforts such as The Cancer Genome Atlas and
the International Cancer Genome Consortium have provided a
comprehensive molecular portrait of human cancers.1,2 The
discovery of the so-called ‘driver genes’ has provided the basis for the
development of the concept of precision medicine, where the
identification of targetable alterations guides the therapeutic
approach in treating patients with cancer. Nowadays, the decreasing
costs of massively parallel sequencing have resulted in increased
adoption of genomic profiling as part of the standard diagnostic
procedures in most tumor types.3,4
In patients with cancer, nucleic acids obtained from tumor biopsies
and resections remain the main source for molecular profiling. How-
ever, these procedures are invasive, costly, time-consuming, and have
only limited potential to be repeated in longitudinal studies.5 Their
relevance is further limited by the prevalence of intra-tumor genetic
heterogeneity as shown in multiple sequencing studies over the past
decade.5,6 Thus, a single biopsy of the primary tumor is not likely to be
genetically representative of the whole tumor. To overcome these
challenges, circulating cell-freeDNA (cfDNA) has been proposed as an
alternative because it can be collected less invasively compared with
conventional biopsies.7,8 Circulating cfDNA is a type of cell-free
nucleic acid that derives from apoptotic and necrotic cells or is
released from living eukaryotic cells.9 The detection of DNA in the
blood originating from tumors in patients with cancer has been
described decades ago.10-12 The fraction of cfDNA derived from tumor
is termed circulating tumor DNA (ctDNA).7,8 ctDNA can be
considered a new source for the detection and surveillance of major
cancers because it is more likely to be present in patients with cancer.7,8
The potential of using cfDNA as an indicator of disease burden
with prognostic implication and clinical applicability during follow-
up and monitoring in both the curative and palliative setting has
been investigated in numerous studies.13,14 Cancer-specific
mutations, copy number alterations, and genomic rearrangements
assessed in ctDNA demonstrated potential prognostic and predictive
significance.15-20 To further evaluate prognostic and predictive
biomarkers in cfDNA and assess its value as a disease monitoring
tool, longitudinal studies with long follow-up are necessary. The
utility of the technology depends on its capability to assess
sequential samples that have been collected and stored over a long
period of time. This study aims to assess the feasibility of cfDNA
extraction and somatic mutation assessment in 30-year-old serum




For this study, we had access to serum samples from 753 patients
with cancer, which were collected between 1983 and 1991 in an
oncologic private practice in Basel, Switzerland. Of 753 patients,
152 were females with breast cancer. The patients were referred to
the medical oncologist either after surgery of the primary tumor
or after the diagnosis of local/regional recurrence and/or distant
metastases. After obtaining informed consent, 10 mL of native
venous blood were collected in a 10-mL BD Vacutainer blood
collection tube and centrifuged in a Hettich centrifuge at 5000 rpm
for 10 minutes. The serum samples were immediately frozen and
stored at !70"C to !80"C in 3 Nunc Cryogenic tubes per patient
(Gibko AG) at a private office during the first 9 years; thereafter,
the samples have been transferred to the Institute of Immunobi-
ology in Freiburg, Germany, by using transportable refrigerating
boxes to avoid thawing. In 1999, the samples were relocated to the
Laboratory for Medical Genetics of the University of Basel,
Switzerland, and stored until processing and analysis. Clinico-
pathologic variables regarding patient demographics, primary
tumor, treatment, recurrence, and survival were retrieved from
clinical files. Approval for the use of these samples and correlating
data has been granted by the responsible ethics committee (approval
number: eknz-2018-00252).
cfDNA Extraction
Circulating DNA was extracted from 2 to 4 mL of isolated serum
from 52 randomly selected patients with breast cancer with the
QIAamp Circulating Nucleic Acid Kit (Qiagen) as previously
described.21 DNA was quantified using the Qubit Fluorometer
(Invitrogen) and analyzed using the 2200 TapeStation system
(Agilent Technologies) with the High Sensitivity DNA Analysis Kit.
Targeted Sequencing and Library Preparation
Sequencing was performed using 2 different amplicon-based
targeted sequencing panels. The first 10 randomly selected
samples were sequenced with the Oncomine Breast cfDNA Assay
(A31183, Thermo Fisher Scientific). This panel covers 152 hotspot
mutations in 10 genes (AKT1, EGFR, ERBB2, ERBB3, ESR1,
FBXW7, KRAS, PIK3CA, SF3B1, and TP53) across 26 amplicons.
This integrates the TagSeq technology (molecular barcode) and
allows detection of rare variants present at 0.1% allelic frequency.
Library preparation, molecular barcoding, and sequencing were
performed according to the instructions and guidelines provided by
Thermo Fisher, using 5 ng of DNA as input. Briefly, the library
preparation protocol was based on a 2-step cycle multiplex touch-
down polymerase chain reaction (PCR) with a temperature
ranging from 64 "C to 58 "C, which allowed to amplify target
regions and to introduce unique molecular identifiers. The obtained
tagged amplicons of around 100 to 140 bp length were then cleaned
up using Agencourt AMPure XP (Beckman Coulter), then eluted in
24 ml low TE buffer. A second round of PCR (18 cycles) was
performed in a total volume of 50 ml to amplify the purified
amplicons and to introduce Ion Torrent Tag-Sequencing adapters
containing sample-specific barcodes. The resulting library of target
DNA fragments was purified by performing a 2-step cleanup using
Agencourt AMPure XP (Beckman Coulter). The purified libraries
were then diluted 1:1000 and quantified by qPCR using the Ion
Universal Quantitation Kit (Thermo Fisher Scientific). The
quantified stock libraries were then diluted to 100 pM for down-
stream template preparation. Subsequentially, sequencing runs were
planned on the Torrent Suite Software v5.2, and libraries were
pooled and loaded on an Ion 540 chip using the Ion Chef
Instrument (Thermo Fisher Scientific). The loaded chip was then
sequenced using 500 flows on an S5 system (Thermo Fisher
Scientific).
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Mutation Identification in 30-year-old Serum
In a second round, 15 randomly selected samples were
sequenced with a custom targeted sequencing panel focusing on
the most frequently altered genes in breast cancer previously
described.22 Library preparation for the breast panel was per-
formed using the Ion AmpliSeq library kit 2.0 (Thermo Fisher
Scientific) according to the manufacturer’s guidelines. The panel
consists of 2 pools of amplification primers. Ten ng of DNA per
sample were used for library preparation for each pool. Amplifi-
cation was performed according to the manufacturer’s guidelines.
The amplicons from the 2 pools were combined and treated to
digest the primers and to phosphorylate the amplicons. The
amplicons were then ligated to Ion Xpress Barcode Adapters
(Thermo Fisher Scientific) using DNA ligase. Finally, cleaning
and purification of the generated libraries were performed with
Agencourt AMPure XP (Beckman Coulter) according to the
manufacturer’s guidelines. Quantification and quality control
were performed with Ion Library TaqMan Quantitation Kit
(Thermo Fisher Scientific). Samples were diluted to reach the
concentration of 40 pmol and then were pooled for sequencing.
Twenty-five ml of the pooled libraries were loaded on Ion 540
Chip (Thermo Fisher Scientific) and processed in Ion Chef In-
strument (Thermo Fisher Scientific). Sequencing was performed
on Ion S5XL system (Thermo Fisher Scientific).23
Somatic Variants Identification
Raw data were processed automatically on the Torrent Server and
aligned to the reference hg19 genome. The analysis pipeline included
signal processing, base calling, quality score assignment, adapter
trimming, PCR duplicate removal, and control of mapping quality.
All samples passed the quality check and met the requirements of a
minimum molecular average depth. The first round of samples
sequencing data (n ¼ 10) was uploaded in BAM format to the Ion
Reporter Analysis Server for variant calling and annotation. Variant
calling was performed on Ion Reporter (IR) Analysis Software v5.2
using the Oncomine TagSeq Breast Liquid Biopsy w2.0 workflow.
Coverage metrics for each amplicon were obtained by running the
Coverage Analysis Plugin software v5.2.1 (Thermo Fisher Scientific).
Identified variants were only considered if the variant had a molecular
coverage of at least 3, indicating that the variant was detected in 3
independent template molecules. Finally, all candidate mutations
were manually reviewed using the Integrative Genomics Viewer37.





No. patients with clinical data and serum 52
Median age at first diagnosis, y 49.5 (45.5-60.5)
Median follow-up time from diagnosis to death
or last follow-up, y
7.9
(3.7-15.5)
Median time from initial diagnosis to date
of sample collection, y
1.6
(1.0-4.8)
No. breast cancer-specific deaths 32 (62)
No. deaths unrelated to breast cancer 4 (7)
Cause of death unknown 2 (3)
Median overall survival from diagnosis to death, y 6.8 (3.2-13.9)
Median disease-free survival diagnosis to local/regional
or distant recurrence, second breast cancer or death, y
2.7
(1.5-6.4)
Treatment at first diagnosis
Neoadjuvant treatment 2 (3)
Surgery 50 (96)
Adjuvant radiation 18 (35)
Adjuvant tamoxifen 18 (35)
Adjuvant CMF ($v $p) or LMF ($vp)
chemotherapies
15 (28)
Other adjuvant systemic therapies 3 (5)
































Abbreviations: C ¼ cyclophosphamide; F ¼ fluorouracil; IQR ¼ interquartile range;
L ¼ chlorambucil (leukeran); M ¼ methotrexate; P ¼ prednisone; V ¼ vincristine.
aHad not been assessed routinely at the time.
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In the second round of sequenced samples (n ¼ 15), variant
calling was performed with TVC version 5.0.3 (Torrent Variant
Caller, Thermo Fisher Scientific) using low-stringency parameters
previously described.24,25 Briefly, mutations detected by TVC were
subsequently filtered by the following steps. First, all the multiallelic
variants have been split and left aligned. Moreover, the presence and
the relative length of homopolymer sequences were annotated to
take into account the presence of possible wrongly aligned
sequencing reads and, therefore, false-positive variants. Second,
because the 15 samples had no matched germline samples, all the
variants have been annotated using 3 databases: the 1000 Genomes
Project, the Exome Aggregation Consortium, and the NHLBI GO
Exome Sequencing Project.26,27 All the mutations identified by
TVC that were also present within the databases in significative
frequencies (> 5%) have been flagged as probable germline
mutations. Furthermore, a pool of 16 germline samples collected
from an independent cohort was used to provide an additional list of
likely germline mutations that, together with the ones previously
flagged, have been filtered out from the final output list. To avoid
the removal of clinically relevant information, mutations found in
known cancer driver hotspots have been whitelisted and kept even
when they met the criteria for the aforementioned filtering steps.
Results
cfDNA Extraction From 30-year-old Serum of Sufficient
Quality for Sequencing Analysis
We randomly selected 52 of the 152 patients with breast cancer
(clinicopathologic characteristics of patients are shown in Table 1)
to perform cfDNA extraction (Table 2). cfDNA extraction was
successful in all patients, and cfDNA levels were determined for
each sample with a fluorometric quantitation system. We obtained a
range of concentrations from 0.2 to 54 ng/ul (Table 2). To assess
the serum-derived cfDNA integrity and quality, we performed a
capillary electrophoretic separation using the TapeStation system
(Agilent Technology). Electropherograms were generated for each
sample and the fragment size of the cfDNA measured between 2
markers against fluorescence intensity. The mean of cfDNA
fragment size distribution ranged from 106 to 216 bp (average, 136
bp), with no significant differences in cfDNA fragment size between
all samples (Figure 1). Even though the serum samples showed
contamination with high molecular weight genomic DNA in
comparison to samples extracted from plasma (gDNA) (Figure 1), it
was observed that the amount of cfDNA was more than the gDNA
(Figure 1).
Taken together, cfDNA was successfully extracted from all the
samples with sufficient quality for further sequencing analysis,
suggesting the feasibility of the use of long-storage serum for
molecular analysis.
Targeted Sequencing Showed Breast Cancer-specific
Somatic Mutations in cfDNA
From the 52 extracted cfDNA samples, we randomly selected 25
for subsequent mutation investigation. Sequencing was performed
using 2 different targeted panels. Ten samples were sequenced using
the Oncomine Breast cfDNA Assay, which covers the most
common hotspots in 10 highly mutated genes in breast cancer.
Table 2 Circulating Free DNA Extraction Data
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Owing to the molecular barcoding, this panel allows for the
identification of mutations at a very low allelic frequency. We
obtained a mean sequencing depth of 55,612X (ranging from 5227
to 108,393) and identified somatic mutations in 8 of the tested
samples encompassing KRAS, TP53 (Table 3A and Figure 2). The
other 15 samples were instead sequenced with a custom targeted
sequencing panel that covers all exons of 27 protein-coding genes as
well as mutation hotspots in 3 cancer genes and the recurrently
mutated lncRNA genes MALAT1 and NEAT128 (see Supplemental
Table 1 in the online version). In this second round of sequencing,
we obtained a mean sequencing depth of 2891X (ranging from 903
to 18,210), and we identified somatic mutations in 12 of the tested
samples (Table 3B and Figure 2). Mutations were detected in some
of the most commonly mutated genes in breast cancer, as
TP53(p.Arg248Trp) and PTEN(p.Phe278Leu).
Taken together, a total of 24 cancer-specific mutations in 10 of
the most commonly mutated breast cancer genes were found in 22
(88%) of 25 randomly selected 30-year-old serum-derived cfDNA
from patients with breast cancer (Figure 2), suggesting the feasibility
of using very old serum samples for mutational profiles.
Discussion
The present cohort of patients with breast cancer with complete
long-term follow-up and available blood samples taken 30 years ago
Figure 1 Circulating Free DNA Analysis Using the TapeStation System. Representative Electropherograms of Total Extracted
Circulating Free DNA From 4 Patients Selected for Sequencing (#030, #015, #029, #014)
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Figure 2 Heatmap of the Comparison of all the Somatic Mutations Found in 25 Randomly Selected Samples Across the Whole Cohort.
Rows Indicate the Specific Samples, Columns Indicate the Specific Mutations, Annotated With the Gene Name and the
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represents an exceptional opportunity to study the potential of
liquid biopsy-based biomarker identification. The patients were
treated in curative or palliative intent for stage I to IV breast cancer.
Treatment heterogeneity was limited at that time because only
tamoxifen and CMF or LMF (cyclophosphamide- or chlorambucil-
methotrexate-fluorouracil) chemotherapy were used in most
patients who received systemic treatment. The majority of the
patient population recurred at some point, which was the reason
why 35 (62%) of the 52 patients died from breast cancer in this
cohort. The collection of serum started in 1983, whereas the dates
of first diagnosis and treatment go back to 1967. cfDNA was
obtained in sufficient quantity and quality for sequencing in all 52
patients. The sample size was too small to make any firm conclu-
sions on differences between patients with short and long-term
survival. However, the present results suggest that this modern
technology can be used to accurately extract and sequence ctDNA
to detect cancer-specific mutations in these old samples, despite the
long cryopreservation and repeated changes of storage location.
These findings support the use of long-term storage of biological
samples in longitudinal studies prior to analysis, which, in turn, will
increase feasibility by making the study protocols less depending on
consecutive and timely processing at the centralized high-depth tar-
geted sequencing unit. The principle of long-term storage may
facilitate the performance of large international studies that assess the
prognostic role of cancer-associated pathogenic mutations in serum
cfDNA present at diagnosis by comparing overall and relapse-free
survival between patients with or without specific mutations.
Therefore, another potential value of using samples of patients
diagnosed a long time ago is to increase the number of events (eg,
relapse, deaths) and increase the statistical power for survival analyses
(study of the prognostic value of the identified mutations in ctDNA).
The predictive power of response-associated mutations can then be
assessed based on in silico mutation effect predictors and curated
databases of cancer- and response-associated variants.29-35 One would
hypothesize that patients with detectable mutations in the cfDNA
would have higher tumor burden and/or tumor cells with a higher
tendency to shed into the bloodstream and, therefore, poorer
outcome than patients without detectable mutations in the cfDNA.
Candidate somatic mutations can be further evaluated in vitro and
in vivo by using xenograft models. For instance, patient-derived breast
tumor cells can be engineered to express the same mutation found to
be associated with resistance and test their sensitivity to the same
targeted therapy in xenograft models compared with control cancer
cells (ie, wild-type in the corresponding allele).
The blood samples analyzed here were taken at a time when
physicians could not anticipate NGS approaches. Nevertheless,
substantial efforts were made to collect the samples under the
assumption that someday technology would have advanced to the
point where relevant research could be performed with a few mL of
serum and matched clinical data. Storing blood samples over the
entire duration of longitudinal studies allows newly developed
technology to analyze cfDNA more thoroughly and homogenously.
Hence, the most modern state-of-the-art technology for nucleic
acids extraction, sequencing, data analysis, and new targeted panels
that may only become available at the end of the study can be
applied to all serial blood samples, which increases data quality and
comparability. Innovative studies can be designed to track the
evolution of disease-associated mutations in the serum cfDNA. This
would allow to evaluate if variations in the tumor allele fractions of
the mutations mirror the genetic heterogeneity in the tumors and to
determine if disease progression is associated with the emergence of
additional somatic mutations. This, in turn, may help to assess
whether mutational evolution reflects radiologically determined
disease burden, recurrence, or metastasis.
This study has several limitations. First, some of the mutations
may have been germline variants, especially those at high allelic
frequencies. We cannot exclude this possibility owing to the lack of
germline controls or clonal hematopoiesis. However, the primary
aim of the study was to determine whether it was possible to identify
mutations in 30-year-old serum, and the exclusion of germline
variants can be achieved by using germline control. Second, the
custom panel we used in this study was not optimized for mutation
detection in cfDNA, because some of the amplicons are bigger than
the average size of cfDNA fragments. We may thus have missed
some mutations, and the use of a panel with smaller amplicon size
will likely increase the number of mutations that can be detected.
Third, another important limitation is the small sample size that
precluded any analyses on associations between mutations and
clinical endpoints. For example, it would be interesting to see if
patients with detectable mutations in the cfDNA have a higher
tumor stage and therefore poorer outcome than patients without
detectable mutations. This has been shown in patients with late-
stage gastric cancer, where patients with detectable mutations had
a 5.6% 5-year overall survival rate compared with 31.5% in patients
without detectable mutations.36 TP53 is one of the most frequently
mutated genes in breast cancer, and, being a tumor suppressor and
usually associated with the loss of the wild-type allele, TP53
mutations are likely to be more readily detectable in cfDNA than
activating oncogenic mutations. In fact, 7 of 24 detected mutations
in this series were TP53 mutations. However, it would be very
challenging to adjust for the selection bias in this series of high-risk
patients referred to the medical oncologist for systemic treatment
even if a higher sample size could have been achieved. Nevertheless,
evaluating associations between mutations and clinical endpoints is
an area of high potential relevance, particularly when DNA from
matched archival tissue of primary tumors or distant metastases are
available. As outlook for future projects, we plan to assess the
prognostic role of cancer-associated mutations in the serum cfDNA
at diagnosis with the extensive follow-up information and clinico-
pathologic parameters available for our unique cohort of patients.
In conclusion, the present study shows that current NGS tech-
nology is sufficiently robust and specific to analyze 30-year-old serum.
Based on this finding, longitudinal studies can be designed to bemore
feasible and flexible by storing biological samples over a long period of
time. This allows for uniform sequencing with the most modern
technology and adequate statistical power by cumulating oncologic
events. Our study supports the value of liquid biopsies in assessing the
dynamic changes of genetic heterogeneity over time and in the vali-
dation of new cfDNA biomarkers for breast cancer.
Clinical Practice Points
& The potential of using cfDNA as an indicator of disease burden
with prognostic implication and clinical applicability during
follow-up and monitoring in both the curative and palliative
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setting has been investigated in numerous studies. Cancer-
specific mutations, copy number alterations, and genomic
rearrangements assessed in ctDNA demonstrated potential
prognostic and predictive significance.
& To further evaluate prognostic and predictive biomarkers in
cfDNA and assess its value as a disease monitoring tool,
longitudinal studies with long follow-up are necessary. The
utility of the technology depends on its capability to assess
sequential samples that have been collected and stored over a
long period of time.
& The aim of this study was to assess the feasibility of cfDNA
extraction and somatic mutation assessment in 30-year-old
serum. We evaluated samples from 52 patients with breast
cancer, which were collected between 1983 and 1991. cfDNA
extraction was successful in 52 of 52 patients, and 24 cancer-
specific mutations were found in 22 of 25 samples undergoing
sequencing.
& Our results suggest that current NGS technology is sufficiently
robust and specific to analyze 30-year-old serum. Based on this
finding, longitudinal studies can be designed to be more feasible
and flexible by storing biological samples over a long period of
time. This allows for uniform sequencing with the most modern
technology and adequate statistical power by cumulating
oncologic events. Our study supports the value of liquid biopsies
in assessing the dynamic changes of genetic heterogeneity over
time and in the validation of new cfDNA biomarkers for breast
cancer.
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Supplemental Data
Supplemental Table 1 Gene Coverage of the Custom Targeted Sequencing Panel
Gene Name Chromosome Start End Cytoband Remarks
ARID1A 1 27022524 27108595 p36.11 Complete coding region
NRAS 1 115247090 115259515 p13.2 Hotspot residues 12,13 and 61 only
SETD2 3 47057919 47205457 p21.31 Complete coding region
PIK3CA 3 178865902 178957881 q26.32 Complete coding region
FBXW7 4 153242410 153457253 q31.3 Complete coding region
MAP3K1 5 56111401 56191979 q11.2 Complete coding region
PIK3R1 5 67511548 67597649 q13.1 Complete coding region
ARID1B 6 157099063 157531913 q25.3 Complete coding region
EGFR 7 55086714 55324313 p11.2 Complete coding region
KMT2C 7 151832010 152133090 q36.1 Complete coding region
PTPRD 9 8314246 10612723 p23 Complete coding region
GAT A3 10 8095567 8117161 p14 Complete coding region
PTEN 10 89622870 89731687 q23.31 Complete coding region
HRAS 11 532242 537287 p15.5 Hotspot residues 12, 13, and 61 only
NEAT1 11 65190245 65213011 q13.1 Complete coding region
MALAT1 11 65265233 65273940 q13.1 Complete coding region
ATM 11 108093211 108239829 q22.3 Complete coding region
KRAS 12 25357723 25403870 p12.1 Hotspot residues 12, 13, and 61 only
ERBB3 12 56473641 56497289 q13.2 Complete coding region
TBX3 12 115108059 115121969 q24.21 Complete coding region
RBI 13 48877887 49056122 q14.2 Complete coding region
F0XA1 14 38059189 38069245 q21.1 Complete coding region
AKT1 14 105235686 105262088 q32.33 Complete coding region
CBFB 16 67063019 67134961 q22.1 Complete coding region
CTCF 16 67596310 67673086 q22.1 Complete coding region
CDH1 16 68771128 68869451 q22.1 Complete coding region
TP53 17 7565097 7590856 p13.1 Complete coding region
MAP2K4 17 11924141 12047147 P12 Complete coding region
NCOR1 17 15932471 16121499 p11.2 Complete coding region
NF1 17 29421945 29709134 q11.2 Complete coding region
ERBB2 17 37844167 37886679 q12 Complete coding region
RUNX1 21 36160098 37376965 q22.12 Complete coding region
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